var title_f29_44_30400="Greenstick fracture radius";
var content_f29_44_30400=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F80128&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F80128&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Greenstick fracture of distal radius",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 385px; height: 489px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Greenstick fracture of distal radius and complete fracture of ulna, with minimal angulation and no displacement in an 8-year-old child. Both are metaphyseal fractures. Note that the lateral view shows the complete cortical break on the volar aspect of the radial greenstick fracture with bulging of the periosteum dorsally.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paula Schweich, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_44_30400=[""].join("\n");
var outline_f29_44_30400=null;
var title_f29_44_30401="IDUS papillary projections";
var content_f29_44_30401=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F66688&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F66688&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 472px\">",
"   <div class=\"ttl\">",
"    Intraductal ultrasound showing papillary projections in the pancreatic duct",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 452px; height: 326px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Two papillary projections (arrows) identified by intraductal ultrasound of the pancreas raise the suspicion of malignant degeneration.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Michael J Levy, MD, Enrique Vazquez-Sequeiros, MD, and Maurits J Wiersema, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_44_30401=[""].join("\n");
var outline_f29_44_30401=null;
var title_f29_44_30402="Liver mets colon cancer Gross";
var content_f29_44_30402=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F81255&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F81255&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Metastatic colon cancer",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 358px; height: 286px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple liver metastases seen during laparotomy in a patient with colon cancer.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Richard B Freeman, Jr, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_44_30402=[""].join("\n");
var outline_f29_44_30402=null;
var title_f29_44_30403="Anterior wall dyskinesis post MI four chamber echo";
var content_f29_44_30403=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/72843/4chantdy_conv.mp4?title=Anterior+wall+dyskinesis+post+MI+four+chamber+echo\" style=\"width:328px;height:248px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Anterior wall myocardial infarction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 259px; height: 448px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Four chamber view from a 2-D echocardiogram shows a large dyskinetic region of the apex and anterior wall of a dilated left ventricle as a result of a large anterior wall infarction. The anterior wall and interventicular septum are thin and do not thicken during systole.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Thomas Binder, MD. University of Vienna.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_44_30403=[""].join("\n");
var outline_f29_44_30403=null;
var title_f29_44_30404="One hand bag mask ventilation technique";
var content_f29_44_30404=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F80091&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F80091&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 615px\">",
"   <div class=\"ttl\">",
"    One-hand bag mask ventilation technique",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 595px; height: 337px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    To perform this technique, one hand is placed on the mask, with the web space between the thumb and index finger resting against the mask connector. The web space is placed in the center of the mask, allowing for a more even application of pressure. The correct technique is to lift the mandible up into the mask with the middle, ring, and little fingers, while holding the mask tightly against the patient's face with the thumb and index finger. Clinicians should take care to pull up only on the bony parts of the mandible; pressure to the soft tissues of the neck may occlude the airway.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Kathleen Wittels, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_44_30404=[""].join("\n");
var outline_f29_44_30404=null;
var title_f29_44_30405="Epidemiology, clinical manifestations, and diagnosis of Cystoisospora infections";
var content_f29_44_30405=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Epidemiology, clinical manifestations, and diagnosis of Cystoisospora infections",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/44/30405/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/44/30405/contributors\">",
"     Karin Leder, MBBS, FRACP, PhD, MPH, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/44/30405/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/44/30405/contributors\">",
"     Peter F Weller, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/44/30405/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/44/30405/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?29/44/30405/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 6, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cystoisospora belli (formerly known as Isospora belli) is a gastrointestinal protozoan. In patients with AIDS and other immunodeficiencies, it is an opportunistic pathogen that can cause watery diarrhea and weight loss. Like other enteric pathogens such as Cryptosporidium and Cyclospora, C. belli is a coccidian, unicellular protozoan parasite that primarily infects the intestinal epithelium [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30405/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cystoisospora belli is found worldwide, but infections are more common in tropical and subtropical areas [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30405/abstract/2\">",
"     2",
"    </a>",
"    ]. In India, Cystoisospora infections are the most common parasitic cause of diarrhea in HIV-infected subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30405/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Among HIV-infected patients living in France, Cystoisospora infections were seen more commonly among patients who had emigrated from sub-Saharan Africa [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30405/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Gastrointestinal infections secondary to Cystoisospora are uncommon in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30405/abstract/6,7\">",
"     6,7",
"    </a>",
"    ], but can be acquired by travelers to endemic countries [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30405/abstract/6,8,9\">",
"     6,8,9",
"    </a>",
"    ]. In a study of more than 16,000 HIV-infected patients between 1985 and 1992 in Los Angeles County, the prevalence of Cystoisospora infections was highest in foreign-born patients, particularly those from Mexico and El Salvador and among persons of Hispanic ethnicity [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30405/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The main risk factor for chronic infectious diarrhea in an HIV-infected patient is immunosuppression (CD4 cell count &lt;50",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     )",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30405/abstract/10\">",
"     10",
"    </a>",
"    ]. Enteric infections in HIV-infected patients with advanced immunosuppression can have a significant impact on morbidity and mortality. For example, diarrhea secondary to enteric infections, such a Cryptosporidium, Giardia, and Cystoisospora, was found to be an independent predictor of mortality among 688 Haitian AIDS patients initiating antiretroviral therapy (ART) compared with control patients who did not have diarrhea [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30405/abstract/11\">",
"     11",
"    </a>",
"    ]. Cystoisospora can also be identified as a copathogen with other enteric organisms, such as Enterocytozoon bieneusi, in geographic regions with high levels of fecal contamination of surface water [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30405/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, a history of treatment or prophylaxis with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    for Pneumocystis infection in an HIV-infected patient is associated with a decreased risk of developing cystoisosporiasis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30405/abstract/6,13\">",
"     6,13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cystoisospora has also been reported in immunocompetent patients as well as in patients with other cellular immunodeficiencies, such as human T-lymphotropic type 1 infection [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30405/abstract/14\">",
"     14",
"    </a>",
"    ], lymphoblastic leukemia, adult T-cell leukemia, Hodgkin's disease, and non-Hodgkin lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30405/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     TRANSMISSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infections are acquired by the ingestion of sporulated oocysts from food or water contaminated with human feces. After ingestion, the parasite invades enterocytes within the small intestine. The parasite completes its life cycle within the human host and immature oocysts are excreted in stool.",
"   </p>",
"   <p>",
"    Sexual transmission through oral-anal contact has been suggested, but is unlikely since oocysts must exist outside the host for one to two days before sporulation, which is the infective phase [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30405/abstract/16-18\">",
"     16-18",
"    </a>",
"    ]. Person-to-person transmission does not appear to be common; in a study of HIV-infected patients with Cystoisospora infection in Haiti, none of the 170 immunocompetent spouses or siblings cohabitating with the source patients had evidence of infection [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30405/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The principal manifestation of Cystoisospora infection is a watery, nonbloody diarrheal illness of sudden onset [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30405/abstract/7\">",
"     7",
"    </a>",
"    ]. Commonly seen associated symptoms include malaise, anorexia, abdominal pain, headache, vomiting, and dehydration. Fever may also be present [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30405/abstract/5\">",
"     5",
"    </a>",
"    ]. Patients with steatorrhea secondary to malabsorption may complain of malodorous stool. Cystoisospora infection has also been associated with acalculous cholecystitis and reactive arthritis in the HIV-infected host [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30405/abstract/19,20\">",
"     19,20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical course of Cystoisospora infections varies with the immune status of the host. While symptoms are usually self-limited in the immunocompetent host [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30405/abstract/21\">",
"     21",
"    </a>",
"    ], cystoisosporiasis is often a chronic, debilitating diarrheal infection in immunocompromised hosts, who may relapse without long-term antibiotic suppression [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30405/abstract/7,22\">",
"     7,22",
"    </a>",
"    ]. In patients with AIDS, untreated infection is associated with protracted clinical course with severe diarrhea and weight loss, clinically indistinguishable from cryptosporidiosis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30405/abstract/7,17\">",
"     7,17",
"    </a>",
"    ]. The secretory stool output can also lead to severe volume loss, renal insufficiency, and electrolyte disturbances [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30405/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H934725\">",
"    <span class=\"h2\">",
"     Laboratory findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to the general rule that protozoan infections do not elicit blood eosinophilia, increases in circulating eosinophils can occur with Cystoisospora infections and are sufficiently common to raise the diagnosis.",
"   </p>",
"   <p>",
"    Secretory diarrhea may lead to hypokalemia, bicarbonate wasting, and increased creatinine secondary to volume loss [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30405/abstract/17\">",
"     17",
"    </a>",
"    ]. Patients with secretory diarrhea usually have elevated stool osmolality and fecal fats noted on special stains (eg, Sudan III stain) consistent with steatorrhea. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/21/38232?source=see_link&amp;anchor=H8#H8\">",
"     \"Clinical features and diagnosis of malabsorption\", section on 'Tests for fat malabsorption'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H934087\">",
"    <span class=\"h1\">",
"     PATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cystoisospora infection principally affects the small and large intestines. Histologic alterations in the mucosa include shortened villi, crypt hyperplasia, and increases in infiltrating plasma cells, lymphocytes, and granulocytes. On occasion, organisms have been found at autopsy in extraintestinal sites, including the tracheobronchial lymph nodes, spleen, liver, and biliary tract [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30405/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of Cystoisospora infection is usually made by detecting oocysts in the feces.",
"   </p>",
"   <p>",
"    In cases of heavy infection, oocysts can be seen on a simple wet mount of stool [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30405/abstract/24\">",
"     24",
"    </a>",
"    ]. Multiple stool samples may be required for diagnosis among patients who may be intermittently shedding the parasite. However, as with cryptosporidia and Cyclospora, Cystoisospora usually cannot be detected by routine stool ova and parasite examinations. Thus, acid-fast staining [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30405/abstract/7\">",
"     7",
"    </a>",
"    ] or specific fluorescent techniques [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30405/abstract/25,26\">",
"     25,26",
"    </a>",
"    ] must be requested when Cystoisospora infection is suspected [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30405/abstract/1,17,27\">",
"     1,17,27",
"    </a>",
"    ]. A real-time PCR assay has been developed for detecting Cystoisospora DNA in fecal samples, but is not generally available [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30405/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When seen, oocysts of Cystoisospora are thin-walled and ellipsoidal in form, ranging from 20 to 30 micrometers in length by 10 to 19 micrometers in width [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30405/abstract/7\">",
"     7",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    If the stool examination is not diagnostic, parasites may also be detected in duodenal aspirates or within intestinal biopsy tissue examined under light microscopy; morphologically, Cystoisospora resembles Cyclospora on histologic sections [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30405/abstract/29\">",
"     29",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H27632855\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27632855\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other enteric pathogens to consider in the patient with severe watery diarrhea include Cryptosporidia, Cyclospora, Giardia, Campylobacter, Cholera, Shigella and Salmonella. In an immunocompromised patient, cytomegalovirus (CMV) and Enterocytozoon bieneusi should also be considered.",
"   </p>",
"   <p>",
"    Cholera is usually not confused with the other pathogens because of its rapid onset and epidemiology (ie, massive outbreaks in areas of poor sanitation). Salmonella, Shigella and Entamoeba histolytica may be distinguished by their association with bloody diarrhea. A history of recent antibiotic exposure would suggest Clostridium difficile. Giardia is a small bowel pathogen associated with significant flatus and upper gastrointestinal symptoms without blood in the stool. Viral pathogens, such as rotavirus and Norwalk can also cause watery diarrhea, but are self-limited, even in the immunocompromised host. &nbsp;",
"   </p>",
"   <p>",
"    Cryptosporidium infection is difficult to distinguish clinically from Cystoisospora, but on microscopic examination, the latter parasites have a smaller round morphology with a size of approximately 4 to 6 micrometers; each parasite also contains four sporozoites [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30405/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Noninfectious causes of severe diarrhea include inflammatory bowel disease, celiac disease, pancreatic insufficiency, motility disorders, neuroendocrine tumors, villous adenoma, niacin deficiency and laxative abuse. (See appropriate topic reviews.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H934994\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cystoisospora belli (formerly known as Isospora belli) is an opportunistic protozoan pathogen, which can cause self-limited watery diarrhea in immunocompetent patients and severe debilitating chronic diarrhea with wasting in patients with AIDS. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cystoisospora belli is found worldwide, but infections are more common in tropical and subtropical areas. The main risk factor for chronic infectious diarrhea secondary to Cystoisospora infection in an HIV-infected patient is immunosuppression (CD4 cell count &lt;50",
"      <span class=\"nowrap\">",
"       cells/mm",
"       <sup>",
"        3",
"       </sup>",
"       ).",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Infections are acquired by the ingestion of sporulated oocysts from food or water contaminated with human feces. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Transmission'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The principal manifestation of Cystoisospora infection is a watery, nonbloody diarrheal illness of sudden onset. Commonly seen associated symptoms include malaise, anorexia, abdominal pain, headache, vomiting, and dehydration. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical course of Cystoisospora infections varies with the immune status of the host. While symptoms are usually self-limited in the immunocompetent host, cystoisosporiasis is often a chronic, debilitating diarrheal infection in immunocompromised hosts, who may relapse without long-term antibiotic suppression. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Secretory diarrhea may lead to hypokalemia, bicarbonate wasting, and increased creatinine secondary to volume loss. (See",
"      <a class=\"local\" href=\"#H934725\">",
"       'Laboratory findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cystoisospora infection principally affects the small and large intestines. Histologic alterations in the mucosa include shortened villi, crypt hyperplasia, and increases in infiltrating plasma cells, lymphocytes, and granulocytes. (See",
"      <a class=\"local\" href=\"#H934087\">",
"       'Pathology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of Cystoisospora infection is usually made by detecting oocysts in the feces, usually with the aid of special staining techniques such as acid-fast staining or immunofluorescence. Multiple stool samples may be required. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other enteric pathogens to consider in the patient with severe watery diarrhea include Cryptosporidia, Cyclospora, Giardia, Campylobacter, Salmonella, and Enterocytozoon bieneusi. (See",
"      <a class=\"local\" href=\"#H27632855\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30405/abstract/1\">",
"      Goodgame RW. Understanding intestinal spore-forming protozoa: cryptosporidia, microsporidia, isospora, and cyclospora. Ann Intern Med 1996; 124:429.",
"     </a>",
"    </li>",
"    <li>",
"     www.dpd.cdc.gov/dpdx/html/cystoisosporiasis.htm (Accessed on December 19, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30405/abstract/3\">",
"      Vignesh R, Balakrishnan P, Shankar EM, et al. High proportion of isosporiasis among HIV-infected patients with diarrhea in southern India. Am J Trop Med Hyg 2007; 77:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30405/abstract/4\">",
"      Gupta S, Narang S, Nunavath V, Singh S. Chronic diarrhoea in HIV patients: prevalence of coccidian parasites. Indian J Med Microbiol 2008; 26:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30405/abstract/5\">",
"      Lagrange-X&eacute;lot M, Porcher R, Sarfati C, et al. Isosporiasis in patients with HIV infection in the highly active antiretroviral therapy era in France. HIV Med 2008; 9:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30405/abstract/6\">",
"      Sorvillo FJ, Lieb LE, Seidel J, et al. Epidemiology of isosporiasis among persons with acquired immunodeficiency syndrome in Los Angeles County. Am J Trop Med Hyg 1995; 53:656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30405/abstract/7\">",
"      DeHovitz JA, Pape JW, Boncy M, Johnson WD Jr. Clinical manifestations and therapy of Isospora belli infection in patients with the acquired immunodeficiency syndrome. N Engl J Med 1986; 315:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30405/abstract/8\">",
"      Shaffer N, Moore L. Chronic travelers' diarrhea in a normal host due to Isospora belli. J Infect Dis 1989; 159:596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30405/abstract/9\">",
"      Goodgame R. Emerging Causes of Traveler's Diarrhea: Cryptosporidium, Cyclospora, Isospora, and Microsporidia. Curr Infect Dis Rep 2003; 5:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30405/abstract/10\">",
"      Sarfati C, Bourgeois A, Menotti J, et al. Prevalence of intestinal parasites including microsporidia in human immunodeficiency virus-infected adults in Cameroon: a cross-sectional study. Am J Trop Med Hyg 2006; 74:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30405/abstract/11\">",
"      Dillingham RA, Pinkerton R, Leger P, et al. High early mortality in patients with chronic acquired immunodeficiency syndrome diarrhea initiating antiretroviral therapy in Haiti: a case-control study. Am J Trop Med Hyg 2009; 80:1060.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30405/abstract/12\">",
"      Raccurt CP, Fouch&eacute; B, Agnamey P, et al. Presence of Enterocytozoon bieneusi associated with intestinal coccidia in patients with chronic diarrhea visiting an HIV center in Haiti. Am J Trop Med Hyg 2008; 79:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30405/abstract/13\">",
"      Guiguet M, Furco A, Tattevin P, et al. HIV-associated Isospora belli infection: incidence and risk factors in the French Hospital Database on HIV. HIV Med 2007; 8:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30405/abstract/14\">",
"      Greenberg SJ, Davey MP, Zierdt WS, Waldmann TA. Isospora belli enteric infection in patients with human T-cell leukemia virus type I-associated adult T-cell leukemia. Am J Med 1988; 85:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30405/abstract/15\">",
"      Resiere D, Vantelon JM, Bour&eacute;e P, et al. Isospora belli infection in a patient with non-Hodgkin's lymphoma. Clin Microbiol Infect 2003; 9:1065.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30405/abstract/16\">",
"      Forthal DN, Guest SS. Isospora belli enteritis in three homosexual men. Am J Trop Med Hyg 1984; 33:1060.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30405/abstract/17\">",
"      Ryan ET, Cronin CG, Branda JA. Case records of the Massachusetts General Hospital. Case 38-2011. A 34-year-old man with diarrhea and weakness. N Engl J Med 2011; 365:2306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30405/abstract/18\">",
"      Jongwutiwes S, Putaporntip C, Charoenkorn M, et al. Morphologic and molecular characterization of Isospora belli oocysts from patients in Thailand. Am J Trop Med Hyg 2007; 77:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30405/abstract/19\">",
"      Benator DA, French AL, Beaudet LM, et al. Isospora belli infection associated with acalculous cholecystitis in a patient with AIDS. Ann Intern Med 1994; 121:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30405/abstract/20\">",
"      Gonz&aacute;lez-Dominguez J, Rold&aacute;n R, Villanueva JL, et al. Isospora belli reactive arthritis in a patient with AIDS. Ann Rheum Dis 1994; 53:618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30405/abstract/21\">",
"      Gellin BG, Soave R. Coccidian infections in AIDS. Toxoplasmosis, cryptosporidiosis, and isosporiasis. Med Clin North Am 1992; 76:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30405/abstract/22\">",
"      Pape JW, Verdier RI, Johnson WD Jr. Treatment and prophylaxis of Isospora belli infection in patients with the acquired immunodeficiency syndrome. N Engl J Med 1989; 320:1044.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30405/abstract/23\">",
"      Restrepo C, Macher AM, Radany EH. Disseminated extraintestinal isosporiasis in a patient with acquired immune deficiency syndrome. Am J Clin Pathol 1987; 87:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30405/abstract/24\">",
"      Kaplan JE, Benson C, Holmes KH, et al. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 2009; 58:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30405/abstract/25\">",
"      Berlin OG, Conteas CN, Sowerby TM. Detection of Isospora in the stools of AIDS patients using a new rapid autofluorescence technique. AIDS 1996; 10:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30405/abstract/26\">",
"      Bialek R, Binder N, Dietz K, et al. Comparison of autofluorescence and iodine staining for detection of Isospora belli in feces. Am J Trop Med Hyg 2002; 67:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30405/abstract/27\">",
"      Ribes JA, Seabolt JP, Overman SB. Point prevalence of Cryptosporidium, Cyclospora, and Isospora infections in patients being evaluated for diarrhea. Am J Clin Pathol 2004; 122:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30405/abstract/28\">",
"      ten Hove RJ, van Lieshout L, Brienen EA, et al. Real-time polymerase chain reaction for detection of Isospora belli in stool samples. Diagn Microbiol Infect Dis 2008; 61:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30405/abstract/29\">",
"      Sun T, Ilardi CF, Asnis D, et al. Light and electron microscopic identification of Cyclospora species in the small intestine. Evidence of the presence of asexual life cycle in human host. Am J Clin Pathol 1996; 105:216.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5725 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-217.117.136.88-29CCF0041E-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_44_30405=[""].join("\n");
var outline_f29_44_30405=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H934994\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      TRANSMISSION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H934725\">",
"      Laboratory findings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H934087\">",
"      PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27632855\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H934994\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/21/38232?source=related_link\">",
"      Clinical features and diagnosis of malabsorption",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_44_30406="Thoracic aorta in giant cell arteritis";
var content_f29_44_30406=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F83912&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F83912&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Histopathology of thoracic aorta in giant cell arteritis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 333px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Low-power view of the thoracic aorta from a patient with giant cell arteritis. A patchy lymphocytic infiltrate (arrow) is present in various areas of the artery wall, typical of giant cell arteritis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Gene G Hunder, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_44_30406=[""].join("\n");
var outline_f29_44_30406=null;
var title_f29_44_30407="Overview of head and neck cancer";
var content_f29_44_30407=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of head and neck cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/44/30407/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/44/30407/contributors\">",
"     Kerstin M Stenson, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/44/30407/contributors\">",
"     Bruce E Brockstein, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/44/30407/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/44/30407/contributors\">",
"     Marshall R Posner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/44/30407/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/44/30407/contributors\">",
"     Michael E Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?29/44/30407/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 12, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Head and neck cancer describes a range of tumors that arise in the head and neck region, which includes the oral cavity, pharynx, larynx, nasal cavity, paranasal sinuses, thyroid, and salivary glands. The worldwide incidence of head and neck cancer exceeds half a million cases annually, ranking it as the fifth most common cancer worldwide [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30407/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An overview of head and neck cancer will be presented here. Cancers of the brain, eye, ear, scalp, skin, teeth, bones (including skull base), and muscles are not typically grouped with cancers of the head and neck, and many of these are discussed separately.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/17/36117?source=see_link\">",
"       \"Classification of gliomas\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/13/21720?source=see_link\">",
"       \"Paragangliomas of the head and neck\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/30/31209?source=see_link\">",
"       \"Treatment and prognosis of cutaneous squamous cell carcinoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/23/13690?source=see_link\">",
"       \"Treatment and prognosis of basal cell carcinoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/40/7815?source=see_link\">",
"       \"Chordoma and chondrosarcoma of the skull base\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/50/34602?source=see_link\">",
"       \"Head and neck sarcomas\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/36/10821?source=see_link\">",
"       \"Tracheal tumors\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H259549806\">",
"    <span class=\"h1\">",
"     HEAD AND NECK PATHOLOGY AND CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Head and neck cancers arise from a variety of locations and structures within the head and neck region. This region is divided into five sites by which cancers are classified (",
"    <a class=\"graphic graphic_figure graphicRef75396 \" href=\"UTD.htm?26/56/27525\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The oral cavity, which includes the lips, buccal mucosa, anterior tongue, floor of the mouth, hard palate, upper gingiva, lower gingiva, and retromolar trigone (",
"      <a class=\"graphic graphic_figure graphicRef54845 \" href=\"UTD.htm?3/27/3509\">",
"       figure 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The pharynx, which is divided into the nasopharynx, the oropharynx, and the hypopharynx (",
"      <a class=\"graphic graphic_figure graphicRef65105 \" href=\"UTD.htm?1/5/1113\">",
"       figure 3",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The nasopharynx, the narrow tubular passage behind the nasal cavity, is the upper part of the pharynx.",
"     </li>",
"     <li>",
"      The oropharynx, the middle part of the pharynx, includes the tonsillar area, the tongue base, the soft palate, and the posterior pharyngeal wall.",
"     </li>",
"     <li>",
"      The hypopharynx, which is the lower part of the pharynx, includes the pyriform sinuses, the posterior surface of the larynx (postcricoid area) and the inferoposterior, and inferolateral pharyngeal walls.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The larynx (voicebox) contains the vocal cords and epiglottis. It is divided into three anatomic regions: the supraglottic larynx, the glottic larynx (true vocal cords and the anterior and posterior commissures) and the subglottic larynx (",
"      <a class=\"graphic graphic_figure graphicRef58555 \" href=\"UTD.htm?22/27/22967\">",
"       figure 4",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef72411 \" href=\"UTD.htm?28/61/29654\">",
"       figure 5",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The nasal cavity and the paranasal sinuses, which include the maxillary, ethmoid, sphenoid, and frontal sinuses (",
"      <a class=\"graphic graphic_figure graphicRef78790 \" href=\"UTD.htm?20/18/20769\">",
"       figure 6",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The major salivary glands (parotid, submandibular, and sublingual (",
"      <a class=\"graphic graphic_figure graphicRef62744 \" href=\"UTD.htm?6/19/6449\">",
"       figure 7",
"      </a>",
"      )) and the minor salivary glands, which are located throughout the submucosa of the mouth and upper aerodigestive tract, including the oral cavity (especially the palate), paranasal sinuses, larynx, and pharynx.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The head and neck region contains a wide diversity of structures and cell types, including squamous mucosal epithelium, glandular structures (salivary, thyroid, and parathyroid glands), sinuses, bone, cartilage, muscle, nerves, vascular channels, and lymphoid structures. Accordingly, head and neck cancers encompass a wide array of histologies. The World Health Organization's classification of tumors of the nasal cavity and paranasal sinuses encompasses over 50 tumor types for this site alone [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30407/abstract/2\">",
"     2",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    The vast majority of head and neck cancers arise in the mucosa of the upper aerodigestive tract and are predominantly squamous cell in origin. Thus, head and neck squamous cell carcinoma is the focus of this review and others. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/4/12362?source=see_link\">",
"     \"Pathology of head and neck neoplasms\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/59/43959?source=see_link\">",
"     \"Overview of treatment for head and neck squamous cell cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H259549813\">",
"    <span class=\"h1\">",
"     HEAD AND NECK SQUAMOUS CELL CARCINOMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Head and neck squamous cell carcinomas share considerably in etiology, diagnosis, and treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h2\">",
"     Epidemiology and etiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a large geographic variability in the incidence and primary site of head and neck cancers, which likely reflects the prevalence of risk factors, such as tobacco and alcohol consumption, and ethnic and genetic differences among populations. Although the highest rates of head and neck cancer have been in elderly males, the incidence has been increasing in females as more women use tobacco and in young non-smokers as human papillomavirus (HPV) plays an increasingly prominent role as an etiologic factor in the development of oropharyngeal head and neck cancer.",
"   </p>",
"   <p>",
"    Tobacco (smoked and smokeless) is the most important known risk factor for the development of head and neck cancer. There is some evidence for a genetic predisposition to the carcinogenic effects of tobacco. In addition, tobacco and alcohol consumption appear to have a synergistic effect. The repeated exposure of the mucosa of the upper aerodigestive tract to the carcinogenic effects of tobacco and alcohol appears to cause multiple primary and secondary tumors in this &ldquo;condemned mucosa&rdquo;, a phenomenon described as \"field cancerization\".",
"   </p>",
"   <p>",
"    HPV infection has been established as a causative agent for head and neck cancer. HPV associated head and neck cancers occur primarily in the oropharynx (tonsils and base of tongue), account for the changing epidemiology of oropharyngeal squamous cell carcinoma, and define a subset of patients with improved clinical behavior and treatment outcome. However, the use of HPV status in clinical decision-making remains investigational at this time. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/55/887?source=see_link\">",
"     \"Human papillomavirus associated head and neck cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other head and neck cancer risk factors include betel nut chewing, radiation exposure, vitamin deficiencies, periodontal disease, and occupational exposures. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/6/20583?source=see_link\">",
"     \"Epidemiology and risk factors for head and neck cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/58/15270?source=see_link\">",
"     \"Second primary malignancies in patients with head and neck cancers\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2756349\">",
"    <span class=\"h2\">",
"     Pathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several noninvasive lesions, such as leukoplakia, erythroplakia, and leukoerythroplakia, may develop within the squamous mucosa that lines many of the structures of the head and neck. These clonally independent premalignant lesions transform into invasive carcinoma, although each at different rates. The process of transformation is thought to progress in a multistep fashion through hyperplasia and dysplasia to in situ and invasive carcinoma.",
"   </p>",
"   <p>",
"    Multistep carcinogenesis describes the series of events (initiation, promotion, and progression) that leads to the development of invasive carcinoma. Although the specific sequence of genetic events has not been defined, numerous molecular mutations and genetic alterations have been found in both carcinomas and premalignant tissue. Consequently, once a premalignant lesion is recognized, avoidance of further carcinogenic exposure",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    chemoprevention may reverse or inhibit carcinogenic progression. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/0/34825?source=see_link\">",
"     \"Head and neck squamous cell carcinogenesis: Molecular and genetic alterations\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/36/19017?source=see_link\">",
"     \"Chemoprevention in oral dysplasia and head and neck cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The histologic features of head and neck cancer, as well as its variants, verrucous carcinoma, basaloid squamous cell carcinoma, and spindle cell carcinoma, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/4/12362?source=see_link\">",
"     \"Pathology of head and neck neoplasms\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2756465\">",
"    <span class=\"h2\">",
"     Diagnosis and staging",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical presentation of head and neck cancer varies with the primary site. Common symptoms include nonhealing mucosal ulcers, pain including sore throat and referred otalgia, hoarseness, dysphagia, chronic cough, and neck mass. The possibility of a second primary malignancy should be kept in mind during the diagnostic evaluation for head and neck cancer.",
"   </p>",
"   <p>",
"    Physical examination should include careful assessment of the nasal cavity and oral cavity with visual examination and palpation of mucous membranes, the floor of the mouth, the anterior two-thirds of the tongue, palate, tonsillar fossae, buccal and gingival mucosa, and posterior pharyngeal wall. Visualization of lesions outside the mouth is best accomplished by mirror examination",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the use of a flexible fiberoptic endoscope with the goal of examining all of the mucosa in the nasoposterior orohypo-pharynx and larynx. Aside from mucosal irregularities, other abnormalities that should be specifically searched for are vocal cord mobility impairment, pooling of secretions, asymmetries, and bleeding.",
"   </p>",
"   <p>",
"    Imaging studies, including computed tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography (PET), may augment the physical exam and evaluation of patients with head and neck cancer, particularly for assessing the degree of local invasion, involvement of regional lymph nodes, and presence of distant metastases and second primary malignancies. The most common metastatic sites are the lungs, liver, and bone, while the most common sites of second primary malignancies are the head and neck, followed by the lungs and esophagus. Ideally, imaging should take place prior to biopsy, which may distort anatomy and create a false positive finding on PET scanning.",
"   </p>",
"   <p>",
"    An exam under anesthesia should be performed to best characterize the extent of the tumor, to look for synchronous primary tumors, and to take biopsies. An esophagoscopy and bronchoscopy may be performed; however, their yield is relatively low for synchronous tumors and their routine use is debated, especially if other imaging studies will be obtained.",
"   </p>",
"   <p>",
"    A more detailed discussion of the diagnostic evaluation of head and neck cancer, including additional tests used in certain circumstances, such as fine needle biopsy of neck nodes in the patient without an identifiable primary and assessment of HPV status for an oropharyngeal primary, are discussed separately.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/43/36537?source=see_link\">",
"       \"Overview of the diagnosis and staging of head and neck cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/55/887?source=see_link\">",
"       \"Human papillomavirus associated head and neck cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/58/15270?source=see_link\">",
"       \"Second primary malignancies in patients with head and neck cancers\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The tumor node metastases (TNM) staging system of the American Joint Committee on Cancer (AJCC) and the International Union for Cancer Control (UICC) is used to classify cancers of the head and neck [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30407/abstract/3\">",
"     3",
"    </a>",
"    ]. The T classifications indicate the extent of the primary tumor and are site specific; there is considerable overlap in the cervical node (N) classifications.",
"   </p>",
"   <p>",
"    TNM staging tables are separated according to head and neck site.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Oral cavity (",
"      <a class=\"graphic graphic_table graphicRef70195 \" href=\"UTD.htm?38/12/39117\">",
"       table 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Nasopharynx (",
"      <a class=\"graphic graphic_table graphicRef57392 \" href=\"UTD.htm?34/8/34957\">",
"       table 2",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Oropharynx (",
"      <a class=\"graphic graphic_table graphicRef81775 \" href=\"UTD.htm?35/55/36733\">",
"       table 3",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Hypopharynx (",
"      <a class=\"graphic graphic_table graphicRef55865 \" href=\"UTD.htm?36/42/37549\">",
"       table 4",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Larynx (",
"      <a class=\"graphic graphic_table graphicRef66619 \" href=\"UTD.htm?22/14/22766\">",
"       table 5",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Nasal cavity and paranasal sinuses (",
"      <a class=\"graphic graphic_table graphicRef82601 \" href=\"UTD.htm?9/42/9902\">",
"       table 6",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Salivary glands (",
"      <a class=\"graphic graphic_table graphicRef61042 \" href=\"UTD.htm?34/52/35661\">",
"       table 7",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Treatment, rehabilitation, and prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment for head and neck cancer is complex due to the variety of tumor subsites, the anatomic constraints of the head and neck region, and the importance of maintaining organ function. A multidisciplinary approach, including surgeons, medical oncologists, and radiation oncologists, as well as dentists, dieticians, and rehabilitation therapists, is generally required for treatment planning and managing patients with head and neck cancer.",
"   </p>",
"   <p>",
"    An overview of the treatment for head and neck cancer is presented separately, as are discussions of the management of specific sites of involvement:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/59/43959?source=see_link\">",
"       \"Overview of treatment for head and neck squamous cell cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/29/32217?source=see_link\">",
"       \"Treatment of early (stage I and II) head and neck cancer: The oral cavity\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/18/1321?source=see_link\">",
"       \"Treatment of locoregionally advanced (stage III and IV) head and neck cancer: The oral cavity\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/6/3174?source=see_link\">",
"       \"Treatment of early (stage I and II) head and neck cancer: The oropharynx\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/55/15224?source=see_link\">",
"       \"Treatment of locoregionally advanced (stage III and IV) head and neck cancer: The oropharynx\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/4/20552?source=see_link\">",
"       \"Treatment of early (stage I and II) head and neck cancer: The larynx\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/27/34232?source=see_link\">",
"       \"Treatment of early (stage I and II) head and neck cancer: The hypopharynx\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/45/41689?source=see_link\">",
"       \"Treatment of locoregionally advanced (stage III and IV) head and neck cancer: The larynx and hypopharynx\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/21/9559?source=see_link\">",
"       \"Treatment of locally recurrent head and neck cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/25/40345?source=see_link\">",
"       \"Treatment of metastatic and recurrent head and neck cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/54/16231?source=see_link\">",
"       \"Alaryngeal speech rehabilitation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/51/31545?source=see_link\">",
"       \"Speech and swallowing rehabilitation of the patient with head and neck cancer\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H259550522\">",
"    <span class=\"h1\">",
"     SPECIAL SITES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Head and neck cancers occurring at certain sites, including the nasopharynx, nasal vestibule and cavity, paranasal sinuses, and salivary glands, have different histology, epidemiology, and biology than typical head and neck squamous cell carcinomas, and have particular treatment considerations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H259550529\">",
"    <span class=\"h2\">",
"     Nasopharyngeal cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nasopharyngeal cancer differs from other head and neck cancers in its epidemiology, pathology, natural history, and treatment, in particular due to a strong etiologic link to Epstein-Barr virus (EBV). Radiation therapy (RT) is the mainstay of treatment for nasopharyngeal cancer, with chemotherapy integrated into therapy for patients with intermediate and advanced stage disease. The five-year overall survival for nasopharynx cancer ranges from 90 percent for stage I disease to 50 percent for stage IV.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/36/26184?source=see_link\">",
"       \"Epidemiology, etiology, and diagnosis of nasopharyngeal carcinoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/3/8250?source=see_link\">",
"       \"Treatment of early and locoregionally advanced nasopharyngeal carcinoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/57/16280?source=see_link\">",
"       \"Treatment of recurrent and metastatic nasopharyngeal carcinoma\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H259550536\">",
"    <span class=\"h2\">",
"     Nasal vestibule and nasal cavity cancers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tumors of the nasal vestibule are essentially skin cancers and are treated primarily with RT or surgery. Cancers of the nasal cavity are similar to those that occur in the paranasal sinuses and have a wide variety of histologies. Both early and moderately advanced tumors of the nasal cavity are treated with surgical resection and postoperative radiation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/45/13013?source=see_link\">",
"     \"Cancer of the nasal vestibule\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/18/39206?source=see_link\">",
"     \"Tumors of the nasal cavity\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/44/23241?source=see_link\">",
"     \"Paranasal sinus cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H259550543\">",
"    <span class=\"h2\">",
"     Paranasal sinus cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Paranasal sinus cancers encompass multiple histologies, with squamous cell carcinoma and adenocarcinoma being the predominant. Aggressive surgical resection remains the mainstay of treatment, but multimodality approaches with surgery, RT, and chemotherapy may be appropriate for certain histologies and for advanced stage cancers. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/44/23241?source=see_link\">",
"     \"Paranasal sinus cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H259550550\">",
"    <span class=\"h2\">",
"     Salivary glands cancers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Salivary gland tumors represent a wide array of benign and malignant histologies that occur in salivary gland tissue throughout the head and neck. Surgical extirpation of the salivary gland is important in diagnosis and treatment. Patients with benign and low-grade tumors are typically treated with surgery alone, whereas patients with high-grade carcinomas and other high-risk features are usually treated with surgery and postoperative RT.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/44/9927?source=see_link\">",
"       \"Salivary gland tumors: Epidemiology, diagnosis, evaluation, and staging\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/41/28313?source=see_link\">",
"       \"Salivary gland tumors: Treatment of locoregional disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/34/11816?source=see_link\">",
"       \"Malignant salivary gland tumors: Treatment of recurrent and metastatic disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H259550557\">",
"    <span class=\"h2\">",
"     Cancer of unknown primary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Squamous cell carcinoma of occult (unknown) primary that involves the upper cervical lymph nodes most likely originated from a head and neck primary, while squamous cell carcinomas involving the lower neck may represent metastases from a head and neck, esophagus, lung, or genitourinary tract primary. Many unknown primary cancers in the upper cervical lymph nodes may be identified as oropharyngeal by the presence of human papillomavirus (HPV) in the tumors. Patients without obvious sites of distant metastatic disease (eg, lung, liver, or bone) are treated with definitive therapy for locoregional head and neck cancer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/28/19911?source=see_link\">",
"     \"Head and neck squamous cell carcinoma of unknown primary\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2756209\">",
"    <span class=\"h2\">",
"     Thyroid and parathyroid gland cancers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thyroid gland malignancies, including papillary, follicular, anaplastic, and medullary, and parathyroid carcinomas, are discussed separately.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/17/44313?source=see_link\">",
"       \"Overview of the management of differentiated thyroid cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/10/23721?source=see_link\">",
"       \"Anaplastic thyroid cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/21/9560?source=see_link\">",
"       \"Medullary thyroid cancer: Clinical manifestations, diagnosis, and staging\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/23/38263?source=see_link\">",
"       \"Medullary thyroid cancer: Treatment and prognosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/23/13688?source=see_link\">",
"       \"Parathyroid carcinoma\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2756217\">",
"    <span class=\"h2\">",
"     Head and neck sarcomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Head and neck sarcomas are relatively uncommon, accounting for less than two percent of all malignancies and about 10 percent of sarcomas. Osteosarcoma, angiosarcoma, malignant fibrous histiocytoma, and fibrosarcoma are the most common head and neck sarcomas in adults, and rhabdomyosarcoma is the most common in children. Certain sarcomas are related to specific risk factors, as with Li Fraumeni syndrome and osteosarcoma, lymphedema and angiosarcoma, and radiation exposure and multiple sarcoma types. Surgical resection is the mainstay of therapy, but because of their proximity to vital structures and the relatively small space of the head and neck region, surgical removal of head and neck sarcomas often cannot achieve the ideal \"wide\" resection margins that are preferred in other anatomic sites. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/50/34602?source=see_link\">",
"     \"Head and neck sarcomas\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2757199\">",
"    <span class=\"h1\">",
"     POSTTREATMENT SURVEILLANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regular posttreatment follow-up has become an essential part of the care of patients after potentially curative treatment of head and neck cancer. Patients should be educated about possible signs and symptoms of tumor recurrence, including hoarseness, pain, dysphagia, bleeding, and enlarged lymph nodes.",
"   </p>",
"   <p>",
"    In general, the intensity of follow-up is greatest in the first two to four years, since approximately 80 to 90 percent of all recurrences after curative intent treatment will occur within this timeframe. Continued follow-up for tumor recurrence is generally suggested for salivary gland and other lower grade tumors that may recur late. Additionally, follow-up beyond five years is recommended for all squamous head and neck patients, as the risk of new primary head and neck cancers is high, and late treatment related sequelae are common. Because of the higher risk of recurrence and second primary malignancy in those who continue tobacco use, many schedule more frequent surveillance visits for these patients and continue for longer duration.",
"   </p>",
"   <p>",
"    Posttreatment surveillance of head and neck cancer, including screening for treatment-related complications (eg, hypothyroidism) and smoking cessation counseling, is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/58/36775?source=see_link\">",
"     \"Posttreatment surveillance of squamous carcinoma of the head and neck\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?8/20/8515?source=see_link\">",
"       \"Patient information: Throat cancer (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2757206\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Head and neck cancer describes a range of tumors that arise in the head and neck region, which includes the oral cavity, pharynx, larynx, nasal cavity, paranasal sinuses, and salivary glands.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Head and neck cancers are predominantly squamous cell carcinomas, which arise through multistep carcinogenesis from premalignant lesions. Tobacco and alcohol are the major etiologic factors, although human papillomavirus and Epstein-Barr virus are also important factors, particularly for cancers of the oropharynx and nasopharynx, respectively. (See",
"      <a class=\"local\" href=\"#H259549813\">",
"       'Head and neck squamous cell carcinoma'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The possibility of a second primary malignancy should be kept in mind during the diagnostic evaluation of head and neck cancers, as well as during the posttreatment surveillance phase. (See",
"      <a class=\"local\" href=\"#H2756465\">",
"       'Diagnosis and staging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Head and neck cancers are generally treated with a combination of surgery, radiation therapy, and chemotherapy. A multidisciplinary approach, including surgeons, medical oncologists, and radiation oncologists, as well as dentists, dieticians, and rehabilitation therapists, is generally required for treatment planning and managing patients with head and neck cancer. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/59/43959?source=see_link\">",
"       \"Overview of treatment for head and neck squamous cell cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Regular posttreatment follow-up is an essential part of the care of patients after curative intent treatment of head and neck cancer. (See",
"      <a class=\"local\" href=\"#H2757199\">",
"       'Posttreatment surveillance'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30407/abstract/1\">",
"      Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55:74.",
"     </a>",
"    </li>",
"    <li>",
"     WHO histological classification of tumors of the nasal cavity and paranasal sinuses. In: World Health Organization Classification of Tumors. Pathology and Genetics of Head and Neck Tumours, Barnes, L,  Eveson, JW, Reichart, P, Sidransky, D (Eds), IARC Press, Lyon 2005. p.10.",
"    </li>",
"    <li>",
"     American Joint Committee on Cancer Staging Manual, 7th, Edge SB, Byrd DR, Compton CC, et al (Eds), Springer, New York 2010.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3398 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-C5FDE4D645-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_44_30407=[""].join("\n");
var outline_f29_44_30407=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H2757206\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H259549806\">",
"      HEAD AND NECK PATHOLOGY AND CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H259549813\">",
"      HEAD AND NECK SQUAMOUS CELL CARCINOMA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      Epidemiology and etiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2756349\">",
"      Pathology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2756465\">",
"      Diagnosis and staging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Treatment, rehabilitation, and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H259550522\">",
"      SPECIAL SITES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H259550529\">",
"      Nasopharyngeal cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H259550536\">",
"      Nasal vestibule and nasal cavity cancers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H259550543\">",
"      Paranasal sinus cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H259550550\">",
"      Salivary glands cancers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H259550557\">",
"      Cancer of unknown primary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2756209\">",
"      Thyroid and parathyroid gland cancers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2756217\">",
"      Head and neck sarcomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2757199\">",
"      POSTTREATMENT SURVEILLANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2757206\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/3398\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/3398|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/56/27525\" title=\"figure 1\">",
"      Anatomy of the head and neck",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?3/27/3509\" title=\"figure 2\">",
"      Anatomy of the oral cavity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?1/5/1113\" title=\"figure 3\">",
"      Subdivisions pharynx",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?22/27/22967\" title=\"figure 4\">",
"      Laryngeal anatomy coronal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/61/29654\" title=\"figure 5\">",
"      Laryngeal anatomy sagittal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?20/18/20769\" title=\"figure 6\">",
"      Paranasal sinus anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/19/6449\" title=\"figure 7\">",
"      Salivary gland anatomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/3398|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/12/39117\" title=\"table 1\">",
"      TNM stage oral cavity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?34/8/34957\" title=\"table 2\">",
"      TNM stage nasopharynx",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?35/55/36733\" title=\"table 3\">",
"      TNM stage oropharynx",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/42/37549\" title=\"table 4\">",
"      TNM stage hypopharynx",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?22/14/22766\" title=\"table 5\">",
"      TNM stage larynx",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/42/9902\" title=\"table 6\">",
"      TNM stage sinonasal sites",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?34/52/35661\" title=\"table 7\">",
"      TNM stage salivary glands",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/54/16231?source=related_link\">",
"      Alaryngeal speech rehabilitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/10/23721?source=related_link\">",
"      Anaplastic thyroid cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/45/13013?source=related_link\">",
"      Cancer of the nasal vestibule",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/36/19017?source=related_link\">",
"      Chemoprevention in oral dysplasia and head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/40/7815?source=related_link\">",
"      Chordoma and chondrosarcoma of the skull base",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/17/36117?source=related_link\">",
"      Classification of gliomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/6/20583?source=related_link\">",
"      Epidemiology and risk factors for head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/36/26184?source=related_link\">",
"      Epidemiology, etiology, and diagnosis of nasopharyngeal carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/50/34602?source=related_link\">",
"      Head and neck sarcomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/0/34825?source=related_link\">",
"      Head and neck squamous cell carcinogenesis: Molecular and genetic alterations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/28/19911?source=related_link\">",
"      Head and neck squamous cell carcinoma of unknown primary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/55/887?source=related_link\">",
"      Human papillomavirus associated head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/34/11816?source=related_link\">",
"      Malignant salivary gland tumors: Treatment of recurrent and metastatic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/21/9560?source=related_link\">",
"      Medullary thyroid cancer: Clinical manifestations, diagnosis, and staging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/23/38263?source=related_link\">",
"      Medullary thyroid cancer: Treatment and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/43/36537?source=related_link\">",
"      Overview of the diagnosis and staging of head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/17/44313?source=related_link\">",
"      Overview of the management of differentiated thyroid cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/59/43959?source=related_link\">",
"      Overview of treatment for head and neck squamous cell cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/13/21720?source=related_link\">",
"      Paragangliomas of the head and neck",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/44/23241?source=related_link\">",
"      Paranasal sinus cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/23/13688?source=related_link\">",
"      Parathyroid carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/4/12362?source=related_link\">",
"      Pathology of head and neck neoplasms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?8/20/8515?source=related_link\">",
"      Patient information: Throat cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/58/36775?source=related_link\">",
"      Posttreatment surveillance of squamous carcinoma of the head and neck",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/44/9927?source=related_link\">",
"      Salivary gland tumors: Epidemiology, diagnosis, evaluation, and staging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/41/28313?source=related_link\">",
"      Salivary gland tumors: Treatment of locoregional disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/58/15270?source=related_link\">",
"      Second primary malignancies in patients with head and neck cancers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/51/31545?source=related_link\">",
"      Speech and swallowing rehabilitation of the patient with head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/36/10821?source=related_link\">",
"      Tracheal tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/23/13690?source=related_link\">",
"      Treatment and prognosis of basal cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/30/31209?source=related_link\">",
"      Treatment and prognosis of cutaneous squamous cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/27/34232?source=related_link\">",
"      Treatment of early (stage I and II) head and neck cancer: The hypopharynx",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/4/20552?source=related_link\">",
"      Treatment of early (stage I and II) head and neck cancer: The larynx",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/29/32217?source=related_link\">",
"      Treatment of early (stage I and II) head and neck cancer: The oral cavity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/6/3174?source=related_link\">",
"      Treatment of early (stage I and II) head and neck cancer: The oropharynx",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/3/8250?source=related_link\">",
"      Treatment of early and locoregionally advanced nasopharyngeal carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/21/9559?source=related_link\">",
"      Treatment of locally recurrent head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/45/41689?source=related_link\">",
"      Treatment of locoregionally advanced (stage III and IV) head and neck cancer: The larynx and hypopharynx",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/18/1321?source=related_link\">",
"      Treatment of locoregionally advanced (stage III and IV) head and neck cancer: The oral cavity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/55/15224?source=related_link\">",
"      Treatment of locoregionally advanced (stage III and IV) head and neck cancer: The oropharynx",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/25/40345?source=related_link\">",
"      Treatment of metastatic and recurrent head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/57/16280?source=related_link\">",
"      Treatment of recurrent and metastatic nasopharyngeal carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/18/39206?source=related_link\">",
"      Tumors of the nasal cavity",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_44_30408="Interventional radiology in management of gynecological disorders";
var content_f29_44_30408=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Interventional radiology in management of gynecological disorders",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/44/30408/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/44/30408/contributors\">",
"     Ducksoo Kim, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/44/30408/contributors\">",
"     Stephen D Baer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/44/30408/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/44/30408/contributors\">",
"     Deborah Levine, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/44/30408/contributors\">",
"     Robert L Barbieri, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/44/30408/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/44/30408/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?29/44/30408/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 19, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Percutaneous transcatheter interventional procedures are increasingly being employed in the management of obstetric and gynecological disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30408/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. This technology offers a minimally invasive and potentially cost effective alternative for management of several common obstetrical and gynecological problems. It is most commonly used for managing fibroids and postpartum hemorrhage. However, these procedures have not been evaluated against other treatment modalities in large randomized trials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TRANSCATHETER EMBOLIZATION PROCEDURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Percutaneous transcatheter embolization (PTE) procedures are typically performed under fluoroscopic guidance in the radiology suite. Intravenous conscious sedation and narcotics, local anesthetics, nonopioid analgesics, or nonsteroidal antiinflammatory agents are administered for management of anxiety and pain. Many radiologists give intravenous broad spectrum antibiotic prophylaxis (eg, cephalothin 1 to 2 g plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    1.5 g,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"     levofloxacin",
"    </a>",
"    500 mg or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    80 mg plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    phosphate 900 mg) to reduce the risk of infection, although randomized controlled clinical trials have never validated the use of antibiotics in this setting for reduction of postoperative morbidity [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30408/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Seldinger technique is used to introduce a catheter into the femoral artery (",
"    <a class=\"graphic graphic_figure graphicRef62884 \" href=\"UTD.htm?22/45/23263\">",
"     figure 1A",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30408/abstract/5\">",
"     5",
"    </a>",
"    ]. The catheter is then advanced into the hypogastric or uterine artery, depending upon the indication for the procedure. After subselective catheterization, diagnostic angiography of the artery is obtained to confirm proper position, look for extravasation suggestive of acute bleeding, and evaluate for abnormal vascularity associated with chronic bleeding. Transcatheter embolization of one or more arteries can then be performed (",
"    <a class=\"graphic graphic_figure graphicRef62884 graphicRef74642 \" href=\"UTD.htm?34/16/35074\">",
"     figure 1A-B",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Tiny particles or microspheres (polyvinyl alcohol particles, 500 to 700",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    700 to 900 microns in size or tris-acryl gelatin microspheres, 500 to 700",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    700 to 900 microns in size) (",
"    <a class=\"graphic graphic_picture graphicRef57559 \" href=\"UTD.htm?0/1/21\">",
"     picture 1",
"    </a>",
"    ) are used to embolize hypervascular lesions, such as leiomyomas or adenomyosis, associated with multiple large feeding vessels. However, particulate embolic agents should be avoided when iliac or uterine or ovarian arteriovenous",
"    <span class=\"nowrap\">",
"     malformation/fistula",
"    </span>",
"    are targeted because inadvertent pulmonary embolization may result. Gelfoam, coils, and glue are more effective than microspheres for embolization of large arteries associated with acute obstetrical hemorrhage, arteriovenous malformation, or some fistula.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     UTERINE FIBROIDS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Uterine fibroid embolization (UFE) is based upon the hypothesis that reduction of myometrial arterial blood flow will result in infarction of fibroids and control symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30408/abstract/6\">",
"     6",
"    </a>",
"    ]. It is an option for symptomatic premenopausal women who wish to retain their uterus, escape side effects associated with prolonged medical therapy, and avoid surgical treatment (eg, hysterectomy, myomectomy) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30408/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. UFE is rarely indicated in postmenopausal women [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30408/abstract/9\">",
"     9",
"    </a>",
"    ]. Other relative contraindications to UFE include current use of GnRH analogs, submucosal fibroids, and, possibly, plans for future pregnancy. The procedure is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/60/22473?source=see_link\">",
"     \"Uterine leiomyoma (fibroid) embolization\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ADENOMYOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adenomyosis refers to the presence of endometrial glands and stroma within the uterine musculature (uterine adenomyomatosis). Approximately 50 percent of affected women have co-existent fibroids and the symptoms of the two conditions often overlap [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30408/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. As a result, uterine artery embolizations (UAE) have been performed in many women with both fibroids and adenomyosis without a clear understanding of what proportion of the patient's symptoms were related to one condition or the other. Nevertheless, UAE has generally led to relief of symptoms (eg, bleeding, pain) in these patients and follow-up imaging has documented morphologic regression (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef53441 graphicRef66196 \" href=\"UTD.htm?26/57/27542\">",
"     image 1A-B",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30408/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/35/27191?source=see_link\">",
"     \"Uterine adenomyosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/17/6426?source=see_link\">",
"     \"Epidemiology, clinical manifestations, diagnosis, and natural history of uterine leiomyomas (fibroids)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These observations led to investigation of UAE for treatment of symptomatic adenomyosis in women without coexistent fibroids. Over 90 percent of patients had resolution or significant reduction of dysmenorrhea and menorrhagia over short-term follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30408/abstract/12-15\">",
"     12-15",
"    </a>",
"    ]. However, limited data suggest these benefits may not be durable: the frequency of recurrent adenomyosis after UAE (up to 44 percent) was greater than the reported frequency of recurrent fibroids after UFE (10 to 15 percent).",
"   </p>",
"   <p>",
"    One study indicated that UAE for adenomyosis is effective in the management of symptomatic adenomyosis without coexisting fibroids and has an acceptable long-term success rate (57.4 percent) with mean follow-up of 4.9 years on 54 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30408/abstract/16\">",
"     16",
"    </a>",
"    ]. UAE should be considered an alternative to surgical option for patients with symptomatic adenomyosis. There was immediate treatment failure (7.4 percent), and relapses (35.2 percent) and 9.2 percent of patients underwent hysterectomy because of symptom recurrence.",
"   </p>",
"   <p>",
"    UAE for management of adenomyosis related symptoms is a nonsurgical option for patients who did not respond to other therapies and want to avoid hysterectomy, the only definitive therapy. While the preliminary experiences presented in literature appear encouraging, larger prospective studies are needed to establish the safety and efficacy of this procedure for patients with adenomyosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     ARTERIOVENOUS MALFORMATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Arteriovenous malformation (AVM) of the uterus is rare, but can be a life-threatening condition [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30408/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. This lesion has been variably described as a cirsoid aneurysm, arteriovenous aneurysm, arteriovenous fistula, and cavernous hemangioma. Approximately one-half are congenital and present with sudden uterine bleeding without any prior history of surgical instrumentation (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef54928 \" href=\"UTD.htm?28/57/29599\">",
"     image 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30408/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. By comparison, acquired AVMs occur after uterine instrumentation (eg, curettage) or associated with disorders such as gestational trophoblastic disease, endometrial adenocarcinoma, or maternal diethylstilbestrol exposure.",
"   </p>",
"   <p>",
"    The most prominent clinical manifestation is a history of refractory uterine bleeding during the reproductive years. It is not unusual for patients with AVMs to present with severe episodes of bleeding, hypotension, and anemia, which tend to be intractable to medical and hormonal treatment. The bleeding presumably occurs when the vessels erode through or abut the endometrium, becoming exposed or shedding.",
"   </p>",
"   <p>",
"    If an AVM is suspected, imaging studies should be performed before any potentially hazardous diagnostic or therapeutic instrumentation is done [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30408/abstract/19\">",
"     19",
"    </a>",
"    ]. Options include Doppler ultrasound and MR imaging with angiography; consultation with a radiologist is suggested [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30408/abstract/20,21\">",
"     20,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Initial treatment consists of hemodynamic stabilization with intrauterine Foley bulb for tamponade,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32549?source=see_link\">",
"     methylergonovine",
"    </a>",
"    (0.2 mg intramuscularly), and intravenous estrogen. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/2/11305?source=see_link\">",
"     \"Managing an episode of severe or prolonged uterine bleeding\"",
"    </a>",
"    .) Hysterectomy is the definitive therapy, but if the patient desires preservation of her uterus, then UAE appears to be an effective option (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef76350 graphicRef55273 graphicRef69077 graphicRef76792 graphicRef57864 \" href=\"UTD.htm?37/26/38314\">",
"     image 3A-E",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30408/abstract/19,22-24\">",
"     19,22-24",
"    </a>",
"    ]. Laparoscopic bipolar coagulation of uterine vessels has also been successful in case reports [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30408/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    More than 85 cases of embolization of uterine AVM have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30408/abstract/17,22-24\">",
"     17,22-24",
"    </a>",
"    ]. Overall, the embolization procedure was effective in controlling bleeding in 96 percent of patients. Complications occurred in 4 percent, and included transient",
"    <span class=\"nowrap\">",
"     paresthesia/paralysis",
"    </span>",
"    of the left arm, difficulty inserting a second coil, and persistence of blue coloration of the cervix and vaginal wall due to ischemic changes [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30408/abstract/19\">",
"     19",
"    </a>",
"    ]. Restoration of normal menstrual cycles and successful pregnancies have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30408/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. Thus, embolization for uterine AVM can be an effective alternative treatment to hysterectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30408/abstract/28,29\">",
"     28,29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PELVIC CONGESTION SYNDROME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Up to 15 percent of premenopausal women have pelvic varicosities and venous stasis, as demonstrated by pelvic venography (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef73402 \" href=\"UTD.htm?15/31/15857\">",
"     image 4",
"    </a>",
"    ), but few experience symptoms. Pelvic congestion syndrome is the term used to describe the subset of these women who have pain and other symptoms in the uterus, ovaries, and vulva that cannot be attributed to any other cause. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/26/41384?source=see_link\">",
"     \"Causes of chronic pelvic pain in women\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Gynecologic examinations are frequently normal in these women. Routine imaging studies may miss ovarian varicosities since the studies are performed in supine position when the veins are flaccid. Ovarian venography may be considered to confirm the suspected diagnosis since it can be performed in the upright or semi-upright position with a tilting table.",
"   </p>",
"   <p>",
"    Venography involves catheterization of the right and left ovarian veins via a percutaneous femoral or jugular approach. Ovarian venograms in patients with pelvic congestion syndrome usually demonstrate abnormally dilated ovarian veins (&gt;10 mm in diameter), reflux causing congestion of the ovarian venous plexus, uterine venous engorgement, and filling of pelvic veins across the midline [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30408/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    After these diagnostic studies, a therapeutic procedure may be done by embolizing the ovarian vein with coils or a sclerosing agent (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef52370 graphicRef66177 \" href=\"UTD.htm?17/58/18339\">",
"     image 5A-B",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/18/28969?source=see_link&amp;anchor=H15#H15\">",
"     \"Treatment of chronic pelvic pain in women\", section on 'Pelvic congestion syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     FALLOPIAN TUBE RECANALIZATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tubal abnormalities account for a significant proportion of female infertility. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/18/3367?source=see_link\">",
"     \"Causes of female infertility\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/61/40921?source=see_link\">",
"     \"Evaluation of female infertility\"",
"    </a>",
"    .) Selective salpingography is a diagnostic procedure in which a catheter is placed in the tubal ostium and contrast media is injected directly into the fallopian tube [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30408/abstract/31-33\">",
"     31-33",
"    </a>",
"    ]. This technique helps to differentiate spasm from true obstruction and to clarify discordant findings from other tests. If persistent proximal tubal occlusion is documented, fallopian tube recanalization may be attempted using a microcatheter and guidewire system to recanalize the occlusion (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef68677 graphicRef63310 graphicRef76139 \" href=\"UTD.htm?41/22/42344\">",
"     image 6A-C",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    There are no randomized controlled trials evaluating this technique. In observational studies, pregnancy rates after the procedure are difficult to compare because of the multifactorial causes of infertility, but are reported to range from 9 to 56 percent (average 30 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30408/abstract/31-37\">",
"     31-37",
"    </a>",
"    ]. The optimum treatment for woman with tubal occlusion is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/5/14425?source=see_link&amp;anchor=H16#H16\">",
"     \"Overview of treatment of female infertility\", section on 'Procedures for improving tubal patency'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Complications of fallopian tube recanalization are uncommon and include tubal perforation (2 percent), ectopic pregnancy (3 to 9 percent) percent, pelvic infection (1 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30408/abstract/31-38\">",
"     31-38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ovarian exposure to radiation is approximately 1 rad (10 mGy), a dose that is considered within acceptable limits for women of reproductive age [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30408/abstract/37\">",
"     37",
"    </a>",
"    ]. The procedure is performed in the follicular phase of the ovulatory cycle to try to ensure that the woman is not pregnant [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30408/abstract/37\">",
"     37",
"    </a>",
"    ]. Although selective salpingography and tubal catheterization under fluoroscopic guidance has been endorsed by professional societies such as the American Fertility Society in 1993 and Royal College of Obstetricians and Gynaecologists in 1998, it is still only offered by a few tertiary reproductive medicine units [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30408/abstract/38\">",
"     38",
"    </a>",
"    ]. The reasons for this might be due to concern about the technical difficulty of the procedure and the consequences of irradiation of ovaries in premenopausal women, as well as being a method relevant only to infertile women with proximal tubal blockage, a relatively infrequent presentation.",
"   </p>",
"   <p>",
"    A wider role for selective salpingography and tubal catheterization in the management of infertility has been advocated since the technique is relatively simple, requires only modest equipment, and appears to be effective [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30408/abstract/39\">",
"     39",
"    </a>",
"    ]. Its use may reduce the utilization of more expensive diagnostic and therapeutic interventions. Falloposcopic tuboplasty has been reported as an alternative to fluoroscopic fallopian tube recanalization [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30408/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     TUMOR-RELATED BLEEDING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bleeding from gynecologic malignancies is initially managed by conservative measures, such as vaginal packing, transfusion, or",
"    <span class=\"nowrap\">",
"     radiation/chemotherapy.",
"    </span>",
"    If these conservative treatments fail or bleeding worsens with rapid deterioration of the patient's condition, transcatheter embolization should be considered [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30408/abstract/41\">",
"     41",
"    </a>",
"    ]. PTE has been used in management of intractable internal or external bleeding caused by both gynecologic malignancies (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef69084 graphicRef80352 \" href=\"UTD.htm?2/47/2805\">",
"     image 7A-B",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef55631 graphicRef68325 graphicRef79711 \" href=\"UTD.htm?0/40/649\">",
"     image 8A-C",
"    </a>",
"    ) and tumors metastatic to the vulvovaginal area (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef59211 graphicRef69719 graphicRef79523 \" href=\"UTD.htm?20/43/21178\">",
"     image 9A-C",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30408/abstract/23,42,43\">",
"     23,42,43",
"    </a>",
"    ]. Early angiographic intervention can reduce the need for an immediate or subsequent surgical procedure and allow conservative management followed by disease-specific therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30408/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several small series have reported successful cessation of malignancy-associated bleeding after embolization [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30408/abstract/23,42,43\">",
"     23,42,43",
"    </a>",
"    ]. In one series, immediate cessation of pelvic bleeding occurred in 17 cervical cancer patients; however, repeat embolization was necessary in seven patients (41 percent) due to recurrent bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30408/abstract/42\">",
"     42",
"    </a>",
"    ]. The risk of recurrent bleeding can be reduced by superselective embolization of the artery feeding the tumor and use of permanent particulate embolic agents, such as polyvinyl alcohol particles or tris-acryl gelatin microspheres.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     UTERINE HEMORRHAGE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Resuscitation and stabilization are the initial focus of intervention in patients who are hemorrhaging from the uterus. After these initial procedures, PTE techniques offer a safe and effective alternative to surgery for controlling acute uterine hemorrhage [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30408/abstract/44-46\">",
"     44-46",
"    </a>",
"    ]. Most such cases involve postpartum hemorrhage [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30408/abstract/47\">",
"     47",
"    </a>",
"    ], but the discussion below also applies to gynecological causes of acute uterine hemorrhage. In addition, PTE has been used in managing vulvovaginal hematomas refractory to conventional first-line therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30408/abstract/48-51\">",
"     48-51",
"    </a>",
"    ]. Preoperative placement of balloon catheters has also been used to prevent or reduce intraoperative hemorrhage in women with suspected placenta accreta undergoing cesarean delivery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/7/8311?source=see_link\">",
"     \"Clinical features and diagnosis of placenta accreta, increta, and percreta\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/60/41929?source=see_link\">",
"     \"Management of postpartum hemorrhage at vaginal delivery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although many patients will stop bleeding spontaneously or with conservative treatment, consultation with an interventional radiologist should be obtained early in the patient's course. This facilitates decision making about the possible need for and timing of a procedure. Furthermore, the physician needs to consider that if embolization is unsuccessful, uterine artery ligation can be attempted subsequently. In contrast, embolization after a failed uterine artery ligation may be more difficult [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30408/abstract/52,53\">",
"     52,53",
"    </a>",
"    ], although not impossible. In one study, arterial embolization was successful in 10 of 11 cases of failed surgical ligation therapy for postpartum hemorrhage [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30408/abstract/54\">",
"     54",
"    </a>",
"    ]. Thus, uterine arterial embolization should be considered an option even after failed surgical ligation due to",
"    <span class=\"nowrap\">",
"     incomplete/ineffective",
"    </span>",
"    occlusion.",
"   </p>",
"   <p>",
"    Decision making and mobilization of personnel and appropriate equipment take time and, in some cases, a significant delay is likely before the uterine vessels can be occluded. Laparotomy should be performed if the woman is not stable enough to wait for the embolization procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30408/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Once the angiographic procedure is anticipated, we suggest the following preangiogaphic laboratory tests: complete blood count, blood urea nitrogen, creatinine, electrolytes, prothrombin time, partial prothrombin time, and platelet count. If coagulopathy is present, we prefer that it be corrected before the procedure, although some radiologists will go ahead while the coagulopathy is being treated since the hemorrhage is generally the cause of the coagulopathy. We consider coagulopathy a relative contraindication to elective interventional procedures; however, under emergency situations, it can be performed as a life saving measure even with coagulopathy.",
"   </p>",
"   <p>",
"    The technique of embolization is basically the same as with other embolization procedures (see",
"    <a class=\"local\" href=\"#H2\">",
"     'Transcatheter embolization procedure'",
"    </a>",
"    above). Diagnostic angiography is initially performed to look for a bleeding site or abnormal vascular findings, such as extravasation, abnormal arteriovenous communication, pseudoaneurysm, spasm, or truncation (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef67041 graphicRef78839 \" href=\"UTD.htm?25/40/26243\">",
"     image 10A-B",
"    </a>",
"    ). Gelfoam is the preferred agent for embolization of the uterine or hypogastric arteries since the duration of occlusion is temporary (two to six weeks), but sufficient to reduce hemorrhage. Slow development of collateral arterial flow occurs a few hours after embolization and serves to prevent ischemia [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30408/abstract/19,45\">",
"     19,45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The patient's physician should monitor her status in the angiography suite at the time of the procedure and be ready to proceed to surgical intervention if the patient becomes hemodynamically unstable. Frequent communication about the patient's status between the interventional radiologist and the physician is recommended. A prolonged embolization procedure should be avoided if there appears to be little chance of therapeutic success because the patient's condition may deteriorate and increase the risk of surgical intervention.",
"   </p>",
"   <p>",
"    If the time permits, angiographic occlusion balloon catheters can be placed to temporarily occlude the hypogastric or common iliac arteries (or even in the aorta) while en route to the operating room or during the surgery. Prolonged (48 hours) balloon catheter occlusion of the hypogastric arteries alone, without embolization, also was reported to successfully control hemorrhage in two hemodynamically unstable patients [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30408/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A literature review of UAE for treatment of pelvic hemorrhage unrelated to malignancy reported a 97 percent success rate [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30408/abstract/53\">",
"     53",
"    </a>",
"    ]. Another review described a 95 percent success rate in controlling bleeding related to postpartum hemorrhage; the failure rate was low (5 percent of cases required hysterectomy) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30408/abstract/19\">",
"     19",
"    </a>",
"    ]. A large series of 100 cases performed at a single center mostly by one radiologist reported 89 percent success for control of postpartum hemorrhage [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30408/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Serious complications are unusual and the procedure-related morbidity of 3 to 6 percent is much less than with laparotomy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30408/abstract/53,54,57\">",
"     53,54,57",
"    </a>",
"    ]. Postembolization fever is the most common complication; other less common complications include buttock ischemia, vascular perforation, and infection [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30408/abstract/58\">",
"     58",
"    </a>",
"    ]. Ovulation and menses generally resume as long as the uterus and ovaries are intact.",
"   </p>",
"   <p>",
"    There is minimal information on subsequent pregnancy outcome after UAE for PPH [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30408/abstract/46,59-61\">",
"     46,59-61",
"    </a>",
"    ]. A note of caution should be taken in view of complications described after a similar procedure, UFE [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30408/abstract/8\">",
"     8",
"    </a>",
"    ] and in one case report [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30408/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Percutaneous transcatheter embolization procedures are performed under fluoroscopic guidance in the radiology suite with intravenous conscious sedation, analgesics, and antibiotic prophylaxis. Gelfoam, coils, and glue are preferred for embolization of large arteries and tiny particles or microspheres are preferred for small arteries. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Transcatheter embolization procedure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Uterine fibroid embolization is a nonsurgical option for management of fibroid related symptoms that has shown excellent technical and clinical success. It is an effective option in women who wish to preserve their uterus, although the risks associated with subsequent pregnancy are unclear. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Uterine fibroids'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Postpartum hemorrhage in hemodynamically stable patients can be managed with percutaneous transcatheter embolization. Consultation with an interventional radiologist should be obtained early to facilitate decision making. The physician needs to consider that if embolization is unsuccessful, uterine artery ligation can be attempted subsequently. In contrast, embolization may be extremely difficult, or even impossible, after an unsuccessful uterine artery ligation. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Uterine hemorrhage'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The patient's physician should monitor her status in the angiography suite at the time of an embolization procedure and be ready to proceed to surgical intervention if the patient becomes hemodynamically unstable. A prolonged embolization procedure should be avoided if there appears to be little chance of therapeutic success because the patient's condition may deteriorate and increase the risk of surgical intervention. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Uterine hemorrhage'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Laparotomy should be performed if the woman is not stable enough to wait for the embolization procedure or for completion of a difficult procedure. If the time permits, angiographic occlusion balloon catheters can be placed to temporarily occlude the hypogastric or common iliac arteries (or even in the aorta) while en route to the operating room or during the surgery. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Uterine hemorrhage'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30408/abstract/1\">",
"      Hovsepian DM, Bonn J, Eschelman DJ, et al. Fallopian tube recanalization in an unrestricted patient population. Radiology 1994; 190:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30408/abstract/2\">",
"      Casola G, vanSonnenberg E, D'Agostino HB, et al. Percutaneous drainage of tubo-ovarian abscesses. Radiology 1992; 182:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30408/abstract/3\">",
"      Gooding JM, D'Agostino HB, Plaxe SC. Transcervical metallic stents for drainage of uterine collections. J Vasc Interv Radiol 1999; 10:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30408/abstract/4\">",
"      Ryan JM, Ryan BM, Smith TP. Antibiotic prophylaxis in interventional radiology. J Vasc Interv Radiol 2004; 15:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30408/abstract/5\">",
"      SELDINGER SI. Catheter replacement of the needle in percutaneous arteriography; a new technique. Acta radiol 1953; 39:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30408/abstract/6\">",
"      Ravina JH, Herbreteau D, Ciraru-Vigneron N, et al. Arterial embolisation to treat uterine myomata. Lancet 1995; 346:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30408/abstract/7\">",
"      McLucas B, Goodwin S, Adler L, et al. Pregnancy following uterine fibroid embolization. Int J Gynaecol Obstet 2001; 74:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30408/abstract/8\">",
"      Goldberg J, Pereira L, Berghella V. Pregnancy after uterine artery embolization. Obstet Gynecol 2002; 100:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30408/abstract/9\">",
"      Committee on Gynecologic Practice, American College of Obstetricians and Gynecologists. ACOG Committee Opinion. Uterine artery embolization. Obstet Gynecol 2004; 103:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30408/abstract/10\">",
"      Azziz R. Adenomyosis: current perspectives. Obstet Gynecol Clin North Am 1989; 16:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30408/abstract/11\">",
"      Bird CC, McElin TW, Manalo-Estrella P. The elusive adenomyosis of the uterus--revisited. Am J Obstet Gynecol 1972; 112:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30408/abstract/12\">",
"      Siskin GP, Tublin ME, Stainken BF, et al. Uterine artery embolization for the treatment of adenomyosis: clinical response and evaluation with MR imaging. AJR Am J Roentgenol 2001; 177:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30408/abstract/13\">",
"      Chen C, Liu P, Lu J, et al. [Uterine arterial embolization in the treatment of adenomyosis]. Zhonghua Fu Chan Ke Za Zhi 2002; 37:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30408/abstract/14\">",
"      Kim MD, Won JW, Lee DY, Ahn CS. Uterine artery embolization for adenomyosis without fibroids. Clin Radiol 2004; 59:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30408/abstract/15\">",
"      Pelage JP, Jacob D, Fazel A, et al. Midterm results of uterine artery embolization for symptomatic adenomyosis: initial experience. Radiology 2005; 234:948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30408/abstract/16\">",
"      Kim MD, Kim S, Kim NK, et al. Long-term results of uterine artery embolization for symptomatic adenomyosis. AJR Am J Roentgenol 2007; 188:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30408/abstract/17\">",
"      Ghai S, Rajan DK, Asch MR, et al. Efficacy of embolization in traumatic uterine vascular malformations. J Vasc Interv Radiol 2003; 14:1401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30408/abstract/18\">",
"      Fleming H, Ost&ouml;r AG, Pickel H, Fortune DW. Arteriovenous malformations of the uterus. Obstet Gynecol 1989; 73:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30408/abstract/19\">",
"      Badawy SZ, Etman A, Singh M, et al. Uterine artery embolization: the role in obstetrics and gynecology. Clin Imaging 2001; 25:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30408/abstract/20\">",
"      Nasu K, Fujisawa K, Yoshimatsu J, Miyakawa I. Uterine arteriovenous malformation: ultrasonographic, magnetic resonance and radiological findings. Gynecol Obstet Invest 2002; 53:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30408/abstract/21\">",
"      Huang MW, Muradali D, Thurston WA, et al. Uterine arteriovenous malformations: gray-scale and Doppler US features with MR imaging correlation. Radiology 1998; 206:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30408/abstract/22\">",
"      Forssman L, Lundberg J, Scherst&eacute;n T. Conservative treatment of uterine arteriovenous fistula. Acta Obstet Gynecol Scand 1982; 61:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30408/abstract/23\">",
"      Lim AK, Agarwal R, Seckl MJ, et al. Embolization of bleeding residual uterine vascular malformations in patients with treated gestational trophoblastic tumors. Radiology 2002; 222:640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30408/abstract/24\">",
"      Kwon JH, Kim GS. Obstetric iatrogenic arterial injuries of the uterus: diagnosis with US and treatment with transcatheter arterial embolization. Radiographics 2002; 22:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30408/abstract/25\">",
"      Wu YC, Liu WM, Yuan CC, Ng HT. Successful treatment of symptomatic arteriovenous malformation of the uterus using laparoscopic bipolar coagulation of uterine vessels. Fertil Steril 2001; 76:1270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30408/abstract/26\">",
"      Chow TW, Nwosu EC, Gould DA, Richmond DH. Pregnancy following successful embolisation of a uterine vascular malformation. Br J Obstet Gynaecol 1995; 102:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30408/abstract/27\">",
"      Gaens J, Desnyder L, Raat H, et al. Selective transcatheter embolization of a uterine arteriovenous malformation with preservation of the reproductive capacity. J Belge Radiol 1996; 79:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30408/abstract/28\">",
"      Peitsidis P, Manolakos E, Tsekoura V, et al. Uterine arteriovenous malformations induced after diagnostic curettage: a systematic review. Arch Gynecol Obstet 2011; 284:1137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30408/abstract/29\">",
"      Molvi SN, Dash K, Rastogi H, Khanna SB. Transcatheter embolization of uterine arteriovenous malformation: report of 2 cases and review of literature. J Minim Invasive Gynecol 2011; 18:812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30408/abstract/30\">",
"      Liddle AD, Davies AH. Pelvic congestion syndrome: chronic pelvic pain caused by ovarian and internal iliac varices. Phlebology 2007; 22:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30408/abstract/31\">",
"      Thurmond AS, Novy M, Uchida BT, R&ouml;sch J. Fallopian tube obstruction: selective salpingography and recanalization. Work in progress. Radiology 1987; 163:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30408/abstract/32\">",
"      Thurmond AS. Selective salpingography and fallopian tube recanalization. AJR Am J Roentgenol 1991; 156:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30408/abstract/33\">",
"      Thurmond AS, Machan LS, Maubon AJ, et al. A review of selective salpingography and fallopian tube catheterization. Radiographics 2000; 20:1759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30408/abstract/34\">",
"      Confino E, Friberg J, Gleicher N. Preliminary experience with transcervical balloon tuboplasty. Am J Obstet Gynecol 1988; 159:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30408/abstract/35\">",
"      Maubon A, Rouanet JP, Cover S, et al. Fallopian tube recanalization by selective salpingography: an alternative to more invasive techniques? Hum Reprod 1992; 7:1425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30408/abstract/36\">",
"      Thurmond AS, R&ouml;sch J. Nonsurgical fallopian tube recanalization for treatment of infertility. Radiology 1990; 174:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30408/abstract/37\">",
"      Thurmond AS. Pregnancies after selective salpingography and tubal recanalization. Radiology 1994; 190:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30408/abstract/38\">",
"      Honor&eacute; GM, Holden AE, Schenken RS. Pathophysiology and management of proximal tubal blockage. Fertil Steril 1999; 71:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30408/abstract/39\">",
"      Papaioannou S, Afnan M, Sharif K. The role of selective salpingography and tubal catheterization in the management of the infertile couple. Curr Opin Obstet Gynecol 2004; 16:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30408/abstract/40\">",
"      Tanaka Y, Tajima H, Sakuraba S, et al. Renaissance of surgical recanalization for proximal fallopian tubal occlusion: falloposcopic tuboplasty as a promising therapeutic option in tubal infertility. J Minim Invasive Gynecol 2011; 18:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30408/abstract/41\">",
"      Tinelli A, Prudenzano R, Malvasi A, et al. Emergency endovascular nanopharmacologic treatment in advanced gynecological cancers. Int J Gynecol Cancer 2010; 20:1250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30408/abstract/42\">",
"      Yamashita Y, Harada M, Yamamoto H, et al. Transcatheter arterial embolization of obstetric and gynaecological bleeding: efficacy and clinical outcome. Br J Radiol 1994; 67:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30408/abstract/43\">",
"      Banaschak A, St&ouml;sslein F, Kielbach O, et al. [Therapeutic vascular embolization in life-threatening gynecologic hemorrhages]. Zentralbl Gynakol 1985; 107:1050.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30408/abstract/44\">",
"      Pelage JP, Le Dref O, Mateo J, et al. Life-threatening primary postpartum hemorrhage: treatment with emergency selective arterial embolization. Radiology 1998; 208:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30408/abstract/45\">",
"      Hansch E, Chitkara U, McAlpine J, et al. Pelvic arterial embolization for control of obstetric hemorrhage: a five-year experience. Am J Obstet Gynecol 1999; 180:1454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30408/abstract/46\">",
"      Salomon LJ, deTayrac R, Castaigne-Meary V, et al. Fertility and pregnancy outcome following pelvic arterial embolization for severe post-partum haemorrhage. A cohort study. Hum Reprod 2003; 18:849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30408/abstract/47\">",
"      Kirby JM, Kachura JR, Rajan DK, et al. Arterial embolization for primary postpartum hemorrhage. J Vasc Interv Radiol 2009; 20:1036.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30408/abstract/48\">",
"      Villella J, Garry D, Levine G, et al. Postpartum angiographic embolization for vulvovaginal hematoma. A report of two cases. J Reprod Med 2001; 46:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30408/abstract/49\">",
"      Heffner LJ, Mennuti MT, Rudoff JC, McLean GK. Primary management of postpartum vulvovaginal hematomas by angiographic embolization. Am J Perinatol 1985; 2:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30408/abstract/50\">",
"      Chin HG, Scott DR, Resnik R, et al. Angiographic embolization of intractable puerperal hematomas. Am J Obstet Gynecol 1989; 160:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30408/abstract/51\">",
"      Hsu YR, Wan YL. Successful management of intractable puerperal hematoma and severe postpartum hemorrhage with DIC through transcatheter arterial embolization--two cases. Acta Obstet Gynecol Scand 1998; 77:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30408/abstract/52\">",
"      Mason BA. Postpartum hemorrhage and arterial embolization. Curr Opin Obstet Gynecol 1998; 10:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30408/abstract/53\">",
"      Vedantham S, Goodwin SC, McLucas B, Mohr G. Uterine artery embolization: an underused method of controlling pelvic hemorrhage. Am J Obstet Gynecol 1997; 176:938.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30408/abstract/54\">",
"      Sentilhes L, Gromez A, Clavier E, et al. Predictors of failed pelvic arterial embolization for severe postpartum hemorrhage. Obstet Gynecol 2009; 113:992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30408/abstract/55\">",
"      Bischofberger A, Savoldelli GL, Irion O. [Multidisciplinary management of post-partum hemorrhage: new strategies]. Rev Med Suisse 2011; 7:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30408/abstract/56\">",
"      Oei SG, Kho SN, ten Broeke ED, Br&ouml;lmann HA. Arterial balloon occlusion of the hypogastric arteries: a life-saving procedure for severe obstetric hemorrhage. Am J Obstet Gynecol 2001; 185:1255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30408/abstract/57\">",
"      Alvarez M, Lockwood CJ, Ghidini A, et al. Prophylactic and emergent arterial catheterization for selective embolization in obstetric hemorrhage. Am J Perinatol 1992; 9:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30408/abstract/58\">",
"      Ganguli S, Stecker MS, Pyne D, et al. Uterine artery embolization in the treatment of postpartum uterine hemorrhage. J Vasc Interv Radiol 2011; 22:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30408/abstract/59\">",
"      Pelage JP, Le Dref O, Jacob D, et al. Selective arterial embolization of the uterine arteries in the management of intractable post-partum hemorrhage. Acta Obstet Gynecol Scand 1999; 78:698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30408/abstract/60\">",
"      Ornan D, White R, Pollak J, Tal M. Pelvic embolization for intractable postpartum hemorrhage: long-term follow-up and implications for fertility. Obstet Gynecol 2003; 102:904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30408/abstract/61\">",
"      Chauleur C, Fanget C, Tourne G, et al. Serious primary post-partum hemorrhage, arterial embolization and future fertility: a retrospective study of 46 cases. Hum Reprod 2008; 23:1553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30408/abstract/62\">",
"      Cordonnier C, Ha-Vien DE, Depret S, et al. Foetal growth restriction in the next pregnancy after uterine artery embolisation for post-partum haemorrhage. Eur J Obstet Gynecol Reprod Biol 2002; 103:183.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3264 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-E57427EB1A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_44_30408=[""].join("\n");
var outline_f29_44_30408=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TRANSCATHETER EMBOLIZATION PROCEDURE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      UTERINE FIBROIDS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ADENOMYOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      ARTERIOVENOUS MALFORMATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PELVIC CONGESTION SYNDROME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      FALLOPIAN TUBE RECANALIZATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      TUMOR-RELATED BLEEDING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      UTERINE HEMORRHAGE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/3264\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/3264|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?29/31/30192\" title=\"diagnostic image 1A\">",
"      Adenomyosis 6a",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?42/27/43441\" title=\"diagnostic image 1B\">",
"      Adenomyosis 6b",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?28/57/29599\" title=\"diagnostic image 2\">",
"      Arteriovenous malformation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?14/53/15191\" title=\"diagnostic image 3A\">",
"      Vascular malformation 9AB",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?15/23/15732\" title=\"diagnostic image 3B\">",
"      Vascular malformation 9c",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?15/21/15696\" title=\"diagnostic image 3C\">",
"      Vascular malformation 9de",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?25/29/26079\" title=\"diagnostic image 3D\">",
"      Vascular malformation 9fg",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?20/50/21294\" title=\"diagnostic image 3E\">",
"      Vascular malformation 9h",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?15/31/15857\" title=\"diagnostic image 4\">",
"      Pelvic congestion syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?41/56/42895\" title=\"diagnostic image 5A\">",
"      Pelvic congestion syndrome 11a",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?13/26/13743\" title=\"diagnostic image 5B\">",
"      Pelvic congestion syndrome 11b",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?39/28/40399\" title=\"diagnostic image 6A\">",
"      Hysterosalpingogram a",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?26/37/27218\" title=\"diagnostic image 6B\">",
"      Tubal recanalization b",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?8/25/8593\" title=\"diagnostic image 6C\">",
"      Tubal recanalization c",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?18/46/19168\" title=\"diagnostic image 7A\">",
"      Bleeding tumor a",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?7/53/8016\" title=\"diagnostic image 7B\">",
"      Bleeding tumor b",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?29/34/30240\" title=\"diagnostic image 8A\">",
"      Tumor bleeding 14a",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?3/28/3522\" title=\"diagnostic image 8B\">",
"      Tumor bleeding 14b",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?41/29/42448\" title=\"diagnostic image 8C\">",
"      Tumor bleeding 14c",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?26/25/27028\" title=\"diagnostic image 9A\">",
"      Tumor bleeding 15a",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?22/53/23379\" title=\"diagnostic image 9B\">",
"      Tumor bleeding 15b",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?7/32/7683\" title=\"diagnostic image 9C\">",
"      Tumor bleeding 15c",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?1/25/1439\" title=\"diagnostic image 10A\">",
"      Angiogram showing postpartum hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?18/58/19360\" title=\"diagnostic image 10B\">",
"      Angiogram after embolization for postpartum hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/3264|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?22/45/23263\" title=\"figure 1A\">",
"      Fibroid embolization 2a",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?11/62/12271\" title=\"figure 1B\">",
"      Fibroid embolization 2b",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/3264|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/1/21\" title=\"picture 1\">",
"      Polyvinyl alcohol particles",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/26/41384?source=related_link\">",
"      Causes of chronic pelvic pain in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/18/3367?source=related_link\">",
"      Causes of female infertility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/7/8311?source=related_link\">",
"      Clinical features and diagnosis of placenta accreta, increta, and percreta",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/17/6426?source=related_link\">",
"      Epidemiology, clinical manifestations, diagnosis, and natural history of uterine leiomyomas (fibroids)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/61/40921?source=related_link\">",
"      Evaluation of female infertility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/60/41929?source=related_link\">",
"      Management of postpartum hemorrhage at vaginal delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/2/11305?source=related_link\">",
"      Managing an episode of severe or prolonged uterine bleeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/5/14425?source=related_link\">",
"      Overview of treatment of female infertility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/18/28969?source=related_link\">",
"      Treatment of chronic pelvic pain in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/35/27191?source=related_link\">",
"      Uterine adenomyosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/60/22473?source=related_link\">",
"      Uterine leiomyoma (fibroid) embolization",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_44_30409="Treatment of kidney disease in multiple myeloma";
var content_f29_44_30409=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of kidney disease in multiple myeloma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/44/30409/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/44/30409/contributors\">",
"     S Vincent Rajkumar, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/44/30409/contributors\">",
"     Andre A Kaplan, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/44/30409/contributors\">",
"     Nelson Leung, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/44/30409/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/44/30409/contributors\">",
"     Richard J Glassock, MD, MACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/44/30409/contributors\">",
"     Robert A Kyle, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/44/30409/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/44/30409/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?29/44/30409/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 19, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Kidney injury is a relatively common problem in patients with multiple myeloma. Approximately 20 percent of patients have impaired renal function (defined as an increase in the serum creatinine to greater than 2.0",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [177",
"    <span class=\"nowrap\">",
"     micromol/L])",
"    </span>",
"    at presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30409/abstract/1\">",
"     1",
"    </a>",
"    ]. Renal disease most often occurs in patients with a high tumor burden [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30409/abstract/2\">",
"     2",
"    </a>",
"    ], and can evolve as either an acute or chronic disorder.",
"   </p>",
"   <p>",
"    Multiple etiologies have been attributed to the acute kidney injury (AKI) in patients with multiple myeloma. Hypercalcemia, volume depletion, hyperuricemia, hyperviscosity (rare) and toxicity due to intravenous radiocontrast media, nonsteroidal antiinflammatory agents, angiotensin converting enzyme (ACE) inhibitors or receptor blockers (ARB), all may contribute [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30409/abstract/2-6\">",
"     2-6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Myeloma cast nephropathy occurs most often in patients with high rates of production and excretion of immunoglobulin free light chains, which may be toxic to the tubules and form obstructing tubular casts, particularly if the patient is volume depleted [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30409/abstract/4\">",
"     4",
"    </a>",
"    ]. Other common renal lesions include primary amyloidosis, or light chain deposition disease [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30409/abstract/2,7\">",
"     2,7",
"    </a>",
"    ]. Concurrent presence of both myeloma cast nephropathy and either amyloidosis or light chain deposition disease can occur but is unusual [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30409/abstract/7-9\">",
"     7-9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with amyloidosis or light chain deposition disease (LCDD) may not have significantly reduced kidney function at the time of presentation (although renal failure may occur if amyloidosis or LCDD is not recognized and left untreated), and are treated with chemotherapy directed against the abnormal plasma cell clone. One of these two disorders should be suspected when there are signs of the nephrotic syndrome, including heavy albuminuria, hypoalbuminemia, and edema [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30409/abstract/10\">",
"     10",
"    </a>",
"    ]. Renal vein thrombosis may rarely be present in patients with nephrotic syndrome, although its contribution to renal failure in multiple myeloma is not well described. The treatment of hypercoagulability associated with the nephrotic syndrome is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/12/3273?source=see_link\">",
"     \"Renal vein thrombosis and hypercoagulable state in nephrotic syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic review will discuss the treatment of typical causes of renal failure in patients with multiple myeloma, with a focus on myeloma cast nephropathy. The types of renal disease in multiple myeloma, the pathogenesis of myeloma cast nephropathy, amyloidosis and light and heavy chain deposition diseases, and the treatment of multiple myeloma are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/48/27400?source=see_link\">",
"     \"Types of renal disease in multiple myeloma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/1/22551?source=see_link\">",
"     \"Pathogenesis and diagnosis of myeloma cast nephropathy (myeloma kidney)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/62/35815?source=see_link\">",
"     \"Pathogenesis of immunoglobulin light chain (AL) amyloidosis and light and heavy chain deposition diseases\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/29/8666?source=see_link\">",
"     \"Determination of initial therapy in patients with multiple myeloma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ACUTE KIDNEY INJURY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Management strategy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute kidney injury (AKI) in patients with multiple myeloma results from a variety of mechanisms. These include cast nephropathy, hypercalcemia, radiocontrast media-induced AKI, nonsteroidal antiinflammatory drugs (NSAIDs), and, infrequently, severe hyperuricemia or hyperviscosity syndrome. Specific treatment is directed at the cause of AKI [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30409/abstract/3,5,6,11-13\">",
"     3,5,6,11-13",
"    </a>",
"    ]. Dialysis should be performed for the usual indications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5238270\">",
"    <span class=\"h3\">",
"     Myeloma cast nephropathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with multiple myeloma who have AKI with a course and findings consistent with myeloma cast nephropathy should receive chemotherapy (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/63/11257?source=see_link\">",
"     bortezomib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    , or thalidomide and dexamethasone, bortezomib,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    and dexamethasone) as rapidly as possible to decrease light chain production (with the possible exception of patients who are in preterminal stages of disease) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30409/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. Once stabilized, hematopoietic cell transplantation can be considered in eligible patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/29/8666?source=see_link\">",
"     \"Determination of initial therapy in patients with multiple myeloma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/47/31482?source=see_link\">",
"     \"Autologous hematopoietic cell transplantation in multiple myeloma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Extracorporeal methods to rapidly lower the level of circulating free light chains, may be indicated for patients with myeloma cast nephropathy. This is discussed in detail in the next section. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Plasmapheresis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In patients who are unresponsive to therapy despite adequate suppression and removal of serum free light chains, a renal biopsy (if not yet performed) should be considered to investigate causes other than cast nephropathy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5238293\">",
"    <span class=\"h3\">",
"     Volume depletion, hypercalcemia, and hyperuricemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravenous fluids are given to treat volume depletion, hypercalcemia and hyperuricemia, if present. If volume depletion is present clinically (eg, hypotension, decreased skin turgor), isotonic fluids must be given for initial volume replacement. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/56/24457?source=see_link\">",
"     \"Etiology, clinical manifestations, and diagnosis of volume depletion in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/7/34935?source=see_link\">",
"     \"Maintenance and replacement fluid therapy in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/20/13639?source=see_link\">",
"     \"Treatment of severe hypovolemia or hypovolemic shock in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Given strong pathophysiologic considerations, vigorous intravenous fluid therapy has been a mainstay of therapy of AKI in multiple myeloma, and it should be provided to all patients, unless contraindicated (eg, heart failure or",
"    <span class=\"nowrap\">",
"     oliguric/anuria",
"    </span>",
"    AKI). The goals of fluid therapy are to decrease the light chain concentration within the tubular lumen and produce a high urine flow rate to minimize light chain precipitation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/1/22551?source=see_link\">",
"     \"Pathogenesis and diagnosis of myeloma cast nephropathy (myeloma kidney)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/48/27400?source=see_link\">",
"     \"Types of renal disease in multiple myeloma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the absence of (or following the correction of) volume depletion, a reasonable regimen is the administration of isotonic or one-half isotonic saline at an initial rate of 150",
"    <span class=\"nowrap\">",
"     mL/h,",
"    </span>",
"    adjusted to maintain the urine output at approximately 100 to 150",
"    <span class=\"nowrap\">",
"     mL/h",
"    </span>",
"    (approximately 3",
"    <span class=\"nowrap\">",
"     L/day).",
"    </span>",
"    This regimen requires careful monitoring and may require modification in patients who cannot excrete the administered fluid because of renal or heart failure. A loop diuretic should be given to patients who develop fluid overload. Loop diuretics should be used judiciously since there is some concern that they may promote cast formation [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30409/abstract/4\">",
"     4",
"    </a>",
"    ]. There are no randomized controlled trials of loop diuretics to help guide therapy. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Prevention'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In patients with AKI and oliguria, we still administer the fluid regimen described above. Within 24 hours, reversal of oliguria should become evident. If oliguria persists, fluid administration should to be modified to prevent volume overload.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5238301\">",
"    <span class=\"h3\">",
"     Hypercalcemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of hypercalcemia is based on the initial serum calcium concentration. Bisphosphonates are preferred for the treatment of severe and refractory hypercalcemia, given their effectiveness in reducing calcium concentration, and possible additional benefit of reducing the incidence of skeletal events in multiple myeloma [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30409/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/42/16041?source=see_link&amp;anchor=H6#H6\">",
"     \"Treatment of hypercalcemia\", section on 'Bisphosphonates'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/27/30137?source=see_link\">",
"     \"The use of bisphosphonates in patients with multiple myeloma\"",
"    </a>",
"    .):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If the corrected serum calcium concentration is elevated, but &lt;14",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (4",
"      <span class=\"nowrap\">",
"       mmol/L),",
"      </span>",
"      we treat initially with the fluid regimen previously mentioned. (See",
"      <a class=\"local\" href=\"#H5238293\">",
"       'Volume depletion, hypercalcemia, and hyperuricemia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If hypercalcemia persists despite 6 to 12 hours of fluids, we administer a bisphosphonate (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/62/3048?source=see_link\">",
"       pamidronate",
"      </a>",
"      60 to 90 mg over two to three hours), with the dose appropriately adjusted for kidney function.",
"     </li>",
"     <li>",
"      If the corrected serum calcium concentration is &ge;14",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (4",
"      <span class=\"nowrap\">",
"       mmol/L),",
"      </span>",
"      bisphosphonates should be administered immediately, concurrently with the fluid regimen described above. (See",
"      <a class=\"local\" href=\"#H5238293\">",
"       'Volume depletion, hypercalcemia, and hyperuricemia'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Bisphosphonates must be used cautiously in patients with significant renal impairment or vitamin D deficiency, as the risk of inducing hypocalcemia is increased. In addition, nephrotic syndrome and acute kidney injury due to collapsing focal segmental glomerulosclerosis and other glomerular lesions have been described among patients with multiple myeloma following treatment with bisphosphonates. There may also be an increased risk of acute kidney injury associated with the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/1/9241?source=see_link\">",
"     zoledronic acid",
"    </a>",
"    and thus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/62/3048?source=see_link\">",
"     pamidronate",
"    </a>",
"    is preferred in patients with renal insufficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30409/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/31/43512?source=see_link&amp;anchor=H5#H5\">",
"     \"Collapsing focal segmental glomerulosclerosis not associated with HIV infection\", section on 'Bisphosphonates and other drugs'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5238345\">",
"    <span class=\"h3\">",
"     Hyperuricemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperuricemia, if present, should be treated. This is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/57/27541?source=see_link\">",
"     \"Uric acid renal diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5238353\">",
"    <span class=\"h3\">",
"     Drugs with renal toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonsteroidal antiinflammatory drugs, ACE inhibitors or angiotensin receptor blockers should be stopped, and radiocontrast dye avoided if possible, to avoid further kidney injury.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Plasmapheresis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evidence evaluating the effectiveness of plasmapheresis in patients with AKI due to myeloma is conflicting [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30409/abstract/5,11,13,19-23\">",
"     5,11,13,19-23",
"    </a>",
"    ], and some patients clearly improve without plasmapheresis. However, substantial benefit in renal outcomes has been shown in some studies that enrolled patients who had circulating free light chains in the plasma or significant Bence Jones proteinuria.",
"   </p>",
"   <p>",
"    Plasmapheresis should therefore be performed for the removal of toxic circulating free light chains from the plasma in patients with AKI and suspected myeloma cast nephropathy (",
"    <a class=\"graphic graphic_figure graphicRef59043 \" href=\"UTD.htm?41/55/42878\">",
"     figure 1",
"    </a>",
"    ). A 2003 review of available studies also led an expert panel to conclude that plasmapheresis was an important adjunct in the management of myeloma cast nephropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30409/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following is a review of some of the randomized trials that have examined the efficacy of plasmapheresis in this setting. One randomized trial involved 29 patients with multiple myeloma, AKI, and significant Bence Jones proteinuria, 24 of whom required dialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30409/abstract/11\">",
"     11",
"    </a>",
"    ]. The patients were randomly assigned to plasma exchange together with glucocorticoids, cytotoxic drugs, and hemodialysis (if required), or to glucocorticoids, cytotoxic drugs, and peritoneal dialysis (if needed). Among the 15 patients randomly assigned to receive plasmapheresis for five consecutive days, 13 (87 percent) recovered renal function (most to a plasma creatinine concentration below 2.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [&lt;220",
"    <span class=\"nowrap\">",
"     micromol/L]),",
"    </span>",
"    whereas improvement occurred in only two of 14 controls (14 percent), with most patients requiring chronic dialysis. Patient survival was also improved in the plasmapheresis group.",
"   </p>",
"   <p>",
"    Less compelling results were reported from a multicenter trial of 97 patients with newly diagnosed multiple myeloma and AKI who were randomly assigned to receive plasmapheresis and chemotherapy, or chemotherapy alone [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30409/abstract/22\">",
"     22",
"    </a>",
"    ]. Patients were included if they met the following criteria: progressive worsening of kidney function (serum creatinine &gt;2.3",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [200",
"    <span class=\"nowrap\">",
"     micromol/L]",
"    </span>",
"    with an increase of &gt;0.6",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [50",
"    <span class=\"nowrap\">",
"     micromol/L]",
"    </span>",
"    over the preceding two weeks) despite correction of hypercalcemia and hypovolemia; monoclonal light chains in urine, plasma, or renal tissue; and no other identifiable precipitating cause of AKI.",
"   </p>",
"   <p>",
"    In the control and plasmapheresis groups, 14 and 15 patients (36 and 26 percent), respectively, were on dialysis at baseline, and five and nine patients (13 and 16 percent), respectively, began dialysis during treatment. At six months, mortality was 33 percent in each group. The following additional results were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The composite outcome (death, dialysis dependence or GFR &lt;30",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m2) was not significantly different (58 versus 69 percent in the plasmapheresis and control patients, respectively [95% CI -8.3 to 29.1 percent]).",
"     </li>",
"     <li>",
"      Among six month survivors, fewer patients in the plasmapheresis group remained dialysis-dependent, but the difference was not significantly different (13 versus 27 percent, respectively [95% CI -5.1 to 34.6 percent]).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The authors concluded that there was no statistically significant nor clinically meaningful difference in outcomes, although the wide confidence interval of the difference did not exclude the possibility of benefit or harm. The accompanying editorial suggested that, based upon this study, plasmapheresis for the treatment of multiple myeloma should no longer be routinely recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30409/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, this trial has serious flaws [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30409/abstract/25\">",
"     25",
"    </a>",
"    ]. At best only 76 (78 percent) of 97 patients could have been expected to benefit from plasmapheresis (eg, the presence of free light chains in the plasma). In addition, there is substantial uncertainty regarding the diagnosis of cast nephropathy, since only 59 patients (61 percent) also had light chains in the urine, it is unknown whether these were free light chains, and relatively few patients had a tissue diagnosis of cast nephropathy by biopsy. The potential benefits of plasmapheresis may also have been obscured since more patients in the control group received a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    -containing regimen, which leads to faster reduction in light chain production than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"     melphalan",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/1/28698?source=see_link\">",
"     \"Initial chemotherapy for symptomatic multiple myeloma in patients who are NOT candidates for transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Importantly, this study does not disprove a renal benefit of plasmapheresis; the procedure was associated with a 52 percent reduction in dialysis dependency among survivors at six months (13 versus 27 percent). The ability to show significant benefit in renal recovery was probably limited by the large number of deaths in both arms, an outcome unlikely to have been affected by plasmapheresis.",
"   </p>",
"   <p>",
"    To address some the limitations described above, a retrospective study analyzed the efficacy of plasmapheresis in patients in whom the diagnosis of cast nephropathy was confirmed by biopsy and in whom serum levels of free light chains were used to guide therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30409/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. Fourteen patients had biopsy-proven cast nephropathy and serum free light chains measured before and after plasmapheresis. A renal response, defined as a 50 percent reduction in serum creatinine and dialysis independence at 180 days, occurred in seven of nine patients (77.8 percent) in whom free light chains were reduced by 50 percent or more. Early institution of plasmapheresis along with effective therapy to treat myeloma results in complete renal response in approximately 40 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30409/abstract/28\">",
"     28",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/63/11257?source=see_link\">",
"     Bortezomib",
"    </a>",
"    -based chemotherapy is preferred in the setting of myeloma and AKI, eg, bortezomib,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    (VCD) or bortezomib,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    , dexamethasone (VTD).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Indications for plasmapheresis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the possible reduction in dialysis dependency among survivors, plasmapheresis is a reasonable therapy for individuals with AKI suspected to be due to cast nephropathy. This includes the following settings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with cast nephropathy on kidney biopsy",
"     </li>",
"     <li>",
"      In cases with highly suggestive clinical presentations, plasmapheresis may be initiated on the basis of high levels of free monoclonal light chains in the serum or urine, even in the absence of a renal biopsy. This includes patients with myeloma presenting with acute kidney injury and a serum free light chain level of 200",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      or more [",
"      <a class=\"abstract\" href=\"UTD.htm?29/44/30409/abstract/28\">",
"       28",
"      </a>",
"      ]. Note that it is possible to have high levels of free light chains in the urine without similarly elevated serum free light chain levels, and vice versa.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Urine protein electrophoresis usually demonstrates a monoclonal spike (immunofixation is done to identify the monoclonal protein) and is the principal test used to monitor monoclonal light chain levels in myeloma cast nephropathy. Monoclonal light chains may also be detected as an M spike in the globulin region on serum protein electrophoresis, but immunofixation must be performed to confirm that this represents a free light chain. However, the sensitivity is low compared to the corresponding urine assay. The newer serum free light chain assay may be beneficial although experience with this assay in the diagnosis of cast nephropathy is limited. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/58/10154?source=see_link\">",
"     \"Recognition of monoclonal proteins\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If a renal biopsy is performed and plasmapheresis then initiated, there is a potential risk of postbiopsy bleeding from pheresis-induced removal of coagulation factors. Partial replacement of the fluid removed with fresh frozen plasma (1 to 2 liters toward the end of the pheresis) rather than albumin should attenuate the coagulopathy. Replacement with fresh frozen plasma may also be reasonable for the final treatment prior to catheter removal. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/33/38420?source=see_link\">",
"     \"Prescription and technique of therapeutic plasma exchange\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Plasmapheresis protocol",
"    </span>",
"    &nbsp;&mdash;&nbsp;The usual plasmapheresis regimen is five to seven exchanges within seven to ten days. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/33/38420?source=see_link\">",
"     \"Prescription and technique of therapeutic plasma exchange\"",
"    </a>",
"    .) However, the duration of plasma exchange should be guided by serum free light chain levels. Evidence suggests a minimum of 60 percent reduction of the pathogenic serum free light chain is required for recovery of renal function [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30409/abstract/29-31\">",
"     29-31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Plasmapheresis must be done in conjunction with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    - containing chemotherapy to reduce the rate of light chain production. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/54/18282?source=see_link\">",
"     \"Initial chemotherapy for symptomatic multiple myeloma in patients who are candidates for transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We recommend repeating the relevant monoclonal light chain assay for a given patient to monitor recurrent light chain accumulation. The frequency and timing of monitoring depend on the clinical condition of the patient and the concurrent therapy that is being administered, but typically measurements are done one to two days after completing the initial course of plasma exchange.",
"   </p>",
"   <p>",
"    If chemotherapy is successful in limiting new light chain synthesis, a single trial of five to seven consecutive plasma exchanges within seven to ten days may be sufficient. Prolonging the initial course of plasma exchanges may be reasonable if there is continued excess light chain production. Recurrence of excess light chain production is possible, and some have advocated repeating a course of plasma exchange.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16988475\">",
"    <span class=\"h2\">",
"     High cutoff dialyzer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Extracorporeal removal of serum free light chains has been demonstrated with the use of high cutoff dialyzers [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30409/abstract/29\">",
"     29",
"    </a>",
"    ]. These dialyzers have pore sizes of 25 to 50 kd, which is significantly larger than pore sizes of the standard high flux dialyzers. The larger pore size allows higher rate of removal of serum free light chains [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30409/abstract/29\">",
"     29",
"    </a>",
"    ]. In a pilot study of 19 patients with biopsy-proven myeloma cast nephropathy, 13 patients became dialysis-independent within 27 days [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30409/abstract/29\">",
"     29",
"    </a>",
"    ]. Two trials (European Trial of Free Light Chain Removal by Extended Hemodialysis in Cast Nephropathy [EuLITE] and Studies in Patients With Multiple Myeloma and Renal Failure Due to Myeloma Cast Nephropathy [MYRE]) are ongoing in Europe to conclusively determine the efficacy of high cutoff dialyzers in myeloma cast nephropathy. Unfortunately, high cutoff dialyzers are not currently available in the United States.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Dialysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Until more evidence is available, dialysis should be initiated for the usual indications (eg, fluid overload, hyperkalemia, and uremia) and not for the removal of free light chains. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/37/4696?source=see_link\">",
"     \"Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure): Recovery of renal function and effect of hemodialysis membrane\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Either peritoneal dialysis or hemodialysis may be used, but we suggest hemodialysis in the acute setting for patients undergoing plasmapheresis, as the same catheter can be used for both procedures. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/37/4696?source=see_link\">",
"     \"Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure): Recovery of renal function and effect of hemodialysis membrane\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients receiving plasmapheresis using citrate anticoagulation may develop alkalemia. If dialysis is also required the same day, it should be performed after plasmapheresis to correct the alkalemia and prevent hypotension during plasmapheresis.",
"   </p>",
"   <p>",
"    Dialysis can also be used to remove circulating light chains, but the efficiency is much less than that with plasmapheresis. In one report using peritoneal dialysis, for example, net light chain removal in 50 liters of peritoneal dialysate was only 2 grams; in comparison, one five liter plasma exchange removed 17 grams [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30409/abstract/32\">",
"     32",
"    </a>",
"    ]. Both standard and high-flux hemodialysis are also unlikely to remove substantial amounts of light chains.",
"   </p>",
"   <p>",
"    However, limited evidence suggests that significant amounts of light chains may be removed with an alternate hemodialysis approach in which extended daily hemodialysis is performed with a protein-leaking dialyzer with very large pores [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30409/abstract/29,33\">",
"     29,33",
"    </a>",
"    ]. In a study that included 19 dialysis-dependent patients with multiple myeloma and cast nephropathy, extended dialysis was performed as an adjunct to chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30409/abstract/29\">",
"     29",
"    </a>",
"    ]. Using the Gambro HCO 1100 hemodialysis membrane, the dialysis schedule was eight hours daily for the first five days, eight hours on alternate days for the next 12 days, and then six hours three times weekly. Among the 13 patients who completed six weeks of uninterrupted chemotherapy and hemodialysis, all sustained early reductions in free light chain concentration and were dialysis-independent at a median of 27 days (range 13 to 120 days). Interruptions in chemotherapy occurred in all six patients who failed to achieve reduction in free light chains; of these, only one patient had recovery of renal function by 105 days. It is therefore unclear whether the long-term benefits resulted from intensive dialysis or response to chemotherapy or both. Confirmation of these benefits is required in a larger number of patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27343464\">",
"    <span class=\"h2\">",
"     Gauging the treatment response",
"    </span>",
"    &nbsp;&mdash;&nbsp;To allow standardization in the reporting of the renal response to therapy, the International Myeloma Working Group published a set of response criteria in its consensus statement [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30409/abstract/34\">",
"     34",
"    </a>",
"    ]. The response categories are based upon the best achieved renal function during therapy and the change from baseline renal function. Complete renal response (CRenal) is defined as achieving a best estimated glomerular filtration rate (eGFR) or creatinine clearance of greater than 60",
"    <span class=\"nowrap\">",
"     mL/min/1.73",
"    </span>",
"    m2 from a baseline eGFR of less than 50",
"    <span class=\"nowrap\">",
"     mL/min/1.73",
"    </span>",
"    m2. Partial renal response (PRenal) is a best eGFR of 20 to 59",
"    <span class=\"nowrap\">",
"     mL/min/1.73",
"    </span>",
"    m2 from baseline of less than 15",
"    <span class=\"nowrap\">",
"     mL/min/1.73",
"    </span>",
"    m2. Minor renal response (MRenal) is defined as a best eGFR of 30 to 59",
"    <span class=\"nowrap\">",
"     mL/min/1.73",
"    </span>",
"    m2 from a baseline of 15 to 29",
"    <span class=\"nowrap\">",
"     mL/min/1.73",
"    </span>",
"    m2 or best eGFR of 15 to 29",
"    <span class=\"nowrap\">",
"     mL/min/1.73",
"    </span>",
"    m2 from a baseline of less than 15",
"    <span class=\"nowrap\">",
"     mL/min/1.73",
"    </span>",
"    m2.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no clinical predictive factors at presentation that help determine which patients will improve. Patients with significant renal dysfunction at presentation, however, tend to have worse outcomes than those without, despite aggressive therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30409/abstract/2,3,35\">",
"     2,3,35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    With directed and supportive therapies, reported rates of improvement in kidney function range between 50 and 80 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30409/abstract/3,5,6,11-13,19\">",
"     3,5,6,11-13,19",
"    </a>",
"    ]. Many of these studies included patients who initially required dialysis or had plasma creatinine concentration &ge;5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (440",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    prior to therapy; posttreatment values were often below 2",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (176",
"    <span class=\"nowrap\">",
"     micromol/L).",
"    </span>",
"   </p>",
"   <p>",
"    Patients with AKI due to hypercalcemia and volume depletion are most likely to do well. By comparison, those with dense cast formation and significant tubular damage are less likely to recover kidney function [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30409/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     CHRONIC KIDNEY DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Optimal therapy is less certain in slowly progressive disease that appears to be due to myeloma cast nephropathy. Plasmapheresis plus chemotherapy has been used in uncontrolled studies, with some patients with preserved urine output showing improvement in renal function [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30409/abstract/12,20\">",
"     12,20",
"    </a>",
"    ]. Improvement is much less likely in patients with diffuse, dense intratubular cast formation on kidney biopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30409/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is insufficient evidence of benefit from plasmapheresis among patients with chronic, slowly progressive renal failure. Thus, we generally suggest chemotherapy alone to reduce light chain production.",
"   </p>",
"   <p>",
"    Issues related to the general management of complications of chronic kidney disease are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/35/37434?source=see_link\">",
"     \"Overview of the management of chronic kidney disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     End-stage renal disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with progression to end-stage renal disease (ESRD) can be treated with hemodialysis or peritoneal dialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30409/abstract/36-38\">",
"     36-38",
"    </a>",
"    ]. Of patients with ESRD due to multiple myeloma who survive the first two months, actuarial survival is approximately 45 percent at one year, and 25 to 30 percent at two to three years [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30409/abstract/36\">",
"     36",
"    </a>",
"    ]. Patients with ESRD who respond to chemotherapy with a reduction in light chain production appear to do much better, with a mean survival of 47 months in one study (versus only 17 months in nonresponders) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30409/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The survival of patients requiring dialysis for renal failure may be similar to that of patients with less severe renal impairment:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One retrospective study evaluated mortality among 140 patients with multiple myeloma [",
"      <a class=\"abstract\" href=\"UTD.htm?29/44/30409/abstract/39\">",
"       39",
"      </a>",
"      ]. Median survival was 22 months for those with renal failure treated with dialysis as well as those with lesser degrees of renal dysfunction.",
"     </li>",
"     <li>",
"      In another report, the median survival of 38 patients on hemodialysis was more than 51 months following autologous hematopoietic cell transplantation, which was similar to the reported survival of 43 patients with renal insufficiency but not on hemodialysis who received the same treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?29/44/30409/abstract/40\">",
"       40",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/47/31482?source=see_link\">",
"       \"Autologous hematopoietic cell transplantation in multiple myeloma\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Kidney transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The experience with kidney transplantation in multiple myeloma is limited to case reports and case series, with fewer than 50 patients being reported [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30409/abstract/30,41,42\">",
"     30,41,42",
"    </a>",
"    ]. A review of eight case reports noted renal and patient survival of 14 to &gt;96 months [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30409/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, in the absence of control of excessive light chain production, outcomes are not favorable. This was illustrated in a retrospective review of seven patients with light chain deposition disease (LCDD) who underwent renal transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30409/abstract/30\">",
"     30",
"    </a>",
"    ]. One patient died shortly after transplant of progression of multiple myeloma, and LCDD recurred in five patients after a median of 33 months (range 2 to 45). Four of the patients with recurrent disease died shortly after recurrence; only one patient had a successful transplant outcome.",
"   </p>",
"   <p>",
"    However, kidney transplantation could theoretically be considered in patients who have undergone successful hematopoietic cell transplantation and have achieved a hematologic stringent complete response.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most effective therapy of myeloma cast nephropathy is prevention by minimizing the risk factors that promote light chain filtration and subsequent tubular obstruction by casts [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30409/abstract/5\">",
"     5",
"    </a>",
"    ]. This includes fluid therapy, which has long been considered a mainstay of therapy to \"flush\" out intratubular casts, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    , which has been demonstrated to rapidly reduce light chain formation. Thus, two modalities are indicated in almost all patients:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intravenous fluids to prevent volume depletion and maintain a high urine output (approximately 3",
"      <span class=\"nowrap\">",
"       L/day),",
"      </span>",
"      unless contraindicated. The goals of fluid therapy are to decrease the light chain concentration within the tubular lumen and produce a high urine flow rate to minimize light chain precipitation. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Management strategy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       Dexamethasone",
"      </a>",
"      -based chemotherapy (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"       thalidomide",
"      </a>",
"      and dexamethasone, or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/63/11257?source=see_link\">",
"       bortezomib",
"      </a>",
"      , thalidomide, and dexamethasone) initiated as rapidly as possible to decrease light chain production. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/54/18282?source=see_link\">",
"       \"Initial chemotherapy for symptomatic multiple myeloma in patients who are candidates for transplantation\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, it is important to avoid nonsteroidal antiinflammatory drugs and intravenous radiocontrast materials, as well as any other potential nephrotoxins.",
"   </p>",
"   <p>",
"    Experimental studies suggest that the following modalities may be beneficial by decreasing the pathogenetically important interaction of filtered light chains with Tamm-Horsfall mucoprotein that is secreted by the thick ascending limb of the loop of Henle [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30409/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/1/22551?source=see_link\">",
"     \"Pathogenesis and diagnosis of myeloma cast nephropathy (myeloma kidney)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Alkalinization of the urine. Raising the urine pH above 6.0 to 6.5 (toward or above the isoelectric point of the light chain) will make light chains that have a net positive charge become neutral or even anionic [",
"      <a class=\"abstract\" href=\"UTD.htm?29/44/30409/abstract/4,43\">",
"       4,43",
"      </a>",
"      ]. This will decrease the charge interaction between the light chains and highly anionic Tamm-Horsfall mucoprotein.",
"     </li>",
"     <li>",
"      Avoidance of loop diuretics unless the patient is hypercalcemic. By raising the tubular fluid sodium chloride concentration, these drugs create an environment that appears to favor the coaggregation of light chains with Tamm-Horsfall mucoprotein [",
"      <a class=\"abstract\" href=\"UTD.htm?29/44/30409/abstract/4\">",
"       4",
"      </a>",
"      ]. Diuretics may also promote cast formation by a second mechanism: the induction of volume depletion, leading to a lower urine flow rate after the diuretic effect has worn off.",
"     </li>",
"     <li>",
"      The administration of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"       colchicine",
"      </a>",
"      . Colchicine protects animals against intratubular cast formation both by decreasing Tamm-Horsfall mucoprotein secretion into the lumen and by partially impairing the interaction between this protein and the light chains [",
"      <a class=\"abstract\" href=\"UTD.htm?29/44/30409/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The therapeutic efficacy of urine alkalinization,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    and avoidance of loop diuretics in humans remains to be proven.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16988507\">",
"    <span class=\"h2\">",
"     Future directions",
"    </span>",
"    &nbsp;&mdash;&nbsp;A cyclized peptide designed to interfere with the binding of immunoglobulin light chain to Tamm Horsfall protein (THP) was successfully tested in animals [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30409/abstract/44\">",
"     44",
"    </a>",
"    ]. This cyclic peptide mimics the complementarity-determining region 3 (CDR3) on the immunoglobulin light chain, and competitively inhibits the binding of THP to the immunoglobulin light chain. In animal models, coadministration of the cyclized peptide with monoclonal immunoglobulin light chains capable of causing myeloma cast nephropathy prevented the development of acute kidney injury which was observed in the vehicle-treated animals. More exciting is the rescue experiment which showed protection from acute kidney injury when the cyclized peptide was injected 4 hours after the immunoglobulin light chains. Experiments with longer duration between immunoglobulin light chains and cyclized peptide are needed to confirm its efficacy in the treatment of myeloma cast nephropathy. However, the concept represents a new paradigm in the treatment of immunoglobulin light chain-related kidney diseases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?12/16/12547?source=see_link\">",
"       \"Patient information: Multiple myeloma symptoms, diagnosis, and staging (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?30/40/31366?source=see_link\">",
"       \"Patient information: Multiple myeloma treatment (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal failure is a relatively common problem in patients with multiple myeloma, with approximately 20 percent having a plasma creatinine &ge;2",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (176",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    at presentation. Common causes of acute kidney injury (AKI) are hypercalcemia, volume depletion, and excess light chain production. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/48/27400?source=see_link\">",
"     \"Types of renal disease in multiple myeloma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For the management of patients with AKI associated with multiple myeloma:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/63/11257?source=see_link\">",
"       bortezomib",
"      </a>",
"      -based chemotherapy (eg, bortezomib,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"       thalidomide",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      [VTD], bortezomib,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      and dexamethasone or bortezomib,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      , and dexamethasone [VCD]) initiated as rapidly as possible to decrease light chain production for patients with multiple myeloma who have AKI with a course and findings consistent with myeloma cast nephropathy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/1/28698?source=see_link\">",
"       \"Initial chemotherapy for symptomatic multiple myeloma in patients who are NOT candidates for transplantation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      If volume depletion is present clinically (eg, hypotension, decreased skin turgor), isotonic fluids should be provided for initial volume replacement (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/56/24457?source=see_link\">",
"       \"Etiology, clinical manifestations, and diagnosis of volume depletion in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/7/34935?source=see_link\">",
"       \"Maintenance and replacement fluid therapy in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/20/13639?source=see_link\">",
"       \"Treatment of severe hypovolemia or hypovolemic shock in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We recommend fluid therapy for the maintenance of euvolemia and high urine output (&ge;3",
"      <span class=\"nowrap\">",
"       L/day),",
"      </span>",
"      in the treatment of AKI related to multiple myeloma (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). We suggest isotonic or one-half isotonic saline at a rate of 100 to 150",
"      <span class=\"nowrap\">",
"       mL/hour,",
"      </span>",
"      which is adjusted to achieve a urine output of approximately 3",
"      <span class=\"nowrap\">",
"       L/day.",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Management strategy'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      This regimen requires careful monitoring, since it can lead to fluid overload in patients who cannot excrete the administered fluid because of renal insufficiency or heart failure. In such patients, or those who are fluid overloaded at presentation, a loop diuretic should be given.",
"      <br/>",
"      <br/>",
"      In patients with AKI and oliguria, we still administer the fluid regimen described above. Within 24 hours, reversal of oliguria should become evident. If oliguria persists, fluid administration should to be modified to prevent volume overload.",
"     </li>",
"     <li>",
"      We base treatment of hypercalcemia on the initial serum calcium concentration. For severe or refractory hypercalcemia, we recommend treatment with bisphosphonates (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Management strategy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/42/16041?source=see_link&amp;anchor=H6#H6\">",
"       \"Treatment of hypercalcemia\", section on 'Bisphosphonates'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/27/30137?source=see_link\">",
"       \"The use of bisphosphonates in patients with multiple myeloma\"",
"      </a>",
"      .) Bisphosphonates must be used cautiously in patients with significant renal impairment or vitamin D deficiency, as the risk of inducing hypocalcemia is increased. We use the following strategy:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      If the corrected serum calcium concentration is elevated, but &lt;14",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (4",
"      <span class=\"nowrap\">",
"       mmol/L),",
"      </span>",
"      we treat initially with the fluid regimen previously mentioned. If hypercalcemia persists despite 6 to 12 hours of fluids, we administer a bisphosphonate (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/1/9241?source=see_link\">",
"       zoledronic acid",
"      </a>",
"      4 mg IV over 15 minutes or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/62/3048?source=see_link\">",
"       pamidronate",
"      </a>",
"      60 to 90 mg over two to three hours, with the dose appropriately adjusted for kidney function).",
"     </li>",
"     <li>",
"      If the corrected serum calcium concentration is &ge;14",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (4",
"      <span class=\"nowrap\">",
"       mmol/L),",
"      </span>",
"      we administer bisphosphonates immediately, concurrently with the fluid regimen described above.",
"     </li>",
"     <li>",
"      Bisphosphonates must be used cautiously in patients with significant renal impairment or vitamin D deficiency, as the risk of inducing hypocalcemia is increased.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hyperuricemia, if present, should be treated. This is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/57/27541?source=see_link&amp;anchor=H2#H2\">",
"       \"Uric acid renal diseases\", section on 'Acute uric acid nephropathy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Nephrotoxic agents, such as nonsteroidal antiinflammatory drugs, and ACE inhibitors or angiotensin receptor blockers should be stopped, and radiocontrast dye avoided if possible.",
"     </li>",
"     <li>",
"      Although the evidence of benefit is limited, we suggest plasmapheresis for the removal of the toxic circulating light chains in patients with multiple myeloma who have AKI with a course consistent with myeloma cast nephropathy and monoclonal free light chains in the serum or urine, or who have cast nephropathy on kidney biopsy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Indications for plasmapheresis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      We use a regimen of five to seven exchanges within seven to ten days, in conjunction with chemotherapy. A review of the technical issues associated with this procedure is discussed separately. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Plasmapheresis protocol'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/33/38420?source=see_link\">",
"       \"Prescription and technique of therapeutic plasma exchange\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We recommend repeating the relevant monoclonal light chain assay one to two days after completing the initial course of plasmapheresis. We generally target a light chain reduction of60%. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/58/10154?source=see_link\">",
"       \"Recognition of monoclonal proteins\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with AKI who progress to requiring dialysis may be treated with either hemodialysis or peritoneal dialysis; however, we suggest hemodialysis in the acute setting for patients undergoing plasmapheresis, as the same catheter can be used for both procedures (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). For chronic dialysis, either modality is a reasonable option. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'End-stage renal disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For the prevention of myeloma cast nephropathy we recommend Intravenous fluids, unless contraindicated, to prevent volume depletion and maintain a high urine output (approximately 3",
"      <span class=\"nowrap\">",
"       L/day)",
"      </span>",
"      (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ).",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       Dexamethasone",
"      </a>",
"      -based chemotherapy (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"       thalidomide",
"      </a>",
"      and dexamethasone, or dexamethasone alone), is indicated. Nephrotoxic agents should also be avoided. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Prevention'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/54/18282?source=see_link\">",
"       \"Initial chemotherapy for symptomatic multiple myeloma in patients who are candidates for transplantation\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30409/abstract/1\">",
"      Blad&eacute; J, Fern&aacute;ndez-Llama P, Bosch F, et al. Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution. Arch Intern Med 1998; 158:1889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30409/abstract/2\">",
"      Winearls CG. Acute myeloma kidney. Kidney Int 1995; 48:1347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30409/abstract/3\">",
"      Rota S, Mougenot B, Baudouin B, et al. Multiple myeloma and severe renal failure: a clinicopathologic study of outcome and prognosis in 34 patients. Medicine (Baltimore) 1987; 66:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30409/abstract/4\">",
"      Sanders PW, Booker BB. Pathobiology of cast nephropathy from human Bence Jones proteins. J Clin Invest 1992; 89:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30409/abstract/5\">",
"      Cohen DJ, Sherman WH, Osserman EF, Appel GB. Acute renal failure in patients with multiple myeloma. Am J Med 1984; 76:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30409/abstract/6\">",
"      Uchida M, Kamata K, Okubo M. Renal dysfunction in multiple myeloma. Intern Med 1995; 34:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30409/abstract/7\">",
"      Hill GS, Morel-Maroger L, M&eacute;ry JP, et al. Renal lesions in multiple myeloma: their relationship to associated protein abnormalities. Am J Kidney Dis 1983; 2:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30409/abstract/8\">",
"      Buxbaum JN, Chuba JV, Hellman GC, et al. Monoclonal immunoglobulin deposition disease: light chain and light and heavy chain deposition diseases and their relation to light chain amyloidosis. Clinical features, immunopathology, and molecular analysis. Ann Intern Med 1990; 112:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30409/abstract/9\">",
"      Lorenz EC, Sethi S, Poshusta TL, et al. Renal failure due to combined cast nephropathy, amyloidosis and light-chain deposition disease. Nephrol Dial Transplant 2010; 25:1340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30409/abstract/10\">",
"      Leung N, Gertz M, Kyle RA, et al. Urinary albumin excretion patterns of patients with cast nephropathy and other monoclonal gammopathy-related kidney diseases. Clin J Am Soc Nephrol 2012; 7:1964.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30409/abstract/11\">",
"      Zucchelli P, Pasquali S, Cagnoli L, Ferrari G. Controlled plasma exchange trial in acute renal failure due to multiple myeloma. Kidney Int 1988; 33:1175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30409/abstract/12\">",
"      Misiani R, Tiraboschi G, Mingardi G, Mecca G. Management of myeloma kidney: an anti-light-chain approach. Am J Kidney Dis 1987; 10:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30409/abstract/13\">",
"      Johnson WJ, Kyle RA, Pineda AA, et al. Treatment of renal failure associated with multiple myeloma. Plasmapheresis, hemodialysis, and chemotherapy. Arch Intern Med 1990; 150:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30409/abstract/14\">",
"      Ludwig H, Adam Z, Hajek R, et al. Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma: results of a phase II study. J Clin Oncol 2010; 28:4635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30409/abstract/15\">",
"      Sonneveld P, Schmidt-Wolf IG, van der Holt B, et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial. J Clin Oncol 2012; 30:2946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30409/abstract/16\">",
"      Ross JR, Saunders Y, Edmonds PM, et al. A systematic review of the role of bisphosphonates in metastatic disease. Health Technol Assess 2004; 8:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30409/abstract/17\">",
"      Li EC, Davis LE. Zoledronic acid: a new parenteral bisphosphonate. Clin Ther 2003; 25:2669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30409/abstract/18\">",
"      Munier A, Gras V, Andrejak M, et al. Zoledronic Acid and renal toxicity: data from French adverse effect reporting database. Ann Pharmacother 2005; 39:1194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30409/abstract/19\">",
"      Alexanian R, Barlogie B, Dixon D. Renal failure in multiple myeloma. Pathogenesis and prognostic implications. Arch Intern Med 1990; 150:1693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30409/abstract/20\">",
"      Kaplan AA. Therapeutic apheresis for the renal complications of multiple myeloma and the dysglobulinemias. Ther Apher 2001; 5:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30409/abstract/21\">",
"      Durie BG, Kyle RA, Belch A, et al. Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation. Hematol J 2003; 4:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30409/abstract/22\">",
"      Clark WF, Stewart AK, Rock GA, et al. Plasma exchange when myeloma presents as acute renal failure: a randomized, controlled trial. Ann Intern Med 2005; 143:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30409/abstract/23\">",
"      Cserti C, Haspel R, Stowell C, Dzik W. Light-chain removal by plasmapheresis in myeloma-associated renal failure. Transfusion 2007; 47:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30409/abstract/24\">",
"      Gertz MA. Managing myeloma kidney. Ann Intern Med 2005; 143:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30409/abstract/25\">",
"      Leung N. Plasma exchange in multiple myeloma. Ann Intern Med 2006; 144:455; author reply 455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30409/abstract/26\">",
"      Leung N, Gertz MA, Zeldenrust SR, et al. Improvement of cast nephropathy with plasma exchange depends on the diagnosis and on reduction of serum free light chains. Kidney Int 2008; 73:1282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30409/abstract/27\">",
"      Clark WF, Garg AX. Plasma exchange for myeloma kidney: cast(s) away? Kidney Int 2008; 73:1211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30409/abstract/28\">",
"      Burnette BL, Leung N, Rajkumar SV. Renal improvement in myeloma with bortezomib plus plasma exchange. N Engl J Med 2011; 364:2365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30409/abstract/29\">",
"      Hutchison CA, Bradwell AR, Cook M, et al. Treatment of acute renal failure secondary to multiple myeloma with chemotherapy and extended high cut-off hemodialysis. Clin J Am Soc Nephrol 2009; 4:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30409/abstract/30\">",
"      Leung N, Lager DJ, Gertz MA, et al. Long-term outcome of renal transplantation in light-chain deposition disease. Am J Kidney Dis 2004; 43:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30409/abstract/31\">",
"      Hutchison CA, Cockwell P, Stringer S, et al. Early reduction of serum-free light chains associates with renal recovery in myeloma kidney. J Am Soc Nephrol 2011; 22:1129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30409/abstract/32\">",
"      Russell JA, Fitzharris BM, Corringham R, et al. Plasma exchange v peritoneal dialysis for removing Bence Jones protein. Br Med J 1978; 2:1397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30409/abstract/33\">",
"      Hutchison CA, Cockwell P, Reid S, et al. Efficient removal of immunoglobulin free light chains by hemodialysis for multiple myeloma: in vitro and in vivo studies. J Am Soc Nephrol 2007; 18:886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30409/abstract/34\">",
"      Dimopoulos MA, Terpos E, Chanan-Khan A, et al. Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. J Clin Oncol 2010; 28:4976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30409/abstract/35\">",
"      Chow CC, Mo KL, Chan CK, et al. Renal impairment in patients with multiple myeloma. Hong Kong Med J 2003; 9:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30409/abstract/36\">",
"      Iggo N, Palmer AB, Severn A, et al. Chronic dialysis in patients with multiple myeloma and renal failure: a worthwhile treatment. Q J Med 1989; 73:903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30409/abstract/37\">",
"      Korzets A, Tam F, Russell G, et al. The role of continuous ambulatory peritoneal dialysis in end-stage renal failure due to multiple myeloma. Am J Kidney Dis 1990; 16:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30409/abstract/38\">",
"      Torra R, Blad&eacute; J, Cases A, et al. Patients with multiple myeloma requiring long-term dialysis: presenting features, response to therapy, and outcome in a series of 20 cases. Br J Haematol 1995; 91:854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30409/abstract/39\">",
"      Sharland A, Snowdon L, Joshua DE, et al. Hemodialysis: an appropriate therapy in myeloma-induced renal failure. Am J Kidney Dis 1997; 30:786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30409/abstract/40\">",
"      Badros A, Barlogie B, Siegel E, et al. Results of autologous stem cell transplant in multiple myeloma patients with renal failure. Br J Haematol 2001; 114:822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30409/abstract/41\">",
"      Dagher F, Sammett D, Abbi R, et al. Renal transplantation in multiple myeloma. Case report and review of the literature. Transplantation 1996; 62:1577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30409/abstract/42\">",
"      Heher EC, Spitzer TR, Goes NB. Light chains: heavy burden in kidney transplantation. Transplantation 2009; 87:947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30409/abstract/43\">",
"      Holland MD, Galla JH, Sanders PW, Luke RG. Effect of urinary pH and diatrizoate on Bence Jones protein nephrotoxicity in the rat. Kidney Int 1985; 27:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30409/abstract/44\">",
"      Ying WZ, Allen CE, Curtis LM, et al. Mechanism and prevention of acute kidney injury from cast nephropathy in a rodent model. J Clin Invest 2012; 122:1777.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7211 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-956556EC73-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_44_30409=[""].join("\n");
var outline_f29_44_30409=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ACUTE KIDNEY INJURY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Management strategy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5238270\">",
"      - Myeloma cast nephropathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5238293\">",
"      - Volume depletion, hypercalcemia, and hyperuricemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5238301\">",
"      - Hypercalcemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5238345\">",
"      - Hyperuricemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5238353\">",
"      - Drugs with renal toxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Plasmapheresis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Indications for plasmapheresis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Plasmapheresis protocol",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16988475\">",
"      High cutoff dialyzer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Dialysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27343464\">",
"      Gauging the treatment response",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      CHRONIC KIDNEY DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      End-stage renal disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Kidney transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16988507\">",
"      Future directions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/7211\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/7211|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/55/42878\" title=\"figure 1\">",
"      Plasmapheresis in myeloma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/47/31482?source=related_link\">",
"      Autologous hematopoietic cell transplantation in multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/31/43512?source=related_link\">",
"      Collapsing focal segmental glomerulosclerosis not associated with HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/29/8666?source=related_link\">",
"      Determination of initial therapy in patients with multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/56/24457?source=related_link\">",
"      Etiology, clinical manifestations, and diagnosis of volume depletion in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/1/28698?source=related_link\">",
"      Initial chemotherapy for symptomatic multiple myeloma in patients who are NOT candidates for transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/54/18282?source=related_link\">",
"      Initial chemotherapy for symptomatic multiple myeloma in patients who are candidates for transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/7/34935?source=related_link\">",
"      Maintenance and replacement fluid therapy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/35/37434?source=related_link\">",
"      Overview of the management of chronic kidney disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/1/22551?source=related_link\">",
"      Pathogenesis and diagnosis of myeloma cast nephropathy (myeloma kidney)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/62/35815?source=related_link\">",
"      Pathogenesis of immunoglobulin light chain (AL) amyloidosis and light and heavy chain deposition diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?12/16/12547?source=related_link\">",
"      Patient information: Multiple myeloma symptoms, diagnosis, and staging (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?30/40/31366?source=related_link\">",
"      Patient information: Multiple myeloma treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/33/38420?source=related_link\">",
"      Prescription and technique of therapeutic plasma exchange",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/58/10154?source=related_link\">",
"      Recognition of monoclonal proteins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/37/4696?source=related_link\">",
"      Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure): Recovery of renal function and effect of hemodialysis membrane",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/12/3273?source=related_link\">",
"      Renal vein thrombosis and hypercoagulable state in nephrotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/27/30137?source=related_link\">",
"      The use of bisphosphonates in patients with multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/42/16041?source=related_link\">",
"      Treatment of hypercalcemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/20/13639?source=related_link\">",
"      Treatment of severe hypovolemia or hypovolemic shock in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/48/27400?source=related_link\">",
"      Types of renal disease in multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/57/27541?source=related_link\">",
"      Uric acid renal diseases",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_44_30410="Diagnostic and prognostic implications of coronary artery calcification detected by computed tomography";
var content_f29_44_30410=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Diagnostic and prognostic implications of coronary artery calcification detected by computed tomography",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/44/30410/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/44/30410/contributors\">",
"     Thomas C Gerber, MD, PhD, FACC, FAHA",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/44/30410/contributors\">",
"     Christopher M Kramer, MD, FACC, FAHA",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/44/30410/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/44/30410/contributors\">",
"     Warren J Manning, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/44/30410/contributors\">",
"     Bernard J Gersh, MB, ChB, DPhil, FRCP, MACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/44/30410/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/44/30410/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?29/44/30410/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 28, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The association between vascular calcification and vascular disease has been known to anatomists and pathologists for several hundred years. Radiologic detection of coronary artery calcification (CAC) in vivo by fluoroscopy was described in the late 1950s [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30410/abstract/1\">",
"     1",
"    </a>",
"    ], and an association between the presence of CAC and the risk of cardiovascular events was subsequently demonstrated [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30410/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic will review the diagnostic and prognostic use of CAC. Coronary computed tomography angiography (CCTA) is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/26/20906?source=see_link\">",
"     \"Noninvasive coronary imaging with cardiac computed tomography and cardiovascular magnetic resonance\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     COMPUTED TOMOGRAPHY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     CT scanner types",
"    </span>",
"    &nbsp;&mdash;&nbsp;The development of electron beam computed tomographic scanning (EBCT) in the early 1980s permitted noninvasive and quantitative detection of CAC for the first time. The most widely used and best-established measure of CAC for assessment of the diagnostic and prognostic value of EBCT CAC scanning is the Agatston score [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30410/abstract/3\">",
"     3",
"    </a>",
"    ]. Other measures, such as the volume score and calcium mass have been less well studied.",
"   </p>",
"   <p>",
"    Since 1999, the temporal resolution of multidetector row or multislice CT scanners (MDCT or MSCT) has improved sufficiently to permit imaging of the beating heart with no or little motion artifact. The early studies examining the diagnostic and prognostic value of CAC scanning that are discussed below have been conducted with EBCT. However, EBCT is now essentially obsolete. 64-detector MDCT is considered state-of-the-art and most newer studies of CAC have been performed with this technology. One study demonstrated that CAC scores using both volume score and Agatston score were equivalent between EBT and 64-detector MDCT [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30410/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The software used to analyze CAC has been shown to generate some variability. However, intra- and inter-scan agreement of CAC measured on the same MDCT scanner is quite high [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30410/abstract/5\">",
"     5",
"    </a>",
"    ]. Methods for measuring CAC from contrast-enhanced CT angiograms have been proposed [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30410/abstract/6\">",
"     6",
"    </a>",
"    ]. However, non-contrast scans remain the standard for making these measurements.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     CAC scanning",
"    </span>",
"    &nbsp;&mdash;&nbsp;CAC scanning by MDCT is often marketed directly to the consumer and may be available without physician referral. As a result, many asymptomatic individuals undergo CAC scanning and then present to their health care providers for a discussion of their normal or abnormal test results.",
"   </p>",
"   <p>",
"    Coronary CT angiography using multidetector CT scanners has also been marketed to the consumer and has lead to decreased use of isolated CAC scanning. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/26/20906?source=see_link&amp;anchor=H22#H22\">",
"     \"Noninvasive coronary imaging with cardiac computed tomography and cardiovascular magnetic resonance\", section on 'Coronary CT angiography'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    CAC scoring was not initially accepted as a screening tool for asymptomatic patients within the cardiovascular community. However, the 2010 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart Association",
"    <span class=\"nowrap\">",
"     (ACC/AHA)",
"    </span>",
"    guidelines on screening for coronary artery disease indicated that measurement of CAC is reasonable for cardiovascular risk assessment in asymptomatic adults at intermediate risk (10 to 20 percent 10-year risk) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30410/abstract/7\">",
"     7",
"    </a>",
"    ]. The guidelines noted that measurement of CAC &ldquo;may be reasonable&rdquo; for patients at low to intermediate risk (6 to 10 percent 10-year risk). It was not recommended for patients at low (&lt;6 percent, 10-year risk) or high risk. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/50/26409?source=see_link\">",
"     \"Screening for coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The data addressing the diagnostic and prognostic implications of CAC scanning will be reviewed here. The use of MDCT and other modalities for noninvasive coronary angiography are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/26/20906?source=see_link\">",
"     \"Noninvasive coronary imaging with cardiac computed tomography and cardiovascular magnetic resonance\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Radiation exposure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Examinations performed to quantify CAC generally impart a lower radiation dose than examinations performed for coronary CT angiography (CCTA) (",
"    <a class=\"graphic graphic_table graphicRef50090 \" href=\"UTD.htm?4/60/5069\">",
"     table 1",
"    </a>",
"    ). A typical dose is 1 to 2 mSv. A study suggested that CAC scoring using a tube voltage of 100 kVp rather than 120 kVp gives the equivalent imaging result with a lower radiation dose (1.17 versus 1.70 mSv) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30410/abstract/8\">",
"     8",
"    </a>",
"    ]. Radiation dose and radiation risk in cardiovascular imaging are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/2/14376?source=see_link\">",
"     \"Radiation dose and risk of malignancy from cardiovascular imaging\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CAC AND CORONARY ARTERY STENOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence and extent of CAC can predict the presence of coronary artery stenoses, but in general it is a better marker of the extent of coronary atherosclerosis than the severity of stenosis. Most of the clinical studies that examined the relationship between CAC and coronary artery stenoses have been performed in patients with chest pain who were referred for x-ray coronary angiography. Other studies evaluated coronary artery specimens obtained at autopsy.",
"   </p>",
"   <p>",
"    Direct relationships have been established between CAC scores and histologic, intracoronary ultrasonic, and angiographic measures of coronary artery atherosclerosis and plaque burden on a vessel-by-vessel and segment-by-segment basis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30410/abstract/9-13\">",
"     9-13",
"    </a>",
"    ]. However, MDCT performed without contrast enhancement has a low sensitivity for detecting plaques without appreciable calcification [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30410/abstract/10\">",
"     10",
"    </a>",
"    ] and in one study, the cross-sectional plaque area found on histologic examination was approximately five times greater than the calcification area measured by EBCT [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30410/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because of vascular remodeling, there is a compensatory enlargement of arteries in early atherosclerosis that serves to accommodate the growing plaque [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30410/abstract/14\">",
"     14",
"    </a>",
"    ]. As a result, extensive CAC may be present before the plaque burden overwhelms vascular remodeling, begins to encroach upon the vessel lumen, and leads to clinically relevant stenosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     CAC scoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;In both men and women, CAC detected by CT is highly sensitive for the presence of &ge;50 percent angiographic stenosis but only moderately specific, especially in individuals over 60 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30410/abstract/11-13,15-17\">",
"     11-13,15-17",
"    </a>",
"    ]. In a review of 16 studies, the sensitivity and specificity of EBCT were 91 and 49 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30410/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, the absence of CAC is highly predictive of the absence of significant (greater than 50 percent) coronary artery stenosis. In three series, patients with no CAC had a probability of significant coronary stenosis of less than 1 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30410/abstract/15\">",
"     15",
"    </a>",
"    ]. The frequency of converting to a positive CAC score from 0 over a mean of 4.1&plusmn;0.9 years in a study of 422 individuals was 25 percent and was associated with age, diabetes, and cigarette smoking [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30410/abstract/19\">",
"     19",
"    </a>",
"    ]. The highest rate of conversion was in the fifth year as the rate of conversion was nonlinear.",
"   </p>",
"   <p>",
"    In a number of studies, the following definitions have been used to relate the CAC score and coronary plaque burden [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30410/abstract/20-24\">",
"     20-24",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      0 &mdash; no identifiable disease",
"     </li>",
"     <li>",
"      1 to 99 &mdash; mild disease",
"     </li>",
"     <li>",
"      100 to 399 &mdash; moderate disease",
"     </li>",
"     <li>",
"      &ge;400 &mdash; severe disease",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Both sensitivity and specificity for the presence of &ge;50 percent angiographic stenosis vary with the amount of CAC; with more marked CAC, sensitivity falls but specificity increases. Diagnostic accuracy can be improved by the use of age- and gender-specific threshold values [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30410/abstract/15-17\">",
"     15-17",
"    </a>",
"    ]. The importance of age and gender was illustrated in a review of 1764 patients in which EBCT was compared to x-ray coronary angiography [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30410/abstract/15\">",
"     15",
"    </a>",
"    ]. The following findings were noted (",
"    <a class=\"graphic graphic_figure graphicRef52901 \" href=\"UTD.htm?43/8/44174\">",
"     figure 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In men &lt;40 years of age, 95 percent of those without significant stenosis (&ge;50 percent narrowing) had a CAC score of 8 or less, while for men &gt;70 years of age, the score in 95 percent of those without significant stenosis was 134 or less. The comparable values in women were 5 and 88.",
"     </li>",
"     <li>",
"      As the Agatston CAC score varied from &gt;20th percentile to &gt;75th percentile for age, the sensitivity fell from 97 to 81 percent in men and from 98 to 76 percent in women but the specificity increased up to 77 percent.",
"     </li>",
"     <li>",
"      The ACCURACY trial confirmed the high sensitivity but low specificity of CAC for obstructive disease (&gt;50 percent stenosis) [",
"      <a class=\"abstract\" href=\"UTD.htm?29/44/30410/abstract/25\">",
"       25",
"      </a>",
"      ]. The",
"      <span class=\"nowrap\">",
"       sensitivity/specificity",
"      </span>",
"      for CAC &gt;0, &gt;100, and &gt;400 were 98",
"      <span class=\"nowrap\">",
"       percent/42",
"      </span>",
"      percent, 88",
"      <span class=\"nowrap\">",
"       percent/71",
"      </span>",
"      percent, and 60",
"      <span class=\"nowrap\">",
"       percent/88",
"      </span>",
"      percent, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Importance of ethnicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ethnicity affects the likelihood of having CAC [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30410/abstract/26-30\">",
"     26-30",
"    </a>",
"    ] but the predictive value of CAC is similar among various ethnic groups. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Effect on prognosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The magnitude of differences in prevalence and extent of CAC among ethnic groups was illustrated in reports from the population-based Multi-Ethnic Study of Atherosclerosis (MESA) of 6814 men and women (mean age 63 years) in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30410/abstract/28-30\">",
"     28-30",
"    </a>",
"    ]. The participants had no clinical cardiovascular disease and treated diabetic patients were excluded. Among men, the prevalence of CAC was significantly higher in whites than in Chinese, Hispanics, and blacks (70 versus 59, 56, and 52 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30410/abstract/28\">",
"     28",
"    </a>",
"    ]. A similar trend was noted in women, although CAC was less common (45 versus 42, 35, and 37 percent, respectively).",
"   </p>",
"   <p>",
"    A later report from MESA assessed the distribution of CAC according to age, gender, race, and ethnicity [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30410/abstract/29\">",
"     29",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      As with the prevalence of clinical coronary disease, CAC scores were higher in men compared to women and increased progressively with age.",
"     </li>",
"     <li>",
"      For men, CAC scores were highest in whites and Hispanics; the scores were lowest in blacks at younger ages and Chinese at older ages.",
"     </li>",
"     <li>",
"      For women, CAC scores were highest in whites and generally lowest in Hispanics, although Chinese women had the lowest scores in the oldest age group.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A third report from MESA evaluated CAC according to ethnicity, acculturation, and socioeconomic status [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30410/abstract/30\">",
"     30",
"    </a>",
"    ]. The following findings were noted, which could not be explained by differences in smoking, body mass index, lipid levels, diabetes, or hypertension.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      After adjustment for age, sex, and income, not being born in the United States was associated with a lower prevalence of CAC in both blacks and Hispanics (adjusted relative prevalence [RP] 0.75 and 0.89, respectively).",
"     </li>",
"     <li>",
"      For Chinese not born in the United States, the prevalence of CAC increased with the duration of residence in the United States (adjusted RP 1.06 for each 10 years of residence).",
"     </li>",
"     <li>",
"      Low education (no high school compared to completed college) was associated with a higher prevalence of CAC in whites (adjusted RP 1.17) but a trend toward a lower prevalence of CAC in Hispanics.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     CAC AND MYOCARDIAL ISCHEMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;CAC is present in most patients with myocardial ischemia, both symptomatic and asymptomatic. Silent (asymptomatic) myocardial ischemia is the most common manifestation of coronary heart disease (CHD), accounting for more than 75 percent of ischemic episodes during daily life. Most silent ischemic episodes occur during minimal or no physical exertion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/9/42135?source=see_link\">",
"     \"Silent myocardial ischemia: Epidemiology and pathogenesis\"",
"    </a>",
"    .) Conversely, because CAC is very prevalent, particularly with increasing age and in men, many patients with CAC do not have ischemia.",
"   </p>",
"   <p>",
"    The relationship between silent ischemia, detected by stress testing, and CAC has been evaluated in a number of studies [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30410/abstract/22,31-33\">",
"     22,31-33",
"    </a>",
"    ]. The following observations illustrate the range of findings, which show only a modest correlation between the abnormalities that is not sufficient to be predictive:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one report, 1195 patients without known CHD underwent both stress radionuclide myocardial perfusion imaging (rMPI) and CAC scanning in close temporal proximity [",
"      <a class=\"abstract\" href=\"UTD.htm?29/44/30410/abstract/22\">",
"       22",
"      </a>",
"      ]. Among the 76 patients with stress-induced ischemia, the CAC score was &gt;0 in 95 percent, &ge;100 in 88 percent, and &ge;400 in 68 percent. Not surprisingly, CAC was also present, although less prevalent, in patients without stress-induced ischemia; the respective values were 78, 56, and 31 percent. The frequency of ischemia on radionuclide myocardial perfusion imaging was less than 2 percent overall in patients with CAC scores &lt;100.",
"     </li>",
"     <li>",
"      Similar findings were noted in a study of 411 patients who had an exercise stress test with rMPI within a close time period of EBCT [",
"      <a class=\"abstract\" href=\"UTD.htm?29/44/30410/abstract/31\">",
"       31",
"      </a>",
"      ]. Although most subjects (78 percent) with CAC on EBCT did",
"      <em>",
"       not",
"      </em>",
"      have inducible ischemia with exercise testing, the likelihood of ischemia increased with CAC score, regardless of age or sex. No subject with a score &lt;10 had ischemia, while ischemia was present in 2.6 percent of those with a score of 11 to 100, 11.3 percent with a score of 101 to 399, and 46 percent of those with a score A higher risk population was evaluated in a review of 260 apparently healthy, asymptomatic middle-aged siblings (mean age 51) of hospitalized patients with premature CHD [",
"      <a class=\"abstract\" href=\"UTD.htm?29/44/30410/abstract/33\">",
"       33",
"      </a>",
"      ]. The siblings underwent both maximal exercise testing (including rMPI) and CT CAC. Inducible ischemia on rMPI was noted in 26 percent overall, in 51 percent with a CAC score &gt;100, and in 13 percent with lower CAC scores. On the other hand, 59 percent of siblings with inducible ischemia had a CAC score &le;100.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Moreover, in a review of 222 asymptomatic men and women in the population-based MESA study, increasing CAC correlated with a progressive reduction in hyperemic myocardial blood flow, but not resting myocardial blood flow [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30410/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These observations suggest that the presence of CAC can be associated with abnormal endothelial physiology (another potential predictor of future cardiac events) at an early stage of CHD when functionally significant, fixed coronary stenoses are still absent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     EMERGENCY DEPARTMENT EVALUATION OF CHEST PAIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of CAC in evaluating patients presenting to the emergency department with chest pain is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/56/29578?source=see_link\">",
"     \"Noninvasive imaging and stress testing in patients with suspected acute coronary syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     CAC AND PROGNOSIS IN ASYMPTOMATIC PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of studies in asymptomatic patients have evaluated the ability of CAC to estimate prognosis alone, as an addition to the Framingham risk score, and in relation to other risk factors such as the serum high-sensitivity C-reactive protein (hsCRP) concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30410/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A potentially limiting factor is that most acute coronary events are due to rupture or a vulnerable or unstable plaque, not a fixed, high-grade stenosis. However, although CAC may not directly identify plaques that are prone to rupture, areas of CAC and vulnerable or unstable plaques colocalize [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30410/abstract/35\">",
"     35",
"    </a>",
"    ] and patients with extensive CAC are likely to have a large burden of noncalcified plaques. Thus, patients with high CAC scores have a high likelihood of plaques that are prone to rupture. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/7/25721?source=see_link\">",
"     \"The role of the vulnerable plaque in acute coronary syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     General predictive value",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is ample evidence that CAC score has prognostic value in asymptomatic individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30410/abstract/21,36-41\">",
"     21,36-41",
"    </a>",
"    ], especially those at intermediate risk. The following observations illustrate the range of findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of 5635 asymptomatic low to intermediate risk patients between the ages of 30 and 76 who were followed for three years, there were 224 confirmed cardiac events (death, infarction, bypass surgery, or percutaneous coronary intervention) [",
"      <a class=\"abstract\" href=\"UTD.htm?29/44/30410/abstract/36\">",
"       36",
"      </a>",
"      ]. At 37-month follow-up, the presence of any CAC at baseline (score greater than 0) was associated with a significantly higher event rate in men (6.1 versus 0.4 percent for those without any CAC) and women (3.3 versus 1.0 percent).",
"     </li>",
"     <li>",
"      The degree of risk appears to correlate with the extent of CAC as illustrated in a report of 1173 initially asymptomatic patients (mean age 53) who were followed for 19 months [",
"      <a class=\"abstract\" href=\"UTD.htm?29/44/30410/abstract/37\">",
"       37",
"      </a>",
"      ]. EBCT CAC score thresholds of 100, 160, and 680 had sensitivities for a subsequent event (mostly myocardial infarction or coronary revascularization) of 89, 89, and 53 percent, respectively, and specificities of 77, 82, and 95 percent, respectively. The odds ratios for development of symptomatic coronary artery disease ranged from 22:1 to 36:1.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The CAC score remained predictive of a cardiac event after an average follow-up of 3.6 years [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30410/abstract/38\">",
"     38",
"    </a>",
"    ]. The mean CAC score for those with and without a cardiac event was 764 and 135, respectively, and a CAC score &ge;160 was associated with an odds ratio of 15.8 for a cardiac event [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30410/abstract/38\">",
"     38",
"    </a>",
"    ]. Similar findings were noted in a prospective, population-based study of 4903 asymptomatic individuals between the ages of 50 and 70 [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30410/abstract/40\">",
"     40",
"    </a>",
"    ]. The 119 subjects who had an atherosclerotic cardiovascular event had a significantly higher CAC score than those without an event (median CAC score 384 versus 10). A CAC score &ge;100 compared to lower values was associated with a relative risk of 9.6 for all events and 9.2 for nonfatal myocardial infarction (MI) or death.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A meta-analysis of four major studies reported an adjusted relative risk of death or myocardial infarction of 2.1 for a CAC score of 1 to 100 compared to a CAC score of 0 [",
"      <a class=\"abstract\" href=\"UTD.htm?29/44/30410/abstract/21\">",
"       21",
"      </a>",
"      ]. Relative risk estimates for higher CAC scores ranged from 3.0 to 17.0 but varied widely among studies, which may have been a consequence of differences in study methodology.",
"     </li>",
"     <li>",
"      The above studies were primarily performed in middle-aged individuals, but similar relationships apply in older individuals. This was illustrated in a 3.3-year follow-up of 1795 asymptomatic participants between the ages of 62 and 85 (mean 71 years) in the population-based Rotterdam Study [",
"      <a class=\"abstract\" href=\"UTD.htm?29/44/30410/abstract/42\">",
"       42",
"      </a>",
"      ]. There were 88 cardiovascular events. The multivariate adjusted relative risk compared to a CAC score of 0 to 100 was 3.1, 4.6, and 8.3 for CAC scores of 101 to 400, 401 to 1000, and more than 1000, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Most studies evaluating the predictive value of CAC have used absolute values of the Agatston score, although few asymptomatic patients who undergo screening have Agatston scores in the range that is most predictive of CHD. In one series, for example, only 7 percent of 632 individuals in a screening population (mean age 52) had an Agatston score &gt;400; an Agatston score &gt;75th percentile for age and gender was a better predictor of future cardiac events than the absolute score [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30410/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Added value to Framingham risk score",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Framingham risk score and the modified version of this score from the National Cholesterol Education",
"    <span class=\"nowrap\">",
"     Program/Adult",
"    </span>",
"    Treatment Panel III",
"    <span class=\"nowrap\">",
"     (NCEP/ATP",
"    </span>",
"    III) uses established risk factors to estimate the 10-year absolute risk of developing coronary heart disease (CHD) in individuals without known cardiovascular disease (",
"    <a class=\"graphic graphic_table graphicRef64978 graphicRef76742 \" href=\"UTD.htm?30/1/30751\">",
"     table 2A-B",
"    </a>",
"    ) (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?9/63/10226?source=see_link\">",
"     calculator 1",
"    </a>",
"    and",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?43/28/44482?source=see_link\">",
"     calculator 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30410/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/8/39048?source=see_link\">",
"     \"Estimation of cardiovascular risk in an individual patient without known cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Identifying high-risk individuals",
"    </span>",
"    &nbsp;&mdash;&nbsp;The classification of risk according to the modified",
"    <span class=\"nowrap\">",
"     NCEP/ATP",
"    </span>",
"    III Framingham risk score (FRS) has therapeutic implications since the NCEP guidelines suggest using the score to target LDL-cholesterol goals (",
"    <a class=\"graphic graphic_table graphicRef82504 \" href=\"UTD.htm?11/4/11340\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30410/abstract/44\">",
"     44",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/28/5576?source=see_link&amp;anchor=H7#H7\">",
"     \"Overview of primary prevention of coronary heart disease and stroke\", section on 'Dyslipidemia control'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Limitations in the ability of the",
"    <span class=\"nowrap\">",
"     NCEP/ATP",
"    </span>",
"    III FRS to identify those at high risk were illustrated in a report of 1611 asymptomatic subjects (mean age 53) who underwent CAC screening [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30410/abstract/24\">",
"     24",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Severe disease, defined as a CAC score &ge;400, was present in 11 percent of men (3 percent below 55 years of age and 25 percent in older individuals) and 5 percent of women (1 percent below 55 years of age and 19 percent in older individuals).",
"     </li>",
"     <li>",
"      Many fewer subjects were considered to be at high risk according to the guidelines, defined as a 10-year CHD risk &gt;20 percent (",
"      <a class=\"graphic graphic_table graphicRef64978 graphicRef76742 \" href=\"UTD.htm?30/1/30751\">",
"       table 2A-B",
"      </a>",
"      ): 27 men (2.5 percent) and no women. The guidelines performed less well in younger subjects and in women.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The net effect is that, using the guideline recommendations for lipid-lowering drug therapy (",
"    <a class=\"graphic graphic_table graphicRef82504 \" href=\"UTD.htm?11/4/11340\">",
"     table 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef67460 \" href=\"UTD.htm?10/46/10989\">",
"     table 4",
"    </a>",
"    ), 59 percent of subjects with a CAC score &ge;400 and 73 percent with a CAC score &ge;75th percentile would not have been given pharmacotherapy.",
"   </p>",
"   <p>",
"    Similar findings were noted in a report from the Multi-Ethnic Study of Atherosclerosis (MESA) cited above, a multicenter cohort study of 6814 subjects (age 45 to 84) who were free of clinical cardiovascular disease at baseline [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30410/abstract/45\">",
"     45",
"    </a>",
"    ]. Among participants in whom lipid-lowering drug therapy was not indicated by the ATP III guidelines, CAC scores were &gt;400 in 6.8 percent of patients at intermediate risk by the",
"    <span class=\"nowrap\">",
"     NCEP/ATP",
"    </span>",
"    III FRS (",
"    <a class=\"graphic graphic_table graphicRef64978 graphicRef76742 \" href=\"UTD.htm?30/1/30751\">",
"     table 2A-B",
"    </a>",
"    ) and in 19.7 percent of patients at high risk. Overall, 40 percent of eligible persons with a CAC score &gt;400 were not receiving lipid-lowering drugs.",
"   </p>",
"   <p>",
"    Although these observations demonstrate that global risk factor scores do not identify many of the patients with high CAC scores, there is no clear evidence that preventive measures based upon the CAC score alone leads to an improvement in outcomes. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Possible effect of treatment in asymptomatic patients'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Role in moderate risk patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;According to the Framingham risk model, patients with a 10 to 20 percent risk of a cardiac event over 10 years are labeled as being at moderate risk. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/8/39048?source=see_link\">",
"     \"Estimation of cardiovascular risk in an individual patient without known cardiovascular disease\"",
"    </a>",
"    .) In the MESA study, a CAC level of &ge;300 was observed in 24 percent of those with a Framingham risk score of 15.1 to 20 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30410/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among patients deemed to be at moderate risk, some will develop symptomatic CHD in the near term and some will never develop established disease. A detailed argument in favor of selective CAC scanning in this population has been made using much of the data presented below [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30410/abstract/47\">",
"     47",
"    </a>",
"    ]. This approach has been adopted by the AHA, the ACC, and the European Society of Cardiology [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30410/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Effect on prognosis'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H22\">",
"     'Possible effect of treatment in asymptomatic patients'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Effect on prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The CAC score adds independent prognostic information to that determined by the Framingham risk score [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30410/abstract/24,40,50-54\">",
"     24,40,50-54",
"    </a>",
"    ] across ethnic groups [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30410/abstract/55\">",
"     55",
"    </a>",
"    ]. The magnitude of this effect is best illustrated in the following four observational, population-based studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The CAC score was predictive of risk across all but the lowest (0 to 9 percent) categories of Framingham risk score in 1312 asymptomatic adults with at least one coronary risk factor but no prior clinical CHD or diabetes who were followed for up to eight years [",
"      <a class=\"abstract\" href=\"UTD.htm?29/44/30410/abstract/50\">",
"       50",
"      </a>",
"      ]. The increase in events was most pronounced at CAC scores above 300.",
"     </li>",
"     <li>",
"      The predictive value of CAC was also demonstrated in a report of over 10,000 asymptomatic patients who underwent both cardiac risk factor assessment and CAC scoring [",
"      <a class=\"abstract\" href=\"UTD.htm?29/44/30410/abstract/51\">",
"       51",
"      </a>",
"      ]. The CAC score was a significant independent predictor of all-cause mortality after adjustment for family history, hyperlipidemia, hypertension, smoking, and diabetes. Using the",
"      <span class=\"nowrap\">",
"       NCEP/ATP",
"      </span>",
"      III model (",
"      <a class=\"graphic graphic_table graphicRef64978 graphicRef76742 \" href=\"UTD.htm?30/1/30751\">",
"       table 2A-B",
"      </a>",
"      ), five-year mortality varied according to the CAC score (from less than 10 to more than 1000) from 0.9 to 3.9 percent, 1.1 to 9.0 percent, and 2.0 to 12.2 percent in low, intermediate, and high-risk Framingham subsets.",
"     </li>",
"     <li>",
"      Similar findings were demonstrated in a study of over 25,000 asymptomatic individuals who underwent both cardiac risk factor assessment and CAC scoring [",
"      <a class=\"abstract\" href=\"UTD.htm?29/44/30410/abstract/54\">",
"       54",
"      </a>",
"      ]. The death rate was 2 percent after an average follow-up of 6.8 years. The following three significant findings were noted:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The CAC score predicted all-cause mortality independent of and more accurately than standard coronary artery disease risk factors.",
"     </li>",
"     <li>",
"      Risk-adjusted relative risk ratios (for all-cause mortality) were 2.2, 4.5, 6.4, 9.2, 10.4, and 12.5 for CAC scores of 11 to 100, 101 to 299, 300 to 399, 400 to 699, 700 to 999, and &gt;1000, respectively, when compared to a score of 0.",
"     </li>",
"     <li>",
"      After adjustment for age and traditional risk factors, 10-year survival was 99.4 percent for a CAC score of 0 and 87.8 percent for a score &gt;1000.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      4129 subjects without known CAD were followed for five years after CAC was measured and FRS was scored [",
"      <a class=\"abstract\" href=\"UTD.htm?29/44/30410/abstract/56\">",
"       56",
"      </a>",
"      ]. In intermediate risk subjects by FRS, 21.7 percent were reclassified into the low-risk category and 30.6 percent were reclassified into the high-risk category. Adding CAC scores increased the area under the receiver operator curve from 0.681 to 0.749 compared to FRS and from 0.653 to 0.755 compared to",
"      <span class=\"nowrap\">",
"       NCEP/ATPIII.",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Adding CAC to traditional risk factors in the MESA cohort including age, sex, tobacco use, systolic blood pressure, antihypertensive medication use, total and HDL cholesterol, race, and ethnicity resulted in a net reclassification index of 0.25, implying that 25 percent of patients were reclassified into a different risk group based on CAC [",
"      <a class=\"abstract\" href=\"UTD.htm?29/44/30410/abstract/57\">",
"       57",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The preceding studies evaluated patients with a mean age in years in the 50s or 60s. CAC scanning also adds predictive value to the FRS in younger men (mean age 43 years), although the risk was much lower [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30410/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Despite differences in prevalence and extent of CAC in various ethnic groups, the predictive value of CAC score over that of standard coronary risk factors is similar among these groups [",
"      <a class=\"abstract\" href=\"UTD.htm?29/44/30410/abstract/55\">",
"       55",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Importance of ethnicity'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      For each of four ethnic groups (white, black, Hispanic, and Chinese) in the MESA population, a doubling of the CAC score increased the risk of a major coronary event (myocardial infarction or death from coronary heart disease) by 15 to 35 percent and the risk of any coronary event (including probable angina followed by revascularization or definite angina with or without revascularization) by 18 to 39 percent. There was no interaction between ethnic group and the risk associated with increasing calcium score.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5314284\">",
"    <span class=\"h2\">",
"     Role in the elderly",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Rotterdam Study followed 2028 asymptomatic elderly with a mean age of 69.2 for a median of 9.2 years [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30410/abstract/58\">",
"     58",
"    </a>",
"    ]. In the intermediate risk group (10-year FRS 10 to 20 percent), CAC reclassified 52 percent of the population with scores &gt;615 Agatston units reclassifying individuals as high risk and scores &lt;50 reclassifying them as low risk.",
"   </p>",
"   <p>",
"    A review of a study with 3570 patients over the age of 70 demonstrated that 40 percent of these patients could be reclassified, primarily by excluding risk (CAC &lt;400) in those with multiple risk factors [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30410/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Comparison to hsCRP and other biomarkers",
"    </span>",
"    &nbsp;&mdash;&nbsp;The serum concentration of hsCRP, a marker of inflammation, has predictive value for cardiovascular disease in a variety of clinical settings. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/0/27658?source=see_link\">",
"     \"C-reactive protein in cardiovascular disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/54/34665?source=see_link\">",
"     \"Screening for cardiovascular risk with C-reactive protein\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The CAC score and hsCRP appear to contribute independently to risk stratification for cardiovascular events [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30410/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. This was illustrated in a cohort of 1461 patients without known CHD who were followed for 6.4 years; 104 (7 percent) had an MI, stroke, coronary revascularization, or coronary death [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30410/abstract/39\">",
"     39",
"    </a>",
"    ]. The relative risk for those with the highest quartile hsCRP and highest tertile CAC scores (&gt;4.05 and &gt;142.1) was 7.5-fold greater than the risk for those with lower hsCRP (&lt;4.05) and the lowest quartile CAC (&lt;3.7). Another study confirmed this finding in 4129 individuals as CAC and hsCRP [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30410/abstract/60\">",
"     60",
"    </a>",
"    ]. CAC and hsCRP independently predicted coronary events and deaths. The net reclassification improvement was higher for CAC (23.8 percent) than for CRP (10.5 percent).",
"   </p>",
"   <p>",
"    When analyzing MESA patients with hsCRP &gt;2 who would have been candidates for the JUPITER trial of LDL cholesterol lowering, CAC was able to risk stratify better than hsCRP [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30410/abstract/61\">",
"     61",
"    </a>",
"    ]. In patients with CAC of 0, rates of CHD events were negligible and 74 percent of all events were in the 25 percent of participants with CAC &gt;100. The presence of CAC was associated with a hazard ratio of 4.29 for CHD, whereas hsCRP was not after multivariate adjustment.",
"   </p>",
"   <p>",
"    After adjustment for other cardiovascular risk factors, CRP does not independently correlate with CAC [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30410/abstract/62\">",
"     62",
"    </a>",
"    ]. Thus, the correlation of serum CRP with cardiovascular risk may reflect the composition and stability of plaque rather than the total atherosclerotic burden.",
"   </p>",
"   <p>",
"    CAC outperforms serum biomarkers, including hsCRP, in the prediction of cardiac risk. In a study of 1286 patients, the log of CAC increased the c-statistic for cardiac events, whereas multiple biomarkers including hsCRP, interleukin-6, myeloperoxidase, B-type natriuretic peptide, and plasminogen activator-1 did not [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30410/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Added value in smokers",
"    </span>",
"    &nbsp;&mdash;&nbsp;The potential value of CAC in asymptomatic smokers was evaluated in a referred patient registry of over 10,000 individuals (40 percent current smokers) who were followed for all-cause mortality at five years [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30410/abstract/64\">",
"     64",
"    </a>",
"    ]. Smokers had survival rates that varied directly with the CAC score, ranging from 99.5 percent in the 50 percent of patients with a score of 0 to 10 to 81.4 percent in the 4.4 percent of patients with a score &gt;1000. This effect was seen in younger and older patients, with the relative risk being highest in older smokers. For smokers between the ages of 40 and 49, a CAC score &gt;1000 was associated with a relative risk of mortality of 8.9.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Serial measurements",
"    </span>",
"    &nbsp;&mdash;&nbsp;For serial measurements of CAC to be meaningful, their variability must be less than the expected interval change in the CAC score. Although of unproven clinical value, serial measurements of CAC may be useful in several ways:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The annualized progression of CAC, as a measure of the activity of the atherosclerotic process, may be a more powerful predictor of cardiovascular risk than a single measurement.",
"     </li>",
"     <li>",
"      Serial measurements of CAC may permit monitoring the efficacy of therapy with medications known to slow or halt the progression of coronary atherosclerosis, or perhaps proving the efficacy of medications developed to affect coronary atherosclerosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, no intervention has been shown to slow the progression of CAC, including statins [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30410/abstract/65\">",
"     65",
"    </a>",
"    ], and serial studies of CAC are of unproven clinical value. Thus, routine quantification of CAC progression is not recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     CAC progression and risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rapid angiographic progression of coronary atherosclerosis is associated with increased risk of cardiovascular events [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30410/abstract/66\">",
"     66",
"    </a>",
"    ]. The annualized progression of CAC measured by EBCT is approximately 25 percent in the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30410/abstract/67\">",
"     67",
"    </a>",
"    ], but as high as 40 to 50 percent in asymptomatic patients with multiple conventional risk factors [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30410/abstract/68-70\">",
"     68-70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The relationship between CAC progression and CHD risk was assessed in a study of 495 patients treated with statins [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30410/abstract/71\">",
"     71",
"    </a>",
"    ]. At a mean follow-up of 3.2 years, 41 patients (8.3 percent) had a myocardial infarction. There was no difference in mean serum LDL-cholesterol concentrations between patients who did and did not have an MI. However, the patients who had an MI had a significantly higher annualized progression rate of CAC progression (42 versus 17 percent in those without a myocardial infarction). The relative risk of having an MI in the presence of CAC progression was 17.2-fold higher than the absence of CAC progression.",
"   </p>",
"   <p>",
"    A study of 4609 patients who underwent repeat EBCT measurement of CAC at a mean of 3.1 years demonstrated an association of progression with mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30410/abstract/25\">",
"     25",
"    </a>",
"    ]. A &gt;15 percent yearly increase had a hazard ratio of 2.98. In those with a baseline CAC of 0, there was little progression and no ability to predict mortality.",
"   </p>",
"   <p>",
"    In the MESA study, metabolic syndrome and diabetes mellitus were associated with a greater incidence of CAC as well as greater risk of progression than those without either [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30410/abstract/72\">",
"     72",
"    </a>",
"    ]. Progression of CAC in metabolic syndrome and diabetes was associated with CHD events with hazard ratios 4 to 5.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Comparison with carotid intima-media thickness",
"    </span>",
"    &nbsp;&mdash;&nbsp;Various reports indicate that measurements of carotid artery intima-media thickness (CIMT) and CAC are often discordant [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30410/abstract/73-75\">",
"     73-75",
"    </a>",
"    ]. The predictive value of these measures differ, with CAC more strongly associated with risk of incident cardiovascular disease and CIMT more strongly associated with risk of incident stroke [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30410/abstract/73,74\">",
"     73,74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a report from Multi-Ethnic Study of Atherosclerosis (MESA) of 6698 subjects (aged 45 to 84 years) initially free of cardiovascular disease followed over a maximum of 5.3 years, the association of CAC and CIMT with incident cardiovascular disease was evaluated [",
"      <a class=\"abstract\" href=\"UTD.htm?29/44/30410/abstract/73\">",
"       73",
"      </a>",
"      ]. CAC was associated with the risks of incident CHD and total cardiovascular disease more strongly than CIMT. CIMT was a modestly better predictor of stroke than CAC.",
"     </li>",
"     <li>",
"      In a Pittsburgh Field Center of the Cardiovascular Health Study report of 559 subjects (aged 70 to 99 years), CAC was associated more strongly than CIMT with the risk of",
"      <strong>",
"       incident",
"      </strong>",
"      cardiovascular disease, although they had similar hazard ratios for overall cardiovascular disease [",
"      <a class=\"abstract\" href=\"UTD.htm?29/44/30410/abstract/74\">",
"       74",
"      </a>",
"      ]. CIMT was more strongly related than CAC to risk of incident stroke [",
"      <a class=\"abstract\" href=\"UTD.htm?29/44/30410/abstract/74\">",
"       74",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13337131\">",
"    <span class=\"h1\">",
"     CAC AND PROGNOSIS IN SYMPTOMATIC PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;CAC also has prognostic value in symptomatic patients [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30410/abstract/76,77\">",
"     76,77",
"    </a>",
"    ]. However, in symptomatic patients, a CAC score of 0 does not carry the same high negative predictive value as it does in asymptomatic patients. In the CONFIRM registry of 10,037 patients who underwent both CAC and CT angiography, 13 percent of patients with a CAC of 0 had nonobstructive stenosis and 3.5 percent had a &gt;50 percent stenosis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30410/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     POSSIBLE EFFECT OF TREATMENT IN ASYMPTOMATIC PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The observations noted above that CAC is predictive of long-term coronary risk in asymptomatic patients raise the question about possible therapy for primary prevention. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/28/5576?source=see_link\">",
"     \"Overview of primary prevention of coronary heart disease and stroke\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The effect of statins and other therapies on CAC progression and patient outcomes has been evaluated in a number of observational studies and three randomized trials. The effects on CAC progression have been conflicting and there is as yet no clear evidence of improvement in outcomes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Observational studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;A potential benefit from statin therapy on CAC was suggested in an initial retrospective study of 149 patients with no history of CHD who were referred for EBCT screening; 65 were treated with a statin at the discretion of their physician [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30410/abstract/79\">",
"     79",
"    </a>",
"    ]. At 12- to 15-month follow-up, a mean 7 percent reduction in the CAC score was noted in the patients on statin therapy who attained a final serum LDL-cholesterol concentration below 120",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (3.1",
"    <span class=\"nowrap\">",
"     mmol/L).",
"    </span>",
"    In contrast, the CAC score significantly increased by 25 percent in the treated patients with higher LDL-cholesterol values and by 52 percent in untreated patients who began with LDL-cholesterol concentrations above 120",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (3.1",
"    <span class=\"nowrap\">",
"     mmol/L).",
"    </span>",
"   </p>",
"   <p>",
"    Another",
"    report evaluated 66 patients with CAC on EBCT who, at baseline, had a mean serum LDL-cholesterol of 130",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (3.4",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    and no statin therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30410/abstract/80\">",
"     80",
"    </a>",
"    ]. EBCT was repeated at a mean of 14 months; therapy with cerivastatin (which is no longer available) was then initiated and a third EBCT scan was performed after 14 months of therapy. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cerivastatin lowered serum LDL-cholesterol from 164 to 107",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (9.1 to 5.9",
"      <span class=\"nowrap\">",
"       mmol/L).",
"      </span>",
"     </li>",
"     <li>",
"      In the 14-month follow-up before cerivastatin was started, the median calcified volume increased from 155 to 201 mm",
"      <sup>",
"       3",
"      </sup>",
"      at baseline and the annualized absolute increase in CAC was 25 mm",
"      <sup>",
"       3",
"      </sup>",
"      . The median absolute increase in CAC was significantly lower at 11 mm",
"      <sup>",
"       3",
"      </sup>",
"      and, in the patients with serum LDL-cholesterol below 100",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (2.6",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      during therapy, the median relative change was a 27 percent increase in the untreated period and 3.4 percent reduction during treatment.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Randomized trials",
"    </span>",
"    &nbsp;&mdash;&nbsp;The value of medical therapy was more directly addressed in a subsequent randomized trial from the St Francis Heart Study of 1005 asymptomatic, apparently healthy men and women between the ages of 50 and 70 years with CAC scores at or above the 80th percentile for age and gender [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30410/abstract/81\">",
"     81",
"    </a>",
"    ]. All participants were treated with low dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and randomly assigned to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/37/35417?source=see_link\">",
"     atorvastatin",
"    </a>",
"    (20",
"    <span class=\"nowrap\">",
"     mg/day),",
"    </span>",
"    vitamin C (1",
"    <span class=\"nowrap\">",
"     g/day),",
"    </span>",
"    and vitamin E (1000",
"    <span class=\"nowrap\">",
"     U/day)",
"    </span>",
"    or matching placebos. The primary endpoint was a composite of all atherosclerotic cardiovascular events.",
"   </p>",
"   <p>",
"    At a mean follow-up of 4.3 years, the following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Treatment significantly reduced serum total cholesterol by 27 to 30 percent, LDL-cholesterol by 39 to 43 percent from a mean baseline value of 146",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (3.8",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      to a mean value below 80",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (2.1",
"      <span class=\"nowrap\">",
"       mmol/L),",
"      </span>",
"      and triglycerides by 11 to 17 percent.",
"     </li>",
"     <li>",
"      In contrast to the above observational studies, treatment had no effect on progression of the CAC score and was associated with a nonsignificant trend toward a lower rate of the primary end point (6.9 versus 9.9 percent, p = 0.08).",
"     </li>",
"     <li>",
"      Event rates, as in studies noted above, were directly related to the baseline CAC score (a prespecified analysis) and may have been reduced in the subgroup of patients with a baseline CAC score above 400 (8.7 versus 15.0 percent, p = 0.046). The latter subgroup was not a prespecified analysis.",
"     </li>",
"     <li>",
"      In a post-hoc analysis, those patients with CAC &gt;80",
"      <sup>",
"       th",
"      </sup>",
"      percentile and a positive family history of premature CAD demonstrated a hazard ratio of 0.55 in the treated group as compared to placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?29/44/30410/abstract/82\">",
"       82",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The effect of different intensities of statin therapy on CAC in hyperlipidemic postmenopausal women (most with no history of cardiovascular disease) was evaluated in the BELLES trial in which 615 such patients were randomly assigned to intensive (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/37/35417?source=see_link\">",
"     atorvastatin",
"    </a>",
"    80",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    or moderate (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/27/25016?source=see_link\">",
"     pravastatin",
"    </a>",
"    40",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    lipid lowering [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30410/abstract/83\">",
"     83",
"    </a>",
"    ]. The patients underwent EBCT CAC scanning at baseline and at a mean of 344 days; all patients were required to have a calcium volume score &ge;30 at baseline (moderate coronary atherosclerosis). Among the 475 patients who completed the study, the degree of LDL-cholesterol lowering was, as expected, greater in the atorvastatin group (47 versus 25 percent from a baseline value of 174",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [4.5",
"    <span class=\"nowrap\">",
"     mmol/L]).",
"    </span>",
"    However, there was no difference between the two groups in the degree of CAC progression (15.1 versus 14.3 percent).",
"   </p>",
"   <p>",
"    A similar lack of benefit with more intensive statin therapy was noted in another randomized trial of 471 patients (mean age 61 years), no history of CHD, and no &gt;50 percent diameter stenosis who had &ge;2 cardiovascular risk factors, and an EBCT CAC score &ge;30 (moderate atherosclerosis) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30410/abstract/84\">",
"     84",
"    </a>",
"    ]. The patients were assigned to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/37/35417?source=see_link\">",
"     atorvastatin",
"    </a>",
"    at a dose of either 10 mg or 80",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"    High dose atorvastatin lowered LDL-cholesterol from 106 to 87",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (2.7 to 2.2",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    whereas low dose atorvastatin had no effect on LDL-cholesterol. At one year, CAC progression was similar in the two groups (27 versus 25 percent).",
"   </p>",
"   <p>",
"    Potential limitations of these trials include 1. the duration of follow-up (approximately one year in the last two trials) may have been too short to demonstrate an effect on CAC progression, particularly when given for primary prevention, and 2. the first trial used low dose statins. In addition, the later two trials did not assess clinical outcome; this is an important issue since CAC is much more common than clinical coronary disease [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30410/abstract/85\">",
"     85",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Given the results of the above trials, instituting pharmacologic therapy to prevent CHD based solely upon the presence of CAC is",
"    <strong>",
"     not",
"    </strong>",
"    recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5314535\">",
"    <span class=\"h1\">",
"     EFFECTS ON COMPLIANCE AND RESOURCE UTILIZATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5314543\">",
"    <span class=\"h2\">",
"     Compliance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Knowledge of one&rsquo;s CAC score may improve medication and lifestyle compliance, although available data are mixed. In one study, 450 asymptomatic young active-duty US Army personnel were randomly assigned to receive or not receive CAC results [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30410/abstract/86\">",
"     86",
"    </a>",
"    ]. No differences were noted in the change in Framingham Risk Score over one year. However, the population was quite young (39 to 45 years old) and the follow-up was short. Several other studies have suggested a benefit from knowing CAC scores. In a study of 505 individuals on statin therapy at baseline followed for three years, baseline CAC scores were strongly associated with statin compliance (44 percent in the lowest tertile and 91 percent in the highest) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30410/abstract/87\">",
"     87",
"    </a>",
"    ]. In another study of 980 individuals followed for three years, greater baseline CAC was associated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    initiation, dietary improvement, and increased exercise [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30410/abstract/88\">",
"     88",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5314550\">",
"    <span class=\"h2\">",
"     Resource utilization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cost-effectiveness has not been defined since it will vary markedly with the magnitude of benefit from early detection [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30410/abstract/89\">",
"     89",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The EISNER (Early Identification of Subclinical Atherosclerosis by Noninvasive Imaging Research) study examined the effect of CAC scoring on coronary risk factors, downstream testing, and procedural costs. In this study, 2137 volunteers were randomly assigned to CAC scanning or no CAC scanning before risk factor counseling. The scan group showed improved risk factors (blood pressure, LDL cholesterol, and waist circumference) and stable Framingham risk score compared to the no scan group whose Framingham risk score increased during the four-year observation period [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30410/abstract/90\">",
"     90",
"    </a>",
"    ]. Downstream testing and costs were similar in the two groups. In the scan group, patients with low CAC were not tested further, whereas those with CAC &gt;400 had a higher degree of resource utilization.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13337222\">",
"    <span class=\"h1\">",
"     USE OF CAC SCORING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Our recommendations for use of CAC scoring are generally in agreement with the 2007 American College of Cardiology Foundation (ACCF) and the American Heart Association (AHA) consensus document on CAC scoring [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30410/abstract/91\">",
"     91",
"    </a>",
"    ], the 2006 scientific statement on assessment of CHD by cardiac CT from the AHA [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30410/abstract/92\">",
"     92",
"    </a>",
"    ], and the 2010",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines on screening for coronary artery disease [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30410/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We suggest measurement of CAC for cardiovascular risk assessment in selected asymptomatic adults at intermediate risk (10 to 20 percent, 10-year risk) by the Framingham risk score and modified",
"    <span class=\"nowrap\">",
"     Framingham/ATP",
"    </span>",
"    risk scores (",
"    <a class=\"graphic graphic_table graphicRef64978 graphicRef76742 \" href=\"UTD.htm?30/1/30751\">",
"     table 2A-B",
"    </a>",
"    ) when the result is reasonably expected to lead to change in management based upon reclassification to a lower or higher risk group [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30410/abstract/7,91,92\">",
"     7,91,92",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/50/26409?source=see_link\">",
"     \"Screening for coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We recommend against CAC measurement in patients at low (&lt;6 percent, 10-year risk) or high (&gt;20 percent, 10-year) CHD risk as established by the Framingham risk score and modified",
"    <span class=\"nowrap\">",
"     Framingham/ATP",
"    </span>",
"    risk scores (",
"    <a class=\"graphic graphic_table graphicRef64978 graphicRef76742 \" href=\"UTD.htm?30/1/30751\">",
"     table 2A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30410/abstract/91-93\">",
"     91-93",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The best management approach for asymptomatic patients with a high CAC score (eg, CAC &gt;400) is uncertain. We agree with the approach of the 2010",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines on screening for CHD, which suggest consideration of stress rMPI in such individuals, particularly if they are sedentary where absence of symptoms does not imply absence of ischemia [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30410/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We do not recommend serial CAC scanning to monitor progression or regression of disease since the utility of such an approach is unknown [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30410/abstract/91\">",
"     91",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Serial measurements'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The use of statins and other primary prevention modalities should",
"    <strong>",
"     not",
"    </strong>",
"    be based upon the findings on CAC screening. Conversely, pharmacologic risk factor management should not be withheld if CAC is absent [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30410/abstract/91\">",
"     91",
"    </a>",
"    ]. There is as yet no evidence that basing the decision to implement or intensify preventive measures (such as &ldquo;resetting&rdquo; goal LDL to &lt;70",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    in patients in whom CAC is the only manifestation of CAD) on the presence and quantity of CAC leads to an improvement in outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?29/44/30410/abstract/81,83-85\">",
"     81,83-85",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Possible effect of treatment in asymptomatic patients'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/28/5576?source=see_link\">",
"     \"Overview of primary prevention of coronary heart disease and stroke\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The presence of coronary artery calcium (CAC) is highly sensitive for the presence of &ge;50 percent angiographic stenosis but only moderately specific, especially in older patients. Both sensitivity and specificity vary with the degree of CAC; with higher CAC scores, sensitivity decreases but specificity increases. Individual CAC scores should be interpreted in relation to normative data based upon age, sex, and race. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'CAC and coronary artery stenosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The absence of CAC, particularly in an asymptomatic patient, is highly predictive of the absence of significant coronary artery stenosis and implies a favorable prognosis. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'CAC and coronary artery stenosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      CAC screening can enhance the prediction of risk in asymptomatic individuals and increase the predictive value of the Framingham Risk Score. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Added value to Framingham risk score'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Despite the potential benefits of CAC screening, it is also subject to a number of limitations and thus there is disagreement on its value:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Among asymptomatic patients with a low Framingham risk score (&lt; = 5 percent), only a small number (less than 15 percent) of those with CAC will have a cardiac event over the ensuing five years. CAC screening is unlikely to benefit low-risk or high-risk patients, and is not recommended. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'CAC and prognosis in asymptomatic patients'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      It has",
"      <strong>",
"       not",
"      </strong>",
"      been established that instituting or intensifying pharmacologic risk factor modification in asymptomatic patients with CAC improves outcomes. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Possible effect of treatment in asymptomatic patients'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The potential harm associated with false-positive tests and radiation dose (especially with repeated testing) is not known. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Radiation exposure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Providing patients with the results of CAC testing may improve patient compliance with lifestyle changes and medications but results have been mixed. (See",
"      <a class=\"local\" href=\"#H5314543\">",
"       'Compliance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cost-effectiveness of CAC screening has not been defined. (See",
"      <a class=\"local\" href=\"#H5314550\">",
"       'Resource utilization'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest measurement of CAC for cardiovascular risk assessment in selected asymptomatic adults at intermediate risk (10 to 20, percent 10-year risk) by the Framingham risk score and modified",
"      <span class=\"nowrap\">",
"       Framingham/ATP",
"      </span>",
"      risk scores (",
"      <a class=\"graphic graphic_table graphicRef64978 graphicRef76742 \" href=\"UTD.htm?30/1/30751\">",
"       table 2A-B",
"      </a>",
"      ) when the result is reasonably expected to lead to change in management based upon reclassification to a lower or higher risk group. (See",
"      <a class=\"local\" href=\"#H13337222\">",
"       'Use of CAC scoring'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/50/26409?source=see_link\">",
"       \"Screening for coronary heart disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We recommend against CAC measurement in patients at low (&lt;6 percent, 10-year risk) or high (&gt;20 percent, 10-year) coronary heart disease risk as established by the Framingham risk score and modified",
"      <span class=\"nowrap\">",
"       Framingham/ATP",
"      </span>",
"      risk scores (",
"      <a class=\"graphic graphic_table graphicRef64978 graphicRef76742 \" href=\"UTD.htm?30/1/30751\">",
"       table 2A-B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H13337222\">",
"       'Use of CAC scoring'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30410/abstract/1\">",
"      BLANKENHORN DH, STERN D. Calcification of the coronary arteries. Am J Roentgenol Radium Ther Nucl Med 1959; 81:772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30410/abstract/2\">",
"      Margolis JR, Chen JT, Kong Y, et al. The diagnostic and prognostic significance of coronary artery calcification. A report of 800 cases. Radiology 1980; 137:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30410/abstract/3\">",
"      Agatston AS, Janowitz WR, Hildner FJ, et al. Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol 1990; 15:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30410/abstract/4\">",
"      Mao SS, Pal RS, McKay CR, et al. Comparison of coronary artery calcium scores between electron beam computed tomography and 64-multidetector computed tomographic scanner. J Comput Assist Tomogr 2009; 33:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30410/abstract/5\">",
"      Ghadri JR, Goetti R, Fiechter M, et al. Inter-scan variability of coronary artery calcium scoring assessed on 64-multidetector computed tomography vs. dual-source computed tomography: a head-to-head comparison. Eur Heart J 2011; 32:1865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30410/abstract/6\">",
"      Otton JM, L&oslash;nborg JT, Boshell D, et al. A method for coronary artery calcium scoring using contrast-enhanced computed tomography. J Cardiovasc Comput Tomogr 2012; 6:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30410/abstract/7\">",
"      Greenland P, Alpert JS, Beller GA, et al. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2010; 56:e50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30410/abstract/8\">",
"      Nakazato R, Dey D, Gutstein A, et al. Coronary artery calcium scoring using a reduced tube voltage and radiation dose protocol with dual-source computed tomography. J Cardiovasc Comput Tomogr 2009; 3:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30410/abstract/9\">",
"      Rumberger JA, Simons DB, Fitzpatrick LA, et al. Coronary artery calcium area by electron-beam computed tomography and coronary atherosclerotic plaque area. A histopathologic correlative study. Circulation 1995; 92:2157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30410/abstract/10\">",
"      Baumgart D, Schmermund A, Goerge G, et al. Comparison of electron beam computed tomography with intracoronary ultrasound and coronary angiography for detection of coronary atherosclerosis. J Am Coll Cardiol 1997; 30:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30410/abstract/11\">",
"      Rumberger JA, Sheedy PF 3rd, Breen JF, Schwartz RS. Coronary calcium, as determined by electron beam computed tomography, and coronary disease on arteriogram. Effect of patient's sex on diagnosis. Circulation 1995; 91:1363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30410/abstract/12\">",
"      Budoff MJ, Georgiou D, Brody A, et al. Ultrafast computed tomography as a diagnostic modality in the detection of coronary artery disease: a multicenter study. Circulation 1996; 93:898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30410/abstract/13\">",
"      Kajinami K, Seki H, Takekoshi N, Mabuchi H. Coronary calcification and coronary atherosclerosis: site by site comparative morphologic study of electron beam computed tomography and coronary angiography. J Am Coll Cardiol 1997; 29:1549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30410/abstract/14\">",
"      Glagov S, Weisenberg E, Zarins CK, et al. Compensatory enlargement of human atherosclerotic coronary arteries. N Engl J Med 1987; 316:1371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30410/abstract/15\">",
"      Haberl R, Becker A, Leber A, et al. Correlation of coronary calcification and angiographically documented stenoses in patients with suspected coronary artery disease: results of 1,764 patients. J Am Coll Cardiol 2001; 37:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30410/abstract/16\">",
"      Budoff MJ, Diamond GA, Raggi P, et al. Continuous probabilistic prediction of angiographically significant coronary artery disease using electron beam tomography. Circulation 2002; 105:1791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30410/abstract/17\">",
"      Nallamothu BK, Saint S, Bielak LF, et al. Electron-beam computed tomography in the diagnosis of coronary artery disease: a meta-analysis. Arch Intern Med 2001; 161:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30410/abstract/18\">",
"      O'Rourke RA, Brundage BH, Froelicher VF, et al. American College of Cardiology/American Heart Association Expert Consensus document on electron-beam computed tomography for the diagnosis and prognosis of coronary artery disease. Circulation 2000; 102:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30410/abstract/19\">",
"      Min JK, Lin FY, Gidseg DS, et al. Determinants of coronary calcium conversion among patients with a normal coronary calcium scan: what is the \"warranty period\" for remaining normal? J Am Coll Cardiol 2010; 55:1110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30410/abstract/20\">",
"      Rumberger JA, Brundage BH, Rader DJ, Kondos G. Electron beam computed tomographic coronary calcium scanning: a review and guidelines for use in asymptomatic persons. Mayo Clin Proc 1999; 74:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30410/abstract/21\">",
"      Pletcher MJ, Tice JA, Pignone M, Browner WS. Using the coronary artery calcium score to predict coronary heart disease events: a systematic review and meta-analysis. Arch Intern Med 2004; 164:1285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30410/abstract/22\">",
"      Berman DS, Wong ND, Gransar H, et al. Relationship between stress-induced myocardial ischemia and atherosclerosis measured by coronary calcium tomography. J Am Coll Cardiol 2004; 44:923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30410/abstract/23\">",
"      Raggi P, Callister TQ, Cooil B, et al. Identification of patients at increased risk of first unheralded acute myocardial infarction by electron-beam computed tomography. Circulation 2000; 101:850.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30410/abstract/24\">",
"      Nasir K, Michos ED, Blumenthal RS, Raggi P. Detection of high-risk young adults and women by coronary calcium and National Cholesterol Education Program Panel III guidelines. J Am Coll Cardiol 2005; 46:1931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30410/abstract/25\">",
"      Budoff MJ, Hokanson JE, Nasir K, et al. Progression of coronary artery calcium predicts all-cause mortality. JACC Cardiovasc Imaging 2010; 3:1229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30410/abstract/26\">",
"      Lee TC, O'Malley PG, Feuerstein I, Taylor AJ. The prevalence and severity of coronary artery calcification on coronary artery computed tomography in black and white subjects. J Am Coll Cardiol 2003; 41:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30410/abstract/27\">",
"      Budoff MJ, Yang TP, Shavelle RM, et al. Ethnic differences in coronary atherosclerosis. J Am Coll Cardiol 2002; 39:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30410/abstract/28\">",
"      Bild DE, Detrano R, Peterson D, et al. Ethnic differences in coronary calcification: the Multi-Ethnic Study of Atherosclerosis (MESA). Circulation 2005; 111:1313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30410/abstract/29\">",
"      McClelland RL, Chung H, Detrano R, et al. Distribution of coronary artery calcium by race, gender, and age: results from the Multi-Ethnic Study of Atherosclerosis (MESA). Circulation 2006; 113:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30410/abstract/30\">",
"      Diez Roux AV, Detrano R, Jackson S, et al. Acculturation and socioeconomic position as predictors of coronary calcification in a multiethnic sample. Circulation 2005; 112:1557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30410/abstract/31\">",
"      He ZX, Hedrick TD, Pratt CM, et al. Severity of coronary artery calcification by electron beam computed tomography predicts silent myocardial ischemia. Circulation 2000; 101:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30410/abstract/32\">",
"      Anand DV, Lim E, Raval U, et al. Prevalence of silent myocardial ischemia in asymptomatic individuals with subclinical atherosclerosis detected by electron beam tomography. J Nucl Cardiol 2004; 11:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30410/abstract/33\">",
"      Blumenthal RS, Becker DM, Yanek LR, et al. Comparison of coronary calcium and stress myocardial perfusion imaging in apparently healthy siblings of individuals with premature coronary artery disease. Am J Cardiol 2006; 97:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30410/abstract/34\">",
"      Wang L, Jerosch-Herold M, Jacobs DR Jr, et al. Coronary artery calcification and myocardial perfusion in asymptomatic adults: the MESA (Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol 2006; 48:1018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30410/abstract/35\">",
"      Schmermund A, Erbel R. Unstable coronary plaque and its relation to coronary calcium. Circulation 2001; 104:1682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30410/abstract/36\">",
"      Kondos GT, Hoff JA, Sevrukov A, et al. Electron-beam tomography coronary artery calcium and cardiac events: a 37-month follow-up of 5635 initially asymptomatic low- to intermediate-risk adults. Circulation 2003; 107:2571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30410/abstract/37\">",
"      Arad Y, Spadaro LA, Goodman K, et al. Predictive value of electron beam computed tomography of the coronary arteries. 19-month follow-up of 1173 asymptomatic subjects. Circulation 1996; 93:1951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30410/abstract/38\">",
"      Arad Y, Spadaro LA, Goodman K, et al. Prediction of coronary events with electron beam computed tomography. J Am Coll Cardiol 2000; 36:1253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30410/abstract/39\">",
"      Park R, Detrano R, Xiang M, et al. Combined use of computed tomography coronary calcium scores and C-reactive protein levels in predicting cardiovascular events in nondiabetic individuals. Circulation 2002; 106:2073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30410/abstract/40\">",
"      Arad Y, Goodman KJ, Roth M, et al. Coronary calcification, coronary disease risk factors, C-reactive protein, and atherosclerotic cardiovascular disease events: the St. Francis Heart Study. J Am Coll Cardiol 2005; 46:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30410/abstract/41\">",
"      Bielak LF, Rumberger JA, Sheedy PF 2nd, et al. Probabilistic model for prediction of angiographically defined obstructive coronary artery disease using electron beam computed tomography calcium score strata. Circulation 2000; 102:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30410/abstract/42\">",
"      Vliegenthart R, Oudkerk M, Hofman A, et al. Coronary calcification improves cardiovascular risk prediction in the elderly. Circulation 2005; 112:572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30410/abstract/43\">",
"      Wilson PW, D'Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97:1837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30410/abstract/44\">",
"      National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106:3143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30410/abstract/45\">",
"      Goff DC Jr, Bertoni AG, Kramer H, et al. Dyslipidemia prevalence, treatment, and control in the Multi-Ethnic Study of Atherosclerosis (MESA): gender, ethnicity, and coronary artery calcium. Circulation 2006; 113:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30410/abstract/46\">",
"      Okwuosa TM, Greenland P, Ning H, et al. Distribution of coronary artery calcium scores by Framingham 10-year risk strata in the MESA (Multi-Ethnic Study of Atherosclerosis) potential implications for coronary risk assessment. J Am Coll Cardiol 2011; 57:1838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30410/abstract/47\">",
"      Hecht HS, Budoff MJ, Berman DS, et al. Coronary artery calcium scanning: Clinical paradigms for cardiac risk assessment and treatment. Am Heart J 2006; 151:1139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30410/abstract/48\">",
"      DeBacker, G, Ambrosioni, E, Borch-Johnson, K et al. European guidelines on cardiovascular disease prevention in clinical practice. Third joint task force of European and other contries in cardiovascular disease in clinical practice. Eur J Rehab Prev 2003; 10:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30410/abstract/49\">",
"      Scanlon PJ, Faxon DP, Audet AM, et al. ACC/AHA guidelines for coronary angiography. A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on Coronary Angiography). Developed in collaboration with the Society for Cardiac Angiography and Interventions. J Am Coll Cardiol 1999; 33:1756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30410/abstract/50\">",
"      Greenland P, LaBree L, Azen SP, et al. Coronary artery calcium score combined with Framingham score for risk prediction in asymptomatic individuals. JAMA 2004; 291:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30410/abstract/51\">",
"      Shaw LJ, Raggi P, Schisterman E, et al. Prognostic value of cardiac risk factors and coronary artery calcium screening for all-cause mortality. Radiology 2003; 228:826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30410/abstract/52\">",
"      Taylor AJ, Bindeman J, Feuerstein I, et al. Coronary calcium independently predicts incident premature coronary heart disease over measured cardiovascular risk factors: mean three-year outcomes in the Prospective Army Coronary Calcium (PACC) project. J Am Coll Cardiol 2005; 46:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30410/abstract/53\">",
"      Hopkins PN, Ellison RC, Province MA, et al. Association of coronary artery calcified plaque with clinical coronary heart disease in the National Heart, Lung, and Blood Institute's Family Heart Study. Am J Cardiol 2006; 97:1564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30410/abstract/54\">",
"      Budoff MJ, Shaw LJ, Liu ST, et al. Long-term prognosis associated with coronary calcification: observations from a registry of 25,253 patients. J Am Coll Cardiol 2007; 49:1860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30410/abstract/55\">",
"      Detrano R, Guerci AD, Carr JJ, et al. Coronary calcium as a predictor of coronary events in four racial or ethnic groups. N Engl J Med 2008; 358:1336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30410/abstract/56\">",
"      Erbel R, M&ouml;hlenkamp S, Moebus S, et al. Coronary risk stratification, discrimination, and reclassification improvement based on quantification of subclinical coronary atherosclerosis: the Heinz Nixdorf Recall study. J Am Coll Cardiol 2010; 56:1397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30410/abstract/57\">",
"      Polonsky TS, McClelland RL, Jorgensen NW, et al. Coronary artery calcium score and risk classification for coronary heart disease prediction. JAMA 2010; 303:1610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30410/abstract/58\">",
"      Elias-Smale SE, Proen&ccedil;a RV, Koller MT, et al. Coronary calcium score improves classification of coronary heart disease risk in the elderly: the Rotterdam study. J Am Coll Cardiol 2010; 56:1407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30410/abstract/59\">",
"      Raggi P, Gongora MC, Gopal A, et al. Coronary artery calcium to predict all-cause mortality in elderly men and women. J Am Coll Cardiol 2008; 52:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30410/abstract/60\">",
"      M&ouml;hlenkamp S, Lehmann N, Moebus S, et al. Quantification of coronary atherosclerosis and inflammation to predict coronary events and all-cause mortality. J Am Coll Cardiol 2011; 57:1455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30410/abstract/61\">",
"      Blaha MJ, Budoff MJ, DeFilippis AP, et al. Associations between C-reactive protein, coronary artery calcium, and cardiovascular events: implications for the JUPITER population from MESA, a population-based cohort study. Lancet 2011; 378:684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30410/abstract/62\">",
"      Khera A, de Lemos JA, Peshock RM, et al. Relationship between C-reactive protein and subclinical atherosclerosis: the Dallas Heart Study. Circulation 2006; 113:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30410/abstract/63\">",
"      Rana JS, Gransar H, Wong ND, et al. Comparative value of coronary artery calcium and multiple blood biomarkers for prognostication of cardiovascular events. Am J Cardiol 2012; 109:1449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30410/abstract/64\">",
"      Shaw LJ, Raggi P, Callister TQ, Berman DS. Prognostic value of coronary artery calcium screening in asymptomatic smokers and non-smokers. Eur Heart J 2006; 27:968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30410/abstract/65\">",
"      McEvoy JW, Blaha MJ, Defilippis AP, et al. Coronary artery calcium progression: an important clinical measurement? A review of published reports. J Am Coll Cardiol 2010; 56:1613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30410/abstract/66\">",
"      Waters D, Craven TE, Lesp&eacute;rance J. Prognostic significance of progression of coronary atherosclerosis. Circulation 1993; 87:1067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30410/abstract/67\">",
"      Maher JE, Bielak LF, Raz JA, et al. Progression of coronary artery calcification: a pilot study. Mayo Clin Proc 1999; 74:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30410/abstract/68\">",
"      Budoff MJ, Lane KL, Bakhsheshi H, et al. Rates of progression of coronary calcium by electron beam tomography. Am J Cardiol 2000; 86:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30410/abstract/69\">",
"      Janowitz WR, Agatston AS, Viamonte M Jr. Comparison of serial quantitative evaluation of calcified coronary artery plaque by ultrafast computed tomography in persons with and without obstructive coronary artery disease. Am J Cardiol 1991; 68:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30410/abstract/70\">",
"      Budoff MJ. Tracking progression of heart disease with cardiac computed tomography. J Cardiovasc Pharmacol Ther 2004; 9:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30410/abstract/71\">",
"      Raggi P, Callister TQ, Shaw LJ. Progression of coronary artery calcium and risk of first myocardial infarction in patients receiving cholesterol-lowering therapy. Arterioscler Thromb Vasc Biol 2004; 24:1272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30410/abstract/72\">",
"      Wong ND, Nelson JC, Granston T, et al. Metabolic syndrome, diabetes, and incidence and progression of coronary calcium: the Multiethnic Study of Atherosclerosis study. JACC Cardiovasc Imaging 2012; 5:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30410/abstract/73\">",
"      Folsom AR, Kronmal RA, Detrano RC, et al. Coronary artery calcification compared with carotid intima-media thickness in the prediction of cardiovascular disease incidence: the Multi-Ethnic Study of Atherosclerosis (MESA). Arch Intern Med 2008; 168:1333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30410/abstract/74\">",
"      Newman AB, Naydeck BL, Ives DG, et al. Coronary artery calcium, carotid artery wall thickness, and cardiovascular disease outcomes in adults 70 to 99 years old. Am J Cardiol 2008; 101:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30410/abstract/75\">",
"      Lester SJ, Eleid MF, Khandheria BK, Hurst RT. Carotid intima-media thickness and coronary artery calcium score as indications of subclinical atherosclerosis. Mayo Clin Proc 2009; 84:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30410/abstract/76\">",
"      Detrano R, Hsiai T, Wang S, et al. Prognostic value of coronary calcification and angiographic stenoses in patients undergoing coronary angiography. J Am Coll Cardiol 1996; 27:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30410/abstract/77\">",
"      Keelan PC, Bielak LF, Ashai K, et al. Long-term prognostic value of coronary calcification detected by electron-beam computed tomography in patients undergoing coronary angiography. Circulation 2001; 104:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30410/abstract/78\">",
"      Villines TC, Hulten EA, Shaw LJ, et al. Prevalence and severity of coronary artery disease and adverse events among symptomatic patients with coronary artery calcification scores of zero undergoing coronary computed tomography angiography: results from the CONFIRM (Coronary CT Angiography Evaluation for Clinical Outcomes: An International Multicenter) registry. J Am Coll Cardiol 2011; 58:2533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30410/abstract/79\">",
"      Callister TQ, Raggi P, Cooil B, et al. Effect of HMG-CoA reductase inhibitors on coronary artery disease as assessed by electron-beam computed tomography. N Engl J Med 1998; 339:1972.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30410/abstract/80\">",
"      Achenbach S, Ropers D, Pohle K, et al. Influence of lipid-lowering therapy on the progression of coronary artery calcification: a prospective evaluation. Circulation 2002; 106:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30410/abstract/81\">",
"      Arad Y, Spadaro LA, Roth M, et al. Treatment of asymptomatic adults with elevated coronary calcium scores with atorvastatin, vitamin C, and vitamin E: the St. Francis Heart Study randomized clinical trial. J Am Coll Cardiol 2005; 46:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30410/abstract/82\">",
"      Mulders TA, Sivapalaratnam S, Stroes ES, et al. Asymptomatic individuals with a positive family history for premature coronary artery disease and elevated coronary calcium scores benefit from statin treatment: a post hoc analysis from the St. Francis Heart Study. JACC Cardiovasc Imaging 2012; 5:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30410/abstract/83\">",
"      Raggi P, Davidson M, Callister TQ, et al. Aggressive versus moderate lipid-lowering therapy in hypercholesterolemic postmenopausal women: Beyond Endorsed Lipid Lowering with EBT Scanning (BELLES). Circulation 2005; 112:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30410/abstract/84\">",
"      Schmermund A, Achenbach S, Budde T, et al. Effect of intensive versus standard lipid-lowering treatment with atorvastatin on the progression of calcified coronary atherosclerosis over 12 months: a multicenter, randomized, double-blind trial. Circulation 2006; 113:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30410/abstract/85\">",
"      Redberg RF. Coronary artery calcium: should we rely on this surrogate marker? Circulation 2006; 113:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30410/abstract/86\">",
"      O'Malley PG, Feuerstein IM, Taylor AJ. Impact of electron beam tomography, with or without case management, on motivation, behavioral change, and cardiovascular risk profile: a randomized controlled trial. JAMA 2003; 289:2215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30410/abstract/87\">",
"      Kalia NK, Miller LG, Nasir K, et al. Visualizing coronary calcium is associated with improvements in adherence to statin therapy. Atherosclerosis 2006; 185:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30410/abstract/88\">",
"      Orakzai RH, Nasir K, Orakzai SH, et al. Effect of patient visualization of coronary calcium by electron beam computed tomography on changes in beneficial lifestyle behaviors. Am J Cardiol 2008; 101:999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30410/abstract/89\">",
"      O'Malley PG, Greenberg BA, Taylor AJ. Cost-effectiveness of using electron beam computed tomography to identify patients at risk for clinical coronary artery disease. Am Heart J 2004; 148:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30410/abstract/90\">",
"      Rozanski A, Gransar H, Shaw LJ, et al. Impact of coronary artery calcium scanning on coronary risk factors and downstream testing the EISNER (Early Identification of Subclinical Atherosclerosis by Noninvasive Imaging Research) prospective randomized trial. J Am Coll Cardiol 2011; 57:1622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30410/abstract/91\">",
"      Greenland P, Bonow RO, Brundage BH, et al. ACCF/AHA 2007 clinical expert consensus document on coronary artery calcium scoring by computed tomography in global cardiovascular risk assessment and in evaluation of patients with chest pain: a report of the American College of Cardiology Foundation Clinical Expert Consensus Task Force (ACCF/AHA Writing Committee to Update the 2000 Expert Consensus Document on Electron Beam Computed Tomography) developed in collaboration with the Society of Atherosclerosis Imaging and Prevention and the Society of Cardiovascular Computed Tomography. J Am Coll Cardiol 2007; 49:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30410/abstract/92\">",
"      Budoff MJ, Achenbach S, Blumenthal RS, et al. Assessment of coronary artery disease by cardiac computed tomography: a scientific statement from the American Heart Association Committee on Cardiovascular Imaging and Intervention, Council on Cardiovascular Radiology and Intervention, and Committee on Cardiac Imaging, Council on Clinical Cardiology. Circulation 2006; 114:1761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/44/30410/abstract/93\">",
"      Mozaffarian D. Electron-beam computed tomography for coronary calcium: a useful test to screen for coronary heart disease? JAMA 2005; 294:2897.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5297 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-189.2.19.178-DF24B1B659-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_44_30410=[""].join("\n");
var outline_f29_44_30410=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      COMPUTED TOMOGRAPHY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CT scanner types",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CAC scanning",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Radiation exposure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CAC AND CORONARY ARTERY STENOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CAC scoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Importance of ethnicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      CAC AND MYOCARDIAL ISCHEMIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      EMERGENCY DEPARTMENT EVALUATION OF CHEST PAIN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      CAC AND PROGNOSIS IN ASYMPTOMATIC PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      General predictive value",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Added value to Framingham risk score",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Identifying high-risk individuals",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Role in moderate risk patients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Effect on prognosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5314284\">",
"      Role in the elderly",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Comparison to hsCRP and other biomarkers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Added value in smokers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Serial measurements",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - CAC progression and risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Comparison with carotid intima-media thickness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13337131\">",
"      CAC AND PROGNOSIS IN SYMPTOMATIC PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      POSSIBLE EFFECT OF TREATMENT IN ASYMPTOMATIC PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Observational studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Randomized trials",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5314535\">",
"      EFFECTS ON COMPLIANCE AND RESOURCE UTILIZATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5314543\">",
"      Compliance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5314550\">",
"      Resource utilization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13337222\">",
"      USE OF CAC SCORING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/5297\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/5297|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?43/8/44174\" title=\"figure 1\">",
"      Calcium scores CHD men women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/5297|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/60/5069\" title=\"table 1\">",
"      Effective dose estimates for imaging tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/61/10206\" title=\"table 2A\">",
"      Framingham ATPIII score men",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/17/8478\" title=\"table 2B\">",
"      Framingham ATPIII score women",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/4/11340\" title=\"table 3\">",
"      ATPIII LDL goals",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/46/10989\" title=\"table 4\">",
"      Proposed ATPIII LDL goals",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?9/63/10226?source=related_link\" title=\"calculator 1\">",
"      Calculator: Framingham 10 year risk of general cardiovascular disease in women (2008 paper)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?43/28/44482?source=related_link\" title=\"calculator 2\">",
"      Calculator: Framingham 10 year risk of general cardiovascular disease in men (2008 paper)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/0/27658?source=related_link\">",
"      C-reactive protein in cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/8/39048?source=related_link\">",
"      Estimation of cardiovascular risk in an individual patient without known cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/26/20906?source=related_link\">",
"      Noninvasive coronary imaging with cardiac computed tomography and cardiovascular magnetic resonance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/56/29578?source=related_link\">",
"      Noninvasive imaging and stress testing in patients with suspected acute coronary syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/28/5576?source=related_link\">",
"      Overview of primary prevention of coronary heart disease and stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/2/14376?source=related_link\">",
"      Radiation dose and risk of malignancy from cardiovascular imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/54/34665?source=related_link\">",
"      Screening for cardiovascular risk with C-reactive protein",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/50/26409?source=related_link\">",
"      Screening for coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/9/42135?source=related_link\">",
"      Silent myocardial ischemia: Epidemiology and pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/7/25721?source=related_link\">",
"      The role of the vulnerable plaque in acute coronary syndromes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_44_30411="Serum electrolyte levels usually associated with purging";
var content_f29_44_30411=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PSYCH%2F53037&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PSYCH%2F53037&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Serum electrolyte levels usually associated with purging",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Electrolyte",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"3\">",
"        Method of purging",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Vomiting",
"       </td>",
"       <td class=\"subtitle2\">",
"        Laxatives",
"       </td>",
"       <td class=\"subtitle2\">",
"        Diuretics",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sodium",
"       </td>",
"       <td>",
"        increased, decreased or normal",
"       </td>",
"       <td>",
"        increased or normal",
"       </td>",
"       <td>",
"        decreased or normal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Potassium",
"       </td>",
"       <td>",
"        decreased",
"       </td>",
"       <td>",
"        decreased",
"       </td>",
"       <td>",
"        decreased",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chloride",
"       </td>",
"       <td>",
"        decreased",
"       </td>",
"       <td>",
"        increased or decreased",
"       </td>",
"       <td>",
"        decreased",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bicarbonate",
"       </td>",
"       <td>",
"        increased",
"       </td>",
"       <td>",
"        increased or decreased",
"       </td>",
"       <td>",
"        increased",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        pH",
"       </td>",
"       <td>",
"        increased",
"       </td>",
"       <td>",
"        increased or decreased",
"       </td>",
"       <td>",
"        increased",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Mehler PS. Clinical practice. Bulimia nervosa. N Eng J Med 2003; 349:875",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_44_30411=[""].join("\n");
var outline_f29_44_30411=null;
var title_f29_44_30412="Pharmokinetics of second generation antipsychotics";
var content_f29_44_30412=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F60825&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F60825&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Pharmokinetics of second generation antipsychotics",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Therapeutic peak plasma level, h",
"       </td>",
"       <td class=\"subtitle1\">",
"        Half-Life, h, therapeutic",
"       </td>",
"       <td class=\"subtitle1\">",
"        Protein",
"binding, percent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Vol. of",
"distribuion, L/kg",
"       </td>",
"       <td class=\"subtitle1\">",
"        Route of metabloism",
"       </td>",
"       <td class=\"subtitle1\">",
"        Active metabolite",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Traditional agents",
"       </td>",
"       <td>",
"        2-5",
"       </td>",
"       <td>",
"        8-36",
"       </td>",
"       <td>",
"        90-95",
"       </td>",
"       <td>",
"        7-62",
"       </td>",
"       <td>",
"        <p>",
"         CYP2D6",
"        </p>",
"        <p>",
"         CYP1A2",
"        </p>",
"        <p>",
"         CYP3A4",
"        </p>",
"       </td>",
"       <td>",
"        Variable",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Clozapine",
"       </td>",
"       <td>",
"        1-4",
"       </td>",
"       <td>",
"        7-13",
"       </td>",
"       <td>",
"        92-95",
"       </td>",
"       <td>",
"        2-5",
"       </td>",
"       <td>",
"        <p>",
"         CYP1A2",
"        </p>",
"        <p>",
"         CYP3A4",
"        </p>",
"       </td>",
"       <td>",
"        Norclozapine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Olanzapine",
"       </td>",
"       <td>",
"        5-6",
"       </td>",
"       <td>",
"        20-30",
"       </td>",
"       <td>",
"        93",
"       </td>",
"       <td>",
"        10-20",
"       </td>",
"       <td>",
"        <p>",
"         CYP1A2",
"        </p>",
"        <p>",
"         CYP2D6",
"        </p>",
"       </td>",
"       <td>",
"        NO",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Quetiapine",
"       </td>",
"       <td>",
"        1-2",
"       </td>",
"       <td>",
"        4-10",
"       </td>",
"       <td>",
"        83",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        CYP3A4",
"       </td>",
"       <td>",
"        7-hydroxyquetiapine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Risperadone",
"       </td>",
"       <td>",
"        1-2",
"       </td>",
"       <td>",
"        3-24",
"       </td>",
"       <td>",
"        90",
"       </td>",
"       <td>",
"        1-1.5",
"       </td>",
"       <td>",
"        CYP2D6",
"       </td>",
"       <td>",
"        9-hydroxyrisperidone",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ziprasadon",
"       </td>",
"       <td>",
"        4-5",
"       </td>",
"       <td>",
"        4-10",
"       </td>",
"       <td>",
"        &gt;99",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        CYP3A4",
"       </td>",
"       <td>",
"        NO",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Aripiprazole",
"       </td>",
"       <td>",
"        3-5",
"       </td>",
"       <td>",
"        75-146",
"       </td>",
"       <td>",
"        &gt;99",
"       </td>",
"       <td>",
"        4.9",
"       </td>",
"       <td>",
"        <p>",
"         CYP2D6",
"        </p>",
"        <p>",
"         CYP3A4",
"        </p>",
"       </td>",
"       <td>",
"        Dehydroaripiprazole",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_44_30412=[""].join("\n");
var outline_f29_44_30412=null;
var title_f29_44_30413="Medical complications of anorexia nervosa";
var content_f29_44_30413=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PSYCH%2F67080&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PSYCH%2F67080&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Medical complications of anorexia nervosa",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Constitution/whole body",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cachexia and low body mass index",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Arrested growth",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypothermia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Cardiovascular",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Myocardial atrophy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mitral valve prolapse",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pericardial effusion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Brachycardia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Arrhythmia, which may cause sudden death",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Electrocardiogram (ECG) changes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Long QT syndrome (QTc prolongation)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Increased PR interval",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        First-degree heart block",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        ST-T wave abnormalities",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypotension",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acrocyanosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Gynecologic and reproductive",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Amenorrhea",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Infertility",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pregnancy and neonatal complications",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Endocrine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Osteoporosis and pathologic stress fractures",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Euthyroid hypothyroxinemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypercortisolemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypoglycemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neurogenic diabetes insipidus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Gastrointestinal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gastroparesis (delayed gastric emptying)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Constipation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gastric dilatation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Increased colonic transit time",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hepatitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Superior mesenteric artery syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Renal and electrolytes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Decreased glomerular filtration rate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Renal calculi",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Impaired concentration of urine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dehydration",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypokalemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypomagnesemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypophosphatemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypokalemic nephropathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypovolemic nephropathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Pulmonary",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pulmonary muscle wasting",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Decreased pulmonary capacity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Respiratory failure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Spontaneous pneumothorax and pneumomediastinum",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Enlargement of peripheral lung units without alveolar septa destruction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Hematologic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anemia (normocytic, microcytic, or macrocytic)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Leukopenia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thrombycytopenia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Neurologic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cerebral atrophy (decreased gray and white matter)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Enlarged ventricles",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cognitive impairment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Peripheral neuropathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Seizures",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Dermatologic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Xerosis (dry skin)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lanugo hair (fine, downy, dark hair)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Telogen effluvium (hair loss)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Carotenoderma (yellowing)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Scars from self-injurious behavior (cuts and burns)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Muscular",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Muscle wasting",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Vitamin deficiencies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Refeeding syndrome",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_44_30413=[""].join("\n");
var outline_f29_44_30413=null;
var title_f29_44_30414="Metatarsus adductus";
var content_f29_44_30414=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F57425&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F57425&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Metatarsus adductus (medial deviation of the forefoot)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 216px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Hart ES. Pediatric Orthopaedic Ailments. Department of Pediatric Orthopaedics, Massachusetts General Hospital. Available at: www2.massgeneral.org/ortho/pediatric_intoe.htm.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_44_30414=[""].join("\n");
var outline_f29_44_30414=null;
var title_f29_44_30415="Tube in middle ear";
var content_f29_44_30415=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F53611&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F53611&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Medial displacement of a tympanostomy tube",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 288px; height: 321px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Tube has migrated deep to the tympanic membrane.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Glenn C Isaacson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_44_30415=[""].join("\n");
var outline_f29_44_30415=null;
